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Cancer is one of the foremost causes of death worldwide with about 14.1 million 
new incidences and 8.2 cancer related deaths occurring globally. NF-E2 p45-
related factor 2 (Nrf2), a cap-‘n’-collar basic leucine zipper (CNC-bZIP) 
transcription factor, prevents carcinogenesis through expression of genes that 
ensure the excretion, enzymatic modification, and repair of oxidative damage in 
cells containing the antioxidant response element (ARE) in their promoter region. 
Beyond providing cytoprotection against oxidative stress and xenobiotics, Nrf2 
pays a role in maintaining basic physiological processes such as energy 
metabolism and cell cycle regulation. Whilst Nrf2 plays a pivotal role in preventing 
degenerative and inflammatory disease, upregulation of Nrf2 promotes 
tumourigenesis in cancerous cells. Therefore, understanding the mechanisms 
controlling Nrf2 activity is important in translational medicine. 
Nrf2 is regulated by proteasomal degradation by Kelch-like ECH-associated protein 
1 (Keap1) an E3 ubiquitin ligase substrate adaptor protein that recruits of cullin-3 
(Cul3) to Nrf2 via its Neh2 domain. Nrf2 is also negatively regulated by 
phosphorylation by glycogen synthase kinase-3 (GSK-3) causing β-transducin 
repeat-containing protein (β-TrCP) to ubiquitinate Nrf2 by Skp1-Cul1-F-box (SCF) 
ubiquitin ligase through the Neh6 domain of Nrf2. Several research groups have 
shown that induction of ARE-driven genes can be regulated by phosphoinositide 3- 
kinase- protein kinase B (PI3K-Akt/PKB) signalling pathway. The ability of tert-
butylhydroquinone (tBHQ), 1-[2-cyano-3,12-dioxooleana-1,9(11)-diene-28-
oyl]imidazole (CDDO-Im), diethyl maleate (DEM), curcumin, carnosol, ferulic acid 
and sulforaphane (SFN) to activate Nrf2-target genes in a Keap1-dependent or 
Keap1-independent manner was tested. It was discovered that all compounds, 
except for SFN, activate Nrf2-target genes in a Keap1-independent manner, 
inhibiting GSK-3 and functioning through the Neh6 domain of Nrf2.  Analysis of the 
involvement of PI3K-Akt/PKB pathway in Nrf2 activation revealed that regulation of 
Nrf2 through the PI3K-Akt/PKB pathway is independent of Keap1 but dependent 
on GSK-3. Also, it was shown that tBHQ, DEM, CDDO-Im, curcumin, ferulic acid 
xxiv 
 
directly decreased phosphatase and tensin homolog (PTEN) activity, thereby 
preventing formation of the phosphodegron in the Neh6 domain of Nrf2. 
With increased Nrf2 levels reported in various cancers including lung cancer, 
leading to the progression of these cancers, Nrf2 can be seen as a double-edged 
sword. Loss-of-function somatic mutations in KEAP1 as well as somatic mutation in 
NFE2L2 has been reported in several human cancers playing a role in the 
development of such cancer. Using short hairpin RNA (shRNA) and the 
CRISPR/Cas9 system to generate stable Nrf2 knockdown A549 and H460 cells, 
the second part of this thesis investigated biochemical and physiological changes 
that occur, when the Nrf2 is genetically downregulated, and further on to determine 
what mechanism(s) is responsible for decreased cell proliferation in tumours. The 
findings obtained confirm that downregulation of Nrf2 from the human non-small 
lung adenocarcinoma epithelial cell line A549 and H460, in which Nrf2 is 
upregulated though somatic mutations in KEAP1, results in decreased cell 
proliferation. Analysis of the genes involved in NADPH generation and pentose 
phosphate pathway (PPP) show that decrease in Nrf2 caused a decrease in the 
expression of genes involved in PPP. Although knockdown of Nrf2 resulted in a 
decrease in cell proliferation, it was shown that this decrease was not as a result of 
cell death. Nrf2 is able to control cell proliferation by induction of metabolic 
reprogramming geared towards favoring anabolic pathways and influencing the 






1.0  General introduction 
1.1 Molecular basis of cancer 
One in eight deaths worldwide has been attributed to cancer (Stratton, Campbell 
and Futreal, 2009). In developed countries, cancer is now recognized as the 
second primary cause of death (Ren et al., 2011) next to heart disease, with an 
increase in death rate despite the increased availability of chemotherapeutic 
drugs (Knowles and Selby, 2005; Yu and Kensler, 2005; Ren et al., 2011; 
Watson, 2013; Pandey et al., 2017). Research over the past 30 years has 
revealed that cancer is associated with active changes in the genome (Hanahan 
and Weinberg, 2000) that result in uncontrolled cell proliferation that is capable of 
metastasizing into outlying organs beyond normal tissue (Stratton, Campbell and 
Futreal, 2009). In humans, evidence indicates that tumourigenesis is a multistep 
process reflecting genetic changes from normal human cells to highly malignant 
cells (Hanahan and Weinberg, 2000, 2011). These changes in the genome of 
cancer cells is attributed to intrinsic infidelity of DNA replication, exposure to 
exogenous agents such as tobacco smoke, mycotoxins and ultraviolet radiation or 
endogenous mutagens, defective DNA repair as well as enzymatic DNA 
modification (Alexandrov et al., 2013). 
Cancer arises as a consequence of continuous acquisition of (heritable) genetic 
variations in individual cells by random mutation and by natural selection acting on 
the resultant phenotypic diversity (Stratton, Campbell and Futreal, 2009). 
Evidence suggests that human cancer arises from mutations in at least several 
hundreds of the total 21000 genes that result in abnormal cell growth and division 
(Watson, 2013). This mutagenetic process is divided into three major stages 
known as initiation, promotion and progression that ultimately lead to metastasis 
(Pitot, 1993; Vincent and Gatenby, 2008). Initiation is carried out by a driver 
mutation that causes injury to cells resulting in a shift in the ratio of cell birth to cell 
death (Tomasetti, Vogelstein and Parmigiani, 2013). Subsequent clonal 
expansion arising from tumour promoters causes passenger mutations that lead 
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to formation of several benign tumours that progress to cancer (Hennings et al., 
1993; Tomasetti, Vogelstein and Parmigiani, 2013). Experimental models that are 
capable of exhibiting cancer phenotype used in research showed the presence of 
mutated oncogenes that are either tumour suppressor genes having recessive 
loss of function or oncogenes with significant function gain (Hanahan and 
Weinberg, 2000). Signal transduction pathways allow external signals such as 
growth factors to move from cell surface receptor to key promoters, stimulating 
the expression of genes required for cell growth and division as well as those 
required for the evasion of programmed cell death (Watson, 2013). Cell growth 
and proliferation arises through several molecular pathways each possessing its 
own specific surface receptor, cytoplasmic transducers and gene promoters as 
well as enhancers of gene expression. Cross-talk exists between these various 
pathways that allows the generation of new pathways to cancer cells by novel 
DNA mutations when pre-existing pathways are blocked (Lemmon and 
Schlessinger, 2010; Watson, 2013). 
On average, between 33 and 66 somatic gene mutations are observed in 
common solid tumours such as breast, pancreas, brain and colon cancer. About 
95% of these mutations correspond to single nucleotide base changes while 
insertions and deletions of one or a few bases account for the remaining 
percentage of gene mutations (Vogelstein et al., 2013). Some tumour types show 
either greater or fewer mutations than other tumours, with melanomas and lung 
tumours containing about 200 non-synonymous mutations per tumour while 
pediatric tumours and leukemias show an average of about 10 mutations per 
tumour. The participation of potent mutagens such as cigarette smoke, or 
ultraviolet light has been linked to the high levels of mutations seen in melanomas 
and lung cancer (Vogelstein et al., 2013). Govindan et al. (2012) reported a 10-
fold increase in point mutations in individuals with non-small cell lung carcinoma 
(NSCLC) who smoked as opposed to those that had never smoked. A recent 
study carried out by ‘The Cancer Genome Atlas (TCGA)’ on urothelial bladder 
carcinoma reported slightly fewer DNA alteration in urothelial bladder carcinoma 
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than those with lung cancer and melanoma; an average of 302 exonic mutations, 
204 segmental alterations in genomic copy number and 22 genomic 
rearrangement in each sample analyzed as well as mutations in nine genes 
(CDKN1A, ERCC2, RXRA, ELF3, KLF5, FOXQ1, RHOB, PAIP1, BTG2) that has 
not been previously reported as significantly mutated in any cancer (TCGA, 2014). 
The acquisition of additional mutations over time is required to transform a benign 
tumour into a malignant lesion. A normal epithelial cell receives a growth 
advantage from the first or driver mutation to outgrow its surrounding cells in order 
for it to become a microscopic clone. Subsequent mutations may support a round 
of clonal growth that permits an increase in cell number that eventually leads to 
the formation of a malignant tumour that is capable of invading the underlying 
basement membrane and metastasizing into outlying organs (Vogelstein et al., 
2013). A central step in tumour progression is its ability to invade other tissues 
and this acts as a driving force for metastasis with the bulk of tumours displaying 
characteristics of collective invasion cohesively as a multicellular unit (Friedl et al., 
2012; Cheung et al., 2013). Experiments carried out by Cheung et al. (2013) in 
breast tumours using a three-dimensional (3D) organoid assay to identify invasive 
cancer cells within a primary tumour in an unbiased fashion mimicking the 
microenvironment surrounding invasive breast cancers, showed that the cells 
leading to collective invasion are different from bulk tumor cells both molecularly 
and behaviorally and display conserved, basal epithelial gene expression such as 
cytokeratin-14 (K14) and p63 (Cheung et al., 2013).   
Directly linked to age is the frequency of mutations found in some tumours of self-
renewing tissues. An evaluation of the linear regression in these tumours shows 
that more than half of the somatic mutations identified occur during the 
preneoplastic phase (Tomasetti, Vogelstein and Parmigiani, 2013; Vogelstein et 
al., 2013). In a comparative lesion sequencing experiment, Jones et al. (2008) 
showed that approximately 17 years is required for the advancement of a large 
benign colorectal tumour into an advanced carcinoma whereas less than 2 years 
is required for it to metastasize. These results suggest that practically all the 
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mutations required for metastasis are already present in all of the cells of the 
antecedent carcinoma cells and that few, if not any, selective events are required 
to transform an highly invasive cancer cell into one that can metastasize (Jones et 
al., 2008). 
 
1.1.1 Metabolic changes in cancer 
Cancer cells often exhibit characteristic changes in metabolism which differs from 
that of normal cells (Currie et al., 2013). Reprogramming of metabolism in cancer 
cells allows accumulation of intermediates as sources of cellular building blocks 
required for abnormal cell growth and proliferation (Currie et al., 2013). One such 
abnormality is the change in glucose metabolism from oxidative phosphorylation 
employed by cells of normal tissues to the fermentation of glucose into lactate by 
tumour cells even in the presence of high amount of oxygen known as the 
Warburg effect (Warburg, 1956; Vander Heiden, Cantley and Thompson, 2009; 
Currie et al., 2013). Oxidative phosphorylation is down regulated by mitochondria 
of tumour cells (Gaude and Frezza, 2014). Activation of hypoxia inducible factor-1 
(HIF-1) accompanies the warburg effect during normoxia (Sakamoto, Niiya and 
Seiki, 2011). It is interesting to note that the distribution of oxygen within the 
mitochondria is as low as 0.5 – 1 kPa and that cell culture conditions fall short of 
replicating this in vitro (Keeley and Mann, 2018). Tumour growth beyond the 
capacity of the pre-existing capillary network induces hypoxia within a tumour 
mass which inturn leads to activation of HIF-1 switching cellular ATP production 
system predominantly to anaerobic glycolysis (Sakamoto, Niiya and Seiki, 2011).  
Other changes occur in cancer cells, including an increase in glutamine 
metabolism that is required to fuel the tricarboxylic acid (TCA) cycle 
(DeBerardinis, 2007; Mullen et al., 2012) and fatty acid metabolism (DeBerardinis 
and Thompson, 2012; Santos and Schulze, 2012). Carbon molecules are 
converted from energy production to fatty acid synthesis in cancer cells and are 
used for the biosynthesis of membranes and production of signalling molecules 
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required for cell proliferation (Currie et al., 2013). Research has shown that the 
metabolic reprogramming observed in cancer cells arises as a result of somatic 
mutations in cancer-associated genes and alterations in cellular signalling 
(Carracedo, Cantley and Pandolfi, 2013).  
Most tumour suppressor genes and proto-oncogenes encode components of 
signal transduction pathways and as such function in carcinogenesis by regulating 
cell cycle and sustaining proliferative signaling as well as helping cells to evade 
growth suppression and/or cell death (Ward and Thompson, 2012). The 
phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin 
(PI3K/PKB/mTOR) pathway, along with p53, hypoxia inducible factor 1-alpha 
(HIF-1α) and Myc have proven to promote the down regulation of oxidative 
phosphorylation and increased utilization of both glutamine and glucose in tumour 
cells (Figure 1.1) (Ward and Thompson, 2012; Kowalik et al., 2016). By enhancing 
the expression of glutaminase (GLS), oncogenic Myc has been shown to 
stimulate mitochondrial utilization of glutamine (Li et al., 2005a). HIF-1 blocks the 
incorporation of glucose into mitochondrial citrate that is critical for lipid synthesis 
by diverting pyruvate to lactate indicating a role for HIF-1 as a tumour suppressor 
in some cancers (Lum et al., 2007). In a study using a rat model of 
hepatocarcinogenesis, it was shown that early preneoplastic foci and nodules that 
progress into hepatocellular carcinoma (HCC) are fueled by inhibition of oxidative 
phosphorylation and by enhanced consumption of glucose to fuel the pentose 
phosphate pathway (PPP) arising mostly from the increased expression of tumour 
necrosis factor (TNF) receptor associated protein 1 (TRAP1) a mitochondrial 
chaperone and Nuclear factor – (erythroid derived 2) p45- related factor 2 (Nrf2) a 
transcription factor that induces the expression of glucose-6-phosphate 
dehydrogenase (G6PD) a rate limiting enzyme in PPP following microRNA-1 
(miRNA-1) inhibition (Kowalik et al., 2016). Nrf2 has been shown to bind to the 
promoter region of several miRNAs regulating the transcription of these miRNAs 
with miRNA-1 and miRNA-206 shown by Singh et al., 2013 to be indirectly 




Figure 1.1: Metabolic reprogramming in tumours 
Signaling molecules deregulated in tumours promote switch from oxidative phosphorylation to 
promote biosynthesis of membranes taken from (Ward and Thompson, 2012).   
 
1.1.2 Anti-cancer therapies and drug resistance 
The search to provide cures for cancer patients has progressed from the use of 
general cytotoxic agents such as nitrogen mustards in the early 1940s, through to 
the development of natural-product anti-cancer drugs such as vinca alkaloids and 
anthracyclines in the 1960s, and onto the more recent development of specific 
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monoclonal antibodies and immunotoxins targeted at cell surface receptors as 
well as specific agents targeted at inactivating kinases that promote growth 
pathways. Furthermore, recent research has focused on exploiting molecular 
targets based on tumour suppressors and oncogenes known to be involved in 
tumor development. Although some of the newer therapies have reduced side 
effects and increased cancer drug response rates than the older agents, none 
have resulted in cure of patients with metastatic disease owing to innate drug 
resistance of cancer cells (Gottesman, 2002). The resistance of cancer cells to 
therapies often limits the successful treatment of cancer disease (Ren et al., 
2011). More than 90% of patients with metastatic disease experience failure in 
treatment arising from resistance to therapeutic drugs that can ultimately lead to 
death (Agarwal and Kaye, 2003). This resistance can be either in the form of 
intrinsic resistance observed when cancer cells are inherently unresponsive to 
drugs or acquired resistance where cancer cells after an initial response to drugs 
develop resistance, probably due to the outgrowth of a few mutant cells within the 
tumour, and results in reoccurrence of the disease (Hayes and Wolf, 1990; Ren et 
al., 2011). Several studies on ovarian cancer show that many women who react 
favorably to first line treatment subsequently relapse with onset of a 
chemotherapeutic resistant form of the disease (Strathdee et al., 1999; Vaughan 
et al., 2012). 
Resistance of cancer cells to therapeutic drugs may result from several factors 
that have been grouped into three main categories by (Agarwal and Kaye, 2003) 
to include: pharmacokinetics, tumour microenvironment and cancer-cell specific 
processes. 
1. Pharmacokinetics: Factors such as drug delivery mechanism, poor 
absorption of drug (depending on lipophilicity of drug and cell membrane 
structure), low serum concentration of drugs arising from their rapid 
metabolism or renal clearance of drugs and low tolerance to drug effect 
arising from inter-patient differences play a role in drug resistance. 
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2. Tumour Microenvironment: Alterations affecting drug metabolism can also 
initiate drug resistance as well as the manner of interaction of cancer cells 
with each other and with host intestinal cells (Gottesman, 2002). A switch to 
a hypoxic environment in cancer cells causes an epithelial-to-mesenchymal 
cell transition that can result in changes in gene expression leading to 
resistance to anti-cancer drugs (Agarwal and Kaye, 2003; Watson, 2013).   
3. Cancer-cell specific: Different cancer cells from the same patients can 
respond differently to therapeutic drugs and exhibit different mechanisms of 
drug resistance because of variation in their genetic makeup, gene 
expression profile, and mechanism of activation of oncogenes or inactivation 
of tumour suppressor genes (Gottesman, 2002). Tumours are heterogenous 
in nature. Genetic instability within a particular tumour is different as every 
time a cell divides, variations across cells are bound to occur. It has been 
reported that the resistance of cancer cells to therapeutic drugs may result 
from acquired somatic mutations or epigenetic changes within the tumour 
cells (Agarwal and Kaye, 2003), or over expression of the therapeutic drug 
target and/or by increased inactivation of drugs arising from a decrease in 
uptake or enhanced detoxification and drug removal (Ren et al., 2011). The 
ability of tumour cells to repair damaged DNA may also cause drug 
resistance both in-vitro and in-vivo. Several studies have shown that 
resistance to cisplatin, a potent anticancer drug, is observed with enhanced 
nucleotide excision repair (NER), a pathway with which DNA-platinum 
adducts are removed and damaged DNA is repaired (Dabholkar et al., 1994; 
Köberle et al., 1999; Agarwal and Kaye, 2003). 
 
In the presence of an anticancer drug, genetic and epigenetic alterations in 
cancer cells from a given patient can result in the development of new variants 
that can tolerate therapeutic drugs leading to swift attainment of drug resistance 
(Gottesman, 2002). One key point to consider is the fact that even in rapidly 
proliferating tumours, a great proportion of cancer cells are in a quiescent state. 
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As most cytotoxic agents exert their actions against proliferating cells, quiescent 
cells are relatively unharmed by anticancer drug relative to cycling cells (Agarwal 
and Kaye, 2003). The low therapeutic index of many anticancer drugs means that 
only a slight change in sensitivity of tumor cells to the agent can lead to drug 
resistance (Agarwal and Kaye, 2003). Changes in cancer cells that promote drug 
resistance act by either preventing programmed cell death activated by most 
anticancer drugs, or by preventing the activation mechanisms that detoxify drugs 
and repair DNA damage. It can also act by preventing cell cycle, and cell cycle 
check points alterations (Gottesman, 2002).  
 
1.2 Oxidative stress and cancer 
1.2.1 Reactive oxygen species 
Energy generated by aerobic respiration in the mitochondria of eukaryotic cells 
often results in the production of reactive oxygen species (ROS) such as the 
superoxide anion radical (O2–), hydrogen peroxide (H2O2) and the hydroxyl 
radical (HO) (Halliwell and Gutteridge, 2007). Some of these are beneficial to the 
cell as they are involved in signalling processes; however at high intracellular 
concentrations, less than 5% may be toxic to the cell causing several human 
diseases (Poyton, Ball and Castello, 2009; Sosa et al., 2013). Continuous 
exposure to chemically reactive species containing oxygen produced during 
aerobic metabolism or as a result of extracellular insult beyond cell capacity leads 
to a condition known as oxidative stress (Salazar et al., 2006). ROS are selective 
and specific to their targets making the difference as to whether redox signaling 
would occur in the cell or oxidative damage would occur (Schieber and Chandel, 
2014). An imbalance between the generation of ROS and their rate of removal 
that favours the former is called oxidative stress, which may result in damage to 
important biomolecules such as DNA, RNA, lipids and proteins. If excessive, such 
damage may produce lesions that lead to pathological conditions (Kensler, 
Wakabayashi and Biswal, 2007; Niture et al., 2010; Reuter et al., 2010; Gupta et 
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al., 2012; Rotblat, Melino and Knight, 2012; Sosa et al., 2013). Hydroxyl radicals 
that are generated from H2O2 through the Fenton reaction requiring iron or other 
divalent metals such as copper and a source of reducing equivalents (NADH) to 
generate metal is a major cause of the damage exerted by ROS (Cabiscol, 
Tamarit and Ros, 2000). Polyunsaturated fatty acids in membranes are attacked 
by free radicals to initiate lipid peroxidation that arises in a decrease in membrane 
fluidity and disrupt membrane bound proteins (Humphries and Szweda, 1998). 
The base and sugar moieties of DNA are also targeted by ROS causing single 
and double stranded breaks in the backbone of DNA and also lesions that block 
replication (Sies and Menck, 1992; Sies, 1993). The reaction between reactive 
oxygen and nitrogen species with specific functional group of target protein results 
in covalent modifications (Krumova and Cosa, 2016). Accumulation of ROS in 
cells may contribute to several pathologies such as neurodegenerative disorders, 
cancer, atherosclerosis, diabetes and aging (Salazar et al., 2006).    
 
1.2.2  Chemical properties of ROS 
The frequent production of potentially damaging ROS is a disadvantage of 
aerobic life and thus the intracellular ROS levels have to be tightly controlled in 
order to prevent oxidative stress (Niture et al., 2010). Due to the function of single 
electron transfer of oxygen, molecular oxygen reacts quickly with other radicals or 
other species such as transition metals bearing unpaired electrons.  Loss of one 
electron in oxygen brings about the formation of O2●- that will subsequently lead to 
generation of other ROS as more electrons are lost (Krumova and Cosa, 2016). 
The reactivity of several ROS intermediates is dependent on their redox potential 
with O2●- possessing a limited reactivity with electron rich centers due to its 
anionic charge (Krumova and Cosa, 2016). The reactivity is based on ROS 
operating either as one-electron oxidant (radical ROS species) or two-electron 
oxidant (nonradical ROS species) (Halliwell, 2006). The level of ROS in the cell is 
controlled by the actions of several ROS-scavenging systems such as glutathione 
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peroxidase, glutaredoxin, thioredoxin, catalase, superoxide dismutase (SOD) and 
peroxiredoxin (Trachootham, Alexandre and Huang, 2009; Storr, Woolston and 
Martin, 2012). In Escherichia coli (E.coli), an experimental result show that 87% of 
the total H2O2 production is from the respiratory chain (Gonzalez-Flecha and 
Demple, 1995). The impact of ROS on cells can be minimized by some 
biochemical processes developed by cells themselves to combat this imbalance 
such as (i) enzymes that inactivate ROS e.g SOD and catalase that function in 
reduction of O2●- to H2O2 and subsequently to two molecules of water and oxygen 
(Bauer, 2013, 2014) or (ii) antioxidants enzymes that directly or indirectly act 
against ROS. Direct antioxidants that chemically scavenge ROS e.g glutathione, 
tocopherol, thioredoxin (TXN) and indirect antioxidants that act by inducing 
cytoprotective genes involved in the synthesis and regeneration of endogenous 
direct antioxidants many of which can be found in the diet or (iii) drug metabolizing 
enzymes, detoxification enzymes and drug efflux pump that function to eliminate 
harmful xenobiotics (Tebay et al., 2015).   
 
1.2.3 Biological roles of ROS 
The most common and well-studied ROS in cancer are H2O2, O2●-, OH●, and nitric 
oxide (NO) (Gupta et al., 2012), ROS can be generated either internally or 
externally (Table 1.1). pollutants, tobacco, smoke, drugs, xenobiotics or radiation 
are common extracellular sources of ROS. While internally, ROS can be produced 
through the action of several different sources such as mitochondria, 
peroxisomes, endoplasmic reticulum and the NADPH oxidase (NOX) complex in 
cell membrane (Table 1.1) (Gupta et al., 2012). The NOX isoenzymes and 
mitochondria produce O2●-, which when acted upon by SOD1 and SOD2 in the 
cell generates H2O2 (Schieber and Chandel, 2014). Different cellular 
transformations can be triggered in cells depending on the specific NOX enzymes 
expressed in the cell and can bring about different biological outcomes in cells 
(Krumova and Cosa, 2016). Oxidation of cysteine residues in phosphatases 
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inhibits protein phosphorylation and cell proteome in general (Krumova and Cosa, 
2016). The presence of oxidative stress in cell activates transcription factors such 
as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 
activator protein-1 (AP-1), Nrf2, HIF-1α, and signal transducer and activator of 
transcription 3 (STAT3) that control the expression of genes involved in 
inflammation, cell transformation, tumour growth or survival, proliferation, 
invasion, angiogenesis and metastasis (Brigelius-Flohé and Flohé, 2011; Gupta et 
al., 2012). ROS influence several signal transduction pathways in the cell by 
instigating a change in several cellular signaling molecules such as p53, 
telomerase, phosphatidylinositol 3-kinase (PI3K), Ras, Raf, and HIF-1α (Gupta et 
al., 2012).  Several tyrosine kinase receptors employ ROS dependent 
mechanisms in signalling (Schieber and Chandel, 2014). The generation of H2O2 
has been shown to lead to the signalling of both the epidermal growth factor 
receptor and the platelet-derived growth factor receptor (Sundaresan et al., 1995; 
Bae et al., 1997). Signal transduction is modulated by H2O2 because it oxidizes 
the catalytic cysteine of protein tyrosine phosphatase (PTEN), protein tyrosine 
phosphatase 1B (PTP1B), inositol monophosphatase 1 (IMPA1), slingshot protein 
phosphatase 3 (SSH3) and Src thereby preventing the inactivation of tyrosine 
kinase signaling through AP-1 and protein kinase B (PKB/Akt) (Wang et al., 2000; 
Leslie et al., 2003; Salmeen et al., 2003; Groen et al., 2005; Schieber and 
Chandel, 2014). Lipo-polysaccharide (LPS) has been shown to activate apoptosis 
signal regulating kinase 1 (ASK1) a member of the mitogen-activated protein 
(MAP) kinase family in a ROS-dependent manner activating an innate immune 
response (Matsuzawa et al., 2005; Matsuzawa and Ichijo, 2008). 
 
1.2.4 ROS and cancer 
ROS in general are produced and eliminated constantly in the cell functioning in 
driving normal cell processes and regulatory pathways including cell growth 
through to apoptosis and cell death (Gupta et al., 2012; Schieber and Chandel, 
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2014). However, as mentioned earlier, an imbalance in the production of ROS 
versus the elimination of ROS results in oxidative stress that can be detrimental to 
cell. ROS plays a role in the initiation, progression and survival phenotype of 
cancer cells; however, the role it plays whether good or bad is dependent on 
factors such as type of tumour and tissue, the stage of the disease, the treatment 
strategy, the levels, specificity and duration of ROS (Sabharwal and Schumacker, 
2014; Okon and Zou, 2015). Several lines of evidence show that, unlike normal 
cells, cancer cells exhibit high levels of ROS which in-turn leads to the activation 
of transcriptional factors that control expression of genes involved in inflammation, 
cell transformation, cell death or survival, cell proliferation, invasion, angiogenesis 
and metastasis  (Kawanishi et al., 2006; Szatrowski and Nathan, 1991; 
Trachootham, Alexandre and Huang, 2009). Several risk factors linked to cancer 
interact with cells via ROS generation (Figure 1.2). Although the exact pathway(s) 
leading to elevation of  ROS levels in cancer cells remains vague, several intrinsic 
mechanisms such as mitochondrial dysfunction, aberrant metabolism, and loss of 
functional p53 and activation of oncogenes are thought to account for the 
increase in ROS levels during the development and progression of cancer 
(Trachootham, Alexandre and Huang, 2009).  
Tumor growth can be initiated by ROS through the induction of signaling 
pathways required for cell growth and proliferation as well as stimulating DNA 
damage that lead to mutations (Ray, Huang and Tsuji, 2012; Rotblat, Melino and 
Knight, 2012). Increased levels of ROS were observed in the oncogenic 
transformation of ovarian epithelial cells with H-RasV12 (Trachootham, Alexandre 
and Huang, 2009; Gupta et al., 2012). In another similar study, high levels of O2●- 
were seen when fibroblasts were constitutively transformed with active isoforms of 
Rac and Ras (Irani et al., 1997). 
The role of ROS in tumor development is uncertain. The levels of ROS present in 
cell determines its effect on cell fate. Survival and proliferation of cells is driven by 
low levels of ROS through post-translational modification of kinases and 
phosphatases (Cairns, Harris and Mak, 2011). With mitochondria functioning as 
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the major source of ROS in majority of cell types, production of O2●- arising from 
inefficiencies in oxidative phosphorylation accounts for 2% of the total oxygen 
consumed by mitochondria (Orrenius,2007). The intracellular steady state levels 
of O2●- is estimated to be very low, however its activity is spatially limited.  To 
promote cell proliferation in response to growth factors, production of H2O2 at 
nanomolar levels have been estimated to be sufficient (Burch and Heintz, 2005). 
NADPH and NADPH oxidase drive the production of this low levels of ROS and is 
required for homeostatic signaling events. Moderate levels of ROS, however, 
induces the expression of stress-responsive genes which in turn trigger the 
expression of proteins providing pro-survival signals. However, high levels of ROS 
causes damage to macromolecules, trigger senescence and apoptosis (Figure 
1.3) (Cairns, Harris and Mak, 2011).  High intracellular levels of ROS seem to play 
an important role in the initiation and progression of cancer by promoting 
oncogenic stimulation, increased metabolic activity and mitochondrial malfunction. 
ROS also control the expression of several tumor suppressor genes such as p53. 
Moreover, ROS activate the cell cycle inhibitor p21 that suppresses tumor growth, 
as well as promoting the destruction of cancer cells by most chemotherapeutic 
and radiotherapeutic agents (Gupta et al., 2012; Idelchik et al., 2017). Moderate 
levels of ROS are required for tumor promotion whereas extremely high ROS 
levels are required for tumor suppression (Wu and Hua, 2007; Gupta et al., 2012). 
This dual role of ROS has been adopted by researchers as possible therapeutic 
strategy in cancer, either by increasing ROS removal, and as such decreasing 
H2O2 signaling and tumor growth, or by increasing the level of intracellular ROS, 
and thus promoting apoptosis (Dolado et al., 2007; Fruehauf and Meyskens, 
2007; Choudhary, Wang and Wang, 2011; Lee and Lee, 2011; Raj et al., 2011; 
Gupta et al., 2012). This can be seen in the role played by ROS in the signalling 
of the Ras-Raf-MEK1/2-ERK1/2 signalling pathway that is a key pathway in 
oncogenesis and the signalling of p38 mitogen-activated protein kinases (MAPK) 
pathway actively involved in tumor suppression (Dolado et al., 2007; Pan, Hong 
and Ren, 2009; Dozio et al., 2010). Most therapeutic agents used in the treatment 
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of cancer cells function by either directly or indirectly stimulating the formation of 
ROS that results in cell cycle arrest (Seok and Stockwell, 2008; Goga et al., 2007; 
Watson, 2013).  
 
 
Figure 1.2: Dual role of ROS in cancer cell. 
Ros function to promote cancer cell formation, proliferation, survival, invasion and promote 
metastasis of cancer cell as well as regulate inflammation and function in regulation cancer cell 





Figure 1.3: Relationship between ROS levels and cell fate 
Low ROS levels promote cell proliferation and survival pathways. Moderate increase in ROS leads 
to activation of various signalling pathway and activation of transcription factor that promote pro-
survival pathways. Increase in ROS levels beyond threshold that is specific to cell and stimulus, 
cellular response shift to promote oxidative stress that can lead to cell death. Cells uses 
antioxidants to counter the effect of high ROS levels. 
  
1.2.4.1 ROS and tumour cell death 
One key characteristics of cancer cell is their ability to survive and proliferate. 
Most key intrinsic and extrinsic pathways that lead to induction of apoptosis in 
cancer cells depend on high levels of ROS (Ozben, 2007). The tumor suppressor 
p53 induces apoptosis by activating the expression of genes such as p53-induced 
gene 3 (PIG3) which codes for quinine oxidoreductase that is required for ROS 
synthesis (Wang et al., 2012). Raj et al. (2011) showed that cancer cells can be 
selectively killed by piperlongumine because it increases ROS and binds to 
proteins that reregulate oxidative stress through the generation of H2O2. Similar 
work by Shaw et al. (2011) reported that Lanperisone induces non-apoptic cell 
death in a cell cycle and translation-independent manner in K-ras mutant cancer 
cells. It does this by inducing ROS that are inefficiently scavenged in K-ras mutant 
cells leading to oxidative stress and cell death (Shaw et al., 2011). Increased ROS 
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production by HYD1 a 10 D-amino acid containing peptide previously known to 
block cell adhesion was shown to necrotic cell death in multiple myeloma cells 
(Nair et al., 2009). A similar study by Naito et al. (2004) showed that 8-nitrocaffine 
and its analog, candidate radiosensitizer for cancer therapy induced necrotic cell 
death in U937, HL-60, K562 and Jurkat cell lines in a ROS-dependent manner. 
Depending on the ROS content, a switch from apoptosis to necrosis has also 
been shown in prostate cancer cells (Garbarino et al., 2007). ROS has also been 
shown to promote autophagy in cancer cells. Production of H2O2 by 
organotelluride catalyst LAB027 in human colon cancer cells cause cell death via 
autophagy (Coriat et al., 2011). Also, combination treatment of Gemcitabine and 
cannabinoid in pancreatic cancer cell triggered a ROS dependent autoghagic cell 
death (Donadelli et al., 2011). It is important however to emphasize that 
modulation of ROS levels in cancer cells is unpredictable and may not always 
lead to cancer cell death (Trachootham, Alexandre and Huang, 2009). 
 
1.2.4.2 ROS and tumour cell proliferation 
As stated earlier, one key feature of tumour cell is their ability to grow 
uncontrollably. Proliferation of cancer cells is enhanced by intracellular ROS 
produced by exogenous stimuli in cells and endogenous sources. Through 
regulation of precise cell cycle regulators such as cyclins and cyclin dependent 
kinases (CDKs), ROS is able to control cell proliferation. Low concentrations of 
arsenite was shown to enhance cell proliferation in human breast cancer MCF7 
cells by inducing ROS production and promoting the recruitment of cells into the S 
phase of the cell cycle, enhancing the expression of c-Myc and heme oxygenase 
1 (Hmox1) and increasing NF-кB activity (Ruiz-Ramos et al., 2009). Exogenous 
administration of H2O2 caused an increase expression of PKB and extracellular 
signal-regulated kinase (ERK) in hepatoma cells leading to increase cell 
proliferation (Liu et al., 2002). ROS modulator 1 (Romo 1) a novel protein was 
shown to endogenously induce ROS production in the mitochondria and was 
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required for the proliferation of lung cancer cells (Na et al., 2008). Reduction in the 
antioxidant defense has been linked to increase in cell proliferation in breast and 
ovarian cancer cells through increase in endogenous ROS (Hu et al., 2005; De 




(A) Intracellular sources of ROS 
Intracellular sources Major ROS References 
Mitochondria  O2●-, H2O2, OH● (Balaban, Nemoto and 
Finkel, 2005; Orient et al., 
2007; Murphy and M, 
2009; Turrens, 2003). 
Endoplasmic reticulum H2O2, epoxide hydrolase 
1. 
(Balaban, Nemoto and 
Finkel, 2005; Orient et al., 
2007; Cheong et al., 
2009) 
Peroxisomes O2●-, H2O2 (Corpas, Barroso and del 
Rı́o, 2001; Schrader and 
Fahimi, 2006) 
Phagosome O2●-, H2O2 (Pan, Hong and Ren, 
2009) 
NOX RO2-, O2●- (Bedard and Krause, 











(B) External sources of ROS 
External sources Major ROS References 
Environmental pollutants 
such as transition metals, 
benzene, nitrogen oxides. 
H2O2. OH●, ONOO●-, NO (Ahmad, 1995; Orient et al., 
2007; Lodovici and Bigagli, 
2011; Li et al., 2017) 
Virus such as Hepatitis B, 
Hepatitis C.  
H2O2 (Fruehauf and Meyskens, 
2007). 




NO, H2O2 (Huang, Lin and Ma, 2005; 
Tagawa et al., 2008; 
Valavanidis, Vlachogianni 
and Fiotakis, 2009) 
Smoke such as particulate 
matter, organic carbon. 
H2O2, O2●- (Tagawa et al., 2008) 
Diet such as monosaturated 
fatty acid rich oils. 
ONOO●- (Hoeks et al., 2008) 
Radiation such as ozone, 
carbon monoxide, ultraviolet 
light. 










Table 1.1: Sources of reactive oxygen species 
A table describing the common sources of ROS and some examples of the type of ROS they 
generate. (A) Intracellular sources of ROS (B) Extracellular sources of ROS. 
Abbreviations: superoxide anion (O2●-), hydrogen peroxide (H2O2), hydroxyl ion (OH●),  peroxyl 
ion (RO2●-), peroxynitrite (ONOO●-), nitric oxide (NO). 
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1.3 Nrf2 and cytoprotection 
 
1.3.1 Nrf2 and redox homeostasis 
In order to prevent ROS from accumulating within cells, and so maintain cellular 
homeostasis, cells have developed several adaptive mechanisms. These include 
induction of genes encoding antioxidant enzymes, phase I, II and III detoxification 
proteins (Itoh et al., 1999; Kobayashi et al., 2004b; Bryan et al., 2013; Zhang et 
al., 2013). In mammalian cells, 20 or more redox-sensitive transcription factors 
have been identified (Zenkov, Menshchikova and Tkachev, 2013). Many of these 
cytoprotective genes expressed in response to increases in ROS are regulated 
through the Nrf2 antioxidant response pathway (Lau et al., 2008; Osburn et al., 
2008). The Nrf2 transcription factor also known as NF-E2-like 2 (NFE2L2) 
maintains a balanced redox homeostasis by instigating the transcription of over 
100 cytoprotective genes required for cellular adaptation (reviewed in Hayes and 
Dinkova-Kostova, 2014). A common disadvantage that has been seen in cells 
lacking Nrf2 is that they possess a compromised antioxidant system resulting in 
an inability to scavenge ROS (Higgins et al., 2009). Reports from various research 
groups states that the level of ROS in Nrf2-null cells is between 1.6-4.0-fold higher 
than in wildtype (WT) cells having Nrf2, with loss of Nrf2 leading to depolarization 
of mitochondria and reduced levels of ATP in cells (McDonald et al., 2010; 
Holmstrom et al., 2013). 
 
The genes transactivated by Nrf2 include those encoding antioxidant proteins, 
phase II detoxifying enzymes, drug-efflux pumps, NADPH-regeneration enzymes, 
heat shock proteins, 26S proteasomal subunits, growth factors, growth factors 
receptors, and several transcriptional factors (Hayes and McMahon, 2009), which 
play a role in maintaining a balanced redox homeostasis (Figure 1.4). Amongst 
drug metabolizing and detoxifying proteins that are regulated by Nrf2, NAD(P)H: 
quinine oxidoreductase 1 (NQO1) is highly induced by many redox stressors. It is 
a widely distributed FAD-dependent flavoprotein involved in the reduction of 
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quinones, quinonemines, nitroaromatics and azo dyes using NADH, and thus 
helps protect against the formation of ROS generated during oxidative cycling of 
quinones (Nioi and Hayes, 2004; Ross and Zhou, 2010; Baird and Dinkova-
Kostova, 2011). The tumour suppressor p53 is protected against proteasomal 
degradation by binding to NQO1 thereby aiding in p53 mediated apoptosis in 
cancer cells (Asher et al., 2001). The glutamate-cysteine ligase modifier subunit 
(GCLM) and glutamate-cysteine ligase catalytic unit (GCLC) subunits of 
glutamate-cysteine ligase an enzyme that controls the rate-limiting step in the 
synthesis of glutathione that helps in combating the effect of oxidative stress is 
also regulated by Nrf2 (Mitsuishi et al., 2012). The expression of proteins such as 
ferritin that acts as a blockage of free radicals through Fenton reaction is also 
controlled by Nrf2 (Hayes and McMahon, 2009). Hmox1 a rate limiting enzymes in 
the catabolism of heme to give biliverdin, ferrous iron (Fe2+) and carbon monoxide 
(CO) in the presence of NADPH, cytochrome p450 and three molecules of oxygen 
per heme molecule (Maines, 1997) is also regulated by Nrf2. Of the three 
isoforms that has been described (Hmox1, Hmox2, Hmox3), Hmox1 a 32 kDa 
protein is highly inducible by various stimuli while Hmox2 is constitutively 
expressed in most tissues (Siow, Sato and Mann, 1999). Hmox1 functions by 
maintaining redox homeostasis, prevention of vascular injury and has anti-
inflammatory and antiapoptic properties (Abraham and Kappas, 2008). Oxidative 
and nitrosative stresses produced during inflammation induces the basal 
expression of HO-1 gene (Alam et al., 2004). Genes involved in heme 
biogeneration such as ATP binding cassette subfamily B member 6 (ABCB6) and 
ferrochelatase (FECH) have been shown to be regulated by Nrf2 (Wu, Cui and 
Klaassen, 2011; Campbell et al., 2013). The mobilization of iron from heme during 
hemoglobin catabolism is regulated by Nrf2 (Kerins and Ooi, 2018). Thus, Nrf2 
helps in the incorporation of iron back into heme and also in the destruction of 
heme through the induction of Hmox-1, heme-responsive gene-1 (HRG1) and 





Figure 1. 4: Nrf2 regulates cellular homeostasis. 
In the presence of oxidative or electrophilic stresses, Nrf2 instigates the expression of genes 
encoding the antioxidant response element (ARE) in their promoter region leading to a protection 
against oxidative stress, inflammation and diseases associated with redox imbalance.  
 
1.3.2 Nrf2: Discovery, Structure and Function 
Nrf2 was first cloned and characterized by (Moi et al., 1994) based on its ability to 
bind to NF-E2/AP-1 repeat sequences (5ʹ-TGAC/GTCA-3ʹ) in the promoter region 
of the β-globin gene. The Nrf2 protein is a member of a family of transcription 
factors encoding a basic-region leucine zipper (bZip) DNA binding domain with a 
cap‘n’collar (CNC) structure (Moi et al., 1994; Itoh et al., 1995; Lau et al., 2008). 
The human Nrf2 protein is made up of 605 amino acids while that of mouse and 
rat is made up of 597 amino acids (Tebay et al., 2015). Nrf2 possesses a 
relatively short half-life in cells with a half-life of 13 min, 15 min, 7.5 min and 22 
min in mouse hepatoma Hepa cells, Human HepG2 cells, African green monkey 
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COS7 cells and rat hepatocytes respectively (Nguyen et al., 2003; Stewart et al., 
2003; Smith et al., 2015; Kobayashi et al., 2004b).  
 
Human Nrf2 contains seven highly conserved domains known as Nrf2-ECH 
homology (Neh) domains (Figure 1.5) each with varying functions (Itoh et al., 
1995). The CNC-type basic-region leucine zipper required for DNA binding and 
dimerization to other transcriptional factors is located in the Neh1 domain (Mohler 
et al., 1991). In every seventh position of the “leucine zipper” region, a leucine 
residue is located allowing for dimerization to form hydrophobic region (Zenkov et 
al., 2017).  
 
The Neh2 domain of Nrf2 allows binding via its N-terminal domain to the Kelch 
domain of Kelch-like ECH- associated protein 1 (Keap1), a ubiquitin ligase 
substrate adaptor that negatively regulates Nrf2 (Itoh et al., 1999). Contained in 
the N-terminal Neh2 domain are two sequences, the high affinity ETGE motif (Ka = 
20x107 M-1) and the low affinity DLG motif (Ka = 0.1x107 M-1), to which the Keap1 
dimer binds in order to allow cullin-3 (Cul3) to ubiquitylate Nrf2 and target it for 
proteasomal degradation (McMahon et al., 2003; Katoh et al., 2005; McMahon et 
al., 2006; Zenkov et al., 2017; Kobayashi et al., 2004b). Ubiquitination of Nrf2 
within this domain is possible due to the presence of lysine residues between the 
ETGE and DLG motif (Zenkov et al., 2017). 
 
The Neh3 domain situated at the C-terminal region functions in Nrf2 stability and 
transcriptional activation. Interaction of Nrf2 with chromodomain helicase DNA-
binding protein 6 has been shown to occur in this domain confirming its role in 
transcriptional activation of Nrf2 (Nioi et al., 2005). 
  
The acidic residue-rich Neh4 and 5 domains serve as transactivational domains, 
and work synergistically interacting with cyclic adenosine monophosphate (cAMP) 
response element-binding protein (CREB) and brahma-related gene-1 (BRG1) to 
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increase the rate of gene transcription by promoting interaction between RNA 
polymerase complex and promoter regions of DNA due to histone proteins 
acetylation and chromatin de-condensation (Katoh et al., 2001; Zhang et al., 
2006a).  
 
The Neh6 domain contains numerous serine residues and a phospho-degron that 
negatively regulates Nrf2 through its DSGIS and DSAPGS β-transducin repeat-
containing protein (β-Trcp) binding site in a redox independent manner. 
Regulation of Nrf2 via this domain requires phosphorylation by glycogen synthase 
kinase-3 (GSK-3) to the DSGIS motif (McMahon et al., 2004; Rada et al., 2011, 
2012; Cuadrado, 2015; Chowdhry et al., 2013). Whereas very little is known about 
the Neh7 domain, Wang et al. (2013) reported the repression of Nrf2 through its 
Neh7 domain entailed an interaction between the 209-316 amino acid sequence 
of Nrf2 and retinoic X receptor alpha (RXRα).  
 
Contained in the Nrf2 protein are numerous nuclear localization signals (NLS) and 
nuclear export signals (NES) that have been identified to allow the translocation of 
transcription factors into nucleus or cytoplasm respectively. Among these is the 
NES located in the leucine zipper domain of Nrf2 with a sequence of 
537LKKQLSTLYL546 that is redox insensitive identified (Li et al., 2005). Subsequent 
work by (Li, Yu and Kong, 2006) identified another functional NES 
175LLSIPELQCLNI186 in the Neh5 transactivational domain of Nrf2 (Li et al., 2006). 
Another study by Theodore and his colleagues identified two more NLS motifs in 
murine Nrf2 one located near the N-terminal region (amino acid residue 42-53) 
and the other (amino acid residue 587-593) located at the C-terminal region of 
Nrf2 (Theodore et al., 2008). Research by Jain, Bloom and Jaiswal, 2005 
identified a bipartite NLS at the C terminal region of Nrf2 located between amino 
acids 495 and 511 and a NES between amino acids 545 and 554. Deletion of the 
NLS prevented the nuclear localization of Nrf2 and a decrease in transcriptional 
activity of the protein (Jain, Bloom and Jaiswal, 2005). Subsequent work by this 
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group reported that phosphorylation of Tyr-568 is required for Crm1-mediated 
nuclear export and degradation of Nrf2 and that Fyn phosphorylated Nrf2 leading 
to its nuclear export (Jain and Jaiswal, 2006). However, both papers have been 
retracted. Fyn a tyrosine kinase has been reported to phosphorylate Nrf2 at Tyr-
568 leading to the nuclear export of the protein (Jain and Jaiswal, 2006). it has 
been proposed that GSK-3β phosphorylates Fyn at Tyr-213 resulting in the 
accumulation of Fyn in the nucleus which in turn phosphorylate mouse and rat 
Nrf2 at Tyr-568 and human Nrf2 at Tyr-576 resulting in the nuclear export, 
ubiquitination and degradation of Nrf2 (Jain and Jaiswal, 2007; Kaspar and 
Jaiswal, 2011). The consensus is that tyrosine phosphorylation controls nuclear 
export of Nrf2 (Kaspar and Jaiswal, 2011), however much research on this is still 
required.   
 
The other members of this CNC transcription factor family include nuclear factor-
erythroid 2 p45 (NF-E2 p45), NF-E2 p45-related factor 1 (Nrf1), Nrf3, BTB and 
CNC homology 1 (Bach 1) and Bach 2 with Nrf2 having the highest 
transactivational activity (Katoh et al., 2001; Hayes et al., 2015). Although the 
expression of Nrf1 and Nrf2 are ubiquitous, the expression of NF-E2 p45 is limited 
to hematopoietic tissues (Mignotte et al., 1989). Bach 1 and 2 mostly acts as 
antagonists to Nrf2, competing for binding with the ARE with Bach 1 
predominantly localized in the nucleus  (Chapple et al., 2016). Bach 1 serves as a 
heme-binding protein, involved in the cellular balance of heme, oxidative stress 
response, and regulation of cell cycle progression (Davudian et al., 2016). 
Interestingly, contrary to other CNC family members, Bach 1 and 2 acts as 
transcription repressor, however, Bach 1 has been reported to act as a 
transcriptional activator in erythroid cell line whereas Bach 2 acts as a 
transcriptional repressor irrespective of the experimental system (Caterina et al., 
1994; Oyake et al., 1996; Davudian et al., 2016). Nrf1 is localized in the 
endoplasmic reticulum and membrane targeting is mediated by its N-terminal 
transmembrane domain which upon deletion results in nuclear localization of Nrf1 
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(Wang and Chan, 2006; Zhang et al., 2006). Nrf3 is also localized in the 
endoplasmic reticulum and is not ubiquitously expressed but expressed in the 
placenta, B cells and monocytes (Kobayashi et al., 1999; Zhang et al., 2009). 
 
Nrf2 functions in various cellular processes to maintain cellular homeostasis by 
controlling cellular responses to environmental and electrophilic stresses. Nrf2 
also function in inhibition of inflammation and prevention of neurodegenerative 
diseases. The significance of Nrf2 in promoting cellular processes was 
demonstrated in a study, where the knockout of Nrf2 in mice caused the 
development of complex disease manifestations, with a majority exhibiting a 
lupus-like autoimmune syndrome characterized by multiorgan inflammatory 
lesions and premature death arising from rapidly progressing glomerulonephritis 
as opposed to wild type mice (Ma, Battelli and Hubbs, 2006). Other studies also 
show that loss of Nrf2 causes increase susceptibility to several inflammatory 
factors leading to increased production of proinflammatory cytokines (interleukin-
2, interleukin-6) and chemokines and increased progression of inflammatory 
diseases as opposed to Nrf2+/+ Mice (Liu et al., 2009; Lau et al., 2015). Loss of 
Nrf2 in mice increased the sensitivity to pulmonary inflammatory disease. The 
disruption of Nrf2 in mice caused early onset and more aggressive form of 
cigarette smoke-induced emphysema with pronounced bronchoalveolar 
inflammation compared to wildtype mice (Rangasamy et al., 2004). The ability of 
mice to withstand toxic xenobiotics is compromised in the absence of Nrf2.  
Treatment of Nrf2-/- mice with 7,12-dimethylbenz(a)anthracene/12-O-
tetradecanoylphorbol-13 acetate to induce skin cancer resulted in increased 
tumour burden that was not susceptible to sulforaphane treatment as opposed to 
Nrf2+/+ mice (Xu et al., 2006). Overexpression of Nrf2 in astrocytes provided 







Figure 1.5: Structure of Nrf2 protein 
Structure of human Nrf2 showing the different homology domains, function and amino acid 
numbering. Mouse amino acid numbering is different. The Keap1 and β-TrCP domain required for 
proteasomal degradation of Nrf2 are indicated below while the DLG and ETGE Keap1 binding 
motifs and DSGIS and DSAPGS β-Trcp binding motifs shown above the domains.  
 
1.3.3 Nrf2 and its target genes 
The promoter regions of all genes that are transcriptionally activated by Nrf2 
possess an antioxidant response element/electrophile response element 
(ARE/EpRE, 5ʹ-TGACNNNGCA-3ʹ) to which Nrf2 binds as a heterodimer with 
small musculoaponeurotic fibrosarcoma (Maf) proteins; MafF, MafG and MafK (Itoh et 
al., 1997; Toki et al., 1997; Osburn and Kensler, 2008). The ARE which was originally 
defined as a DNA sequence within the regulatory region of rat and mouse 
glutathione S-transferase (GST) class Alpha genes that allowed their induction by 
oxidizable synthetic phenolic antioxidants (Rushmore and Pickett, 1990). 
Subsequently, a Nrf2:small Maf heterodimer was shown to bind to ARE 
sequences (Nioi et al. 2003). Depending on their ability to bind transcription 
cofactors, all members of the bZIP family possess the ability to form active 
regulatory dimers that can either stimulate or impede transcription of ARE-
dependent genes (Zenkov et al., 2017). Over 250 genes that contain an ARE 
consensus sequence in their promoter regions has been identified using analysis 
involving gene expression profiling and chromatin immunoprecipitation in mice 
and humans to date (Thimmulappa et al., 2002; Malhotra et al., 2010; Chorley et 
al., 2012). It is widely recognized that Nrf2 controls the expression of genes 
involved in redox homeostasis, cytoprotection, transcription of genes, drug 
29 
 
metabolizing enzymes, lipid metabolism, glucose/glycogen metabolism, NADPH 
production, growth factors and transport protein as listed in Table 1.2. Research 
carried out by (Itoh et al., 1997) in Nrf2-/- mice to determine if induction of phase II 
drug metabolizing enzymes GST and NQO1 is been regulated by Nrf2 showed 
that induction of phase II enzymes by butylated hydroxyanisole (BHA) was greatly 
abolished in liver and intestine of Nrf2-/- mice (Itoh et al., 1997).   
 
Among the most highly induced Nrf2 genes in humans are the aldo-keto 
reductase (AKR) isoenzymes as evident from experiments involving treatment of 
HaCaT, MCF10A, IMR-32 neuroblastoma cells with Nrf2 inducers sulforaphane 
(SFN) and tBHQ showing a significant increase in AKR1C1, AKR1B10, AKR1C2 
and AKR1C3 (Agyeman et al., 2012; Jung et al., 2013). Alongside the control of 
the expression of phase I and phase II drug-metabolizing enzymes, Nrf2 also 
controls the expression of multi-drug resistance protein (MRP) transporters such 
as MPP1, MRP2, MRP3, MRP4 and MRP5 (Maher et al., 2007) and the 
antiapoptotic protein B-cell lymphoma 2 (Bcl2) contributing to the development of 
multiple drug resistance in tumor cells and resistance to chemotherapy (Hur et al., 
















Nrf2 and intermediary metabolism 
Alongside directing cellular defenses, Nrf2 also plays a role in cell differentiation, 
proliferation, hematopoiesis and more recently in regulation of fatty acid 
metabolism (Shin et al., 2009; Kitteringham et al., 2010; Bryan et al., 2013). Nrf2 
regulates many metabolic pathways such as glucose metabolism, pentose 
phosphate pathway (PPP), lipid synthesis, purine synthesis and mitochondrial 
function. It does this by either directly regulating key metabolic genes or by 
indirectly regulating their expression through crosstalk with other transcription 
factors involved in these pathways. Nrf2 has also been suggested to be involved 
in diabetes mellitus and obesity as an increase in oxidative and nitrosative stress 
levels were observed when Nrf2-null mice were treated with steptozotocin to 
induce diabetes (Yoh et al., 2008). The fate of glucose in the body is dependent 
on its availability with glucose being directed to anabolic reactions under 
conditions of high glucose availability while under conditions of high energy 
requirement; it is broken down to produce two molecules of pyruvate and ATP 
(Voet and Voet, 2015). The levels of glucose in the blood is decreased with the 
expression of Nrf2. Nrf2-null mice exhibit high blood glucose levels due to 
increased expression of hepatic gluconeogenesis-related genes after 
administration of a single intraperitoneal dose of streptozotocin to induce Type 1 
diabetes (Aleksunes et al., 2010). Increased expression of Nrf2 in db/db Type 2 
diabetes (T2D) mouse model caused the suppression of enzymes involved in 
gluconeogenesis including glucose 6-phosphatase (G6pc), fructose-1,6-
bisphosphatase 1 (Fbp1), peroxisome proliferator-activated receptor γ coactivator 
1-α (Ppargc1a) and nuclear receptor subfamily 4,group A member 2 (Nr4a2) 
(Uruno et al., 2013). Similar work was reported by Slocum and his colleagues to 
show that Nrf2 repress genes associated with gluconeogenesis and lipogenesis 
through activation of AMP- activated protein kinase (AMPK) on mouse fed with a 
high fat diet (60 kcal % fat) for 90 days  (Slocum et al., 2016). Glucose uptake in 
fasting alpha mouse liver (AML) hepatocytes was enhanced with knock down of 
Nrf2 via siRNA and the gene expression levels of glucose transporter type 4, 
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insulin-like growth factor 1, forkhead box protein O1 that are involved in glucose 
uptake and gluconeogenesis was altered also in these cells proving the role of 
Nrf2 in the regulation of glucose metabolism (Yuan et al., 2017). Nrf2 has also 
been shown to regulate glycogen metabolism by increasing the expression of 
glycogen branching enzyme (Gbe1), muscle-type PhKα subunit (Phka1) in the 
liver and skeletal muscle (Uruno et al., 2016).  
Many genes encoding enzymes involved in lipid biosynthesis, fatty acid 
metabolism are negatively regulated by Nrf2 (Mitsuishi et al., 2012). Research 
carried out by Yates et al. (2009) showed that upregulation of Nrf2 either 
genetically or pharmacologically causes changes in gene expression of genes 
involved in lipid metabolism including sterol regulatory element-binding factor 
(Srebf1), lipase endothelial (Lipg), fatty acid synthase (Fasn) and acetyl-
coenzyme A carboxylase alpha (Acaca). Subsequent studies also showed that 
loss of Nrf2 in mice caused the development of fatty liver disease (liver steatosis) 
in mice treated with a diet deficient in methionine and choline (Chowdhry et al., 
2010; Sugimoto et al., 2010; Zhang et al., 2010). H&E staining of liver sections in 
experiments carried out by (Meakin et al., 2014) showed that Nrf2-/- mice fed 
chronically with a high-fat diet developed significant microvesicular and 
macrovesicular steatosis, neutrophil infiltration, apoptotic bodies, and disruption of 
hepatic architecture that are consistent with NASH. By contrast, Nrf2+/+ mice fed a 
high-fat diet that developed hepatic steatosis but showed no significant 
inflammation or fibrosis that would be consistent with NASH. The livers of high-fat 
fed Nrf2-/- mice also exhibited significant increase in expression of Srebf1, Srebf2, 
peroxisome proliferator-activated receptor gamma (PPARγ) (Meakin et al., 2014). 
It is important to note that high fat diet increased the expression of genes 
associated with fatty acid uptake, fatty acid oxidation, fatty acid storage, 
lipogenesis and inflammation in Nrf2-null animals as opposed to mice fed on a 
regular chow diet (Meakin et al., 2014). Subsequent work also showed that 
pharmacological activation of Nrf2 using TBE-31 failed to decrease liver steatosis, 
ER stress, genes associated with lipogenesis, inflammation and fibrosis in livers 
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of high fat fructose fed Nrf2-null mice as opposed to high-fat high-fructose fed 
wild-type mice indicating a role for Nrf2 in activation hepatic inflammation, 
lipogenesis, and NASH (Sharma et al., 2018). 
 
Glucose is redirected by Nrf2 into the anabolic pathway under sustained PI3K-Akt 
signaling (Mitsuishi et al., 2012). The genes involved in the production of 
nicotinamide adenine dinucleotide phosphate (NADPH) such as glucose-6-
phosphate dehydrogenase (G6PD), phosphogluconate dehydrogenase (PGD), 
transketolase (TKT), transaldolase 1 (TALDO1) and malic enzyme 1 (ME1) are 
activated by Nrf2 (Mitsuishi et al., 2012; Mitsuishi, Motohashi and Yamamoto, 
2012). Decreases in NADPH levels were reported in Nrf2 knockdown experiments 
in A549 cells whereas an increase in Nrf2 levels in Keap1 knockout mouse 
embryonic fibroblast (MEFs) showed an increase in NADPH levels (Singh et al., 
2013). By regulating expression of NADPH genes, Nrf2 controls the oxidative and 
non-oxidative arms of the PPP (Mitsuishi et al., 2012). Also, it has been seen that; 
Nrf2 catalyses the expression of phosphoribosyl pyrophosphate amidotransferase 
(PPAT), an enzyme required in the de-novo synthesis of purine nucleotides, 
indicating a role for Nrf2 in production of cell building blocks and purine 
biosynthesis. The role of Nrf2 in driving the PPP has linked Nrf2 and in vivo and in 
vitro cell proliferation, ultimately leading to Nrf2 playing a role in increased tumour 
growth (Mitsuishi et al., 2012; Singh et al., 2013). The levels of glutamine and 
glutamate are also considerably increased in cells with Nrf2 deficiency leading to 
increase production of GSH. Nrf2 also regulates the expression of genes for 
nucleotide synthesis as knockdown of Nrf2 resulted in a significant increase in the 
levels of glycolytic intermediates such as glucose 6 phosphate (G6P) and 
fructose-6 phosphate (F6P) (Mitsuishi et al., 2012). Nrf2 controls the expression of 
GCLC and GCLM, key enzymes that are required for glutathione synthesis. By 
regulating the expression of SLC7A11, a subunit for cystine transporter, Nrf2 is 




Also, mutant Nrf2 has been reported to alter mammalian target of rapamycin 
(mTOR) signaling by regulating the expression of RagD, a member of the small G 
protein family which encodes an mTOR pathway activator. Increased 
phosphorylation of the ribosomal S6 protein, a downstream substrate for the 
mTOR pathway and mild increase in AKT phosphorylation was observed in 
mutant Nrf2 expressing cells (Shibata et al., 2010).  
 
1.4 Regulation of Nrf2 
1.4.1 Mechanism of Nrf2 activation and repression 
One key feature of Nrf2 protein is that it is normally maintained at low levels in 
cells under normal homeostatic conditions possessing a relatively short half-life 
but is seen to stabilize rapidly in response to either oxidative or electrophilic 
stresses in the cell. Under normal unstressed conditions, Nrf2 is constantly 
targeted for proteasomal degradation by Keap1. Disruption of the interaction 
between Keap1 and Nrf2 by electrophiles and oxidants allows the CNC-bZIP 
protein to accumulate, initiating adaptive response to stress (Hayes and Dinkova-
Kostova, 2014). The prevailing view for a really long time was that Nrf2 is 
regulated solely at the level of protein stability by Keap1, however, recent 
evidence shows that Nrf2 is also regulated by the combined action of glycogen 
synthase kinase-3 (GSK3) and β-transducin repeat-containing protein (β-TrCP) in 
both stressed and unstressed conditions. The C.elegans WDR-23, a substrate 
receptor for Cul4-DDB1-ubiquitin ligase has been shown to regulate Nrf2 activity 
independent of Keap1(Lo, Spatola and Curran, 2017). Increased expression of 
WDR-23 in Keap1-/- cancer cells increases cellular sensitivity to cytotoxic 
chemotherapeutic agents and  suppresses Nrf2 activity (Lo, Spatola and Curran, 
2017). 
 
Nrf2 has also been shown to be negatively regulated by E3 ubiquitin-protein 
ligase synoviolin (Hrd1) during liver cirrhosis. Activation of the XBP1-Hrd1 arm of 
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Endoplasmic reticulum (ER) stress in cirrhotic livers, led to enhanced Nrf2 
ubiquitination and degradation and attenuation of the Nrf2 signalling pathway 
arising from transcriptional upregulation of Hrd1 (Wu et al., 2014).  
 
The regulation of Nrf2 occurs either at the transcriptional, translational or 
posttranslational levels. Evidence of transcriptional variation in expression of 
NFE2L2 was seen by occurrence of polymorphism at the promoter region at -336 
bp from transcription start site (TSS) in mouse leading to variation in susceptibility 
of mouse to develop acute lung injury (Cho et al., 2002).  The presence of an 
ARE-like sequence in Nrf2 gene suggests that it is able to autoregulate itself and 
its downstream genes in the presence of electrophilic inducing agents (Kwak et 
al., 2002). Xenobiotic response element (XRE)-like sequences found in promoter 
region of Nrf2 causes the recruitment of the aryl hydrocarbon receptor (AhR) that 
allows transcriptional activation of Nrf2 by polycyclic aromatic hydrocarbon (PAH) 
compounds (Miao et al., 2005). Experiments involving HepG2-101L cells stably 
transfected with a XRE-luciferase construct showed that aldo-keto reductases 
(AKRs) generated planar PAH ortho-quinone activate CYP1A1 gene via AhR 
binding in a XRE-dependent mechanism, indicating a cross talk between Nrf2 
regulated genes and their metabolites (Burczynski and Penning, 2000). 
Downstream of the TSS of Nrf2 contains a nuclear factor-кB (NF-кB) binding site 
that allows lipopolysaccharide (LPS) to transcriptionally activation the CNC-bZIP 
factor (Rushworth et al., 2012). LPS is able to upregulate Nrf2 transcription by 
activating NF-кB ang inducing nuclear localization of Nrf2 and NF-кB (Rushworth 
et al., 2012). It has also been reported that LPS is able to induce a cellular 
response leading to increased ROS levels which would trigger Nrf2 activation and 
drives the expression of Nrf2-regulated gene expression (Rushworth, MacEwan 
and O’Connell, 2008). 
 
Regulation of Nrf2 via a translational mechanism has also been examined by 
Purdom-dickinson et al. (2007) who showed that H2O2 caused an increase in Nrf2 
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protein levels, but not Nrf2 mRNA in rat cardiomyocytes. By using incorporation of 
[35S] methionine to measure new protein synthesis these workers demonstrated 
that H2O2 increases Nrf2 protein synthesis in rat cardiomyocytes. Similar to the 
functional internal ribosomal entry site (IRES) contained in yeast Yap1 gene, Nrf2 
mRNA has also been seen to possess a redox sensitive IRES in its 5ʹ-UTR that 
contains a putative 18S rRNA binding site (RBS) that is conserved across species 
and is responsible for independent initiation of translation (Zhou, Edelman and 
Mauro, 2001; Li et al., 2010; Shay et al., 2012).  Located upstream of the RBS of 
the Nrf2 IRES, is a hairpin structured inhibitory element (IE) which when deleted 
remarkably improves translation (Li et al., 2010). It has also been shown that, the 
IRESNrf2-driven translation is redox sensitive as treatment of cells with H2O2 and 
sulforaphane, stimulated IRESNrf2-driven translation initiation (Li et al., 2010; 
Huang et al., 2015). 
 
Posttranslational regulation is one of the main mechanisms by which Nrf2 protein 
level is regulated. Enzymatic ubiquitination of lysine residues in Nrf2 and 
succeeding degradation of the 26S proteasome in the absence of activators 
determines the stability of Nrf2 (Jaramillo and Zhang, 2013). Cell culture 
experiments show that upon inhibition of proteasomal activity, concentrations of 
Nrf2 in cells and nuclei increases (Kwak et al., 2002; McMahon et al., 2003; 
Chowdhry et al., 2013).   
   
1.4.2 Regulation of Nrf2 by Keap1 
The cullin-3 (Cul3)- based E3 ubiquitin ligase substrate adaptor Keap1 is the 
principal negative regulator of Nrf2 as it is responsible for the high turnover of Nrf2 
protein in most cell types under non stressed conditions (Lau et al., 2008). Keap1, 
which was first isolated by (Itoh et al., 1999) using the Neh2 domain of Nrf2 as 
bait in a yeast two-hybrid system, has a relatively large number of cysteine 
residues; 27 in the human protein and 25 in the mouse protein. It is dimeric, 
containing three main domains (Figure 1.6); a broad complex, tramtrack and bric-
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a-brac (BTB) domain, an intervening region (IVR) cysteine-rich domain and a C-
terminal Kelch-repeat domain that simultaneously bind to the ETGE and DLG 
motifs of Nrf2 to initiate ubiquitination (Itoh et al., 1999; Li et al., 2004; Yu and 
Kensler, 2005; Lo et al., 2006).  The Kelch repeat domain (often termed the 
double-glycine repeat, DGR) consisting of six subdomains with distinctive Gly-Gly 
motif forms a six-bladed β-propeller each made up of 4 anti-parallel β-strands that 
forms twisted β-sheet is required for interaction with the Neh2 domain of Nrf2 
(Padmanabhan et al., 2006; Ogura et al., 2010). Mammalian Keap1 consisting of 
624 amino acids has over four individual cysteine based stress sensors that are 
reactive oxygen/nitrogen species and electrophile triggered (Hayes et al., 2015). It 
has subsequently been demonstrated that Keap1 is a substrate adaptor for Cul3, 
and allows Nrf2 to be ubiquitylated by Cul3/Rbx1 under normal homeostatic 
conditions (Cullinan et al., 2004; Kobayashi et al., 2004a). The recruitment of Cul3 
to Keap1 is provided through protein-protein interactions via the BTB domain of 
Keap1 (Kobayashi et al., 2004a). Studies carried out to determine the cellular 
compartmentalization of Nrf2 and Keap1 using GFP-fusion proteins identified 
Keap1 to be located primarily in the cytoplasm while Nrf2 is located in both 
cytoplasm and nucleus, with the CNC bZIP factor located primarily in the 
cytoplasm where it is targeted for degradation by Keap1 or moves into the 
nucleus once activated by electrophiles or antioxidants (Itoh et al., 1999; Watai et 
al., 2007; Baird and Dinkova-Kostova, 2011). In vitro alkylation and in vivo site 
directed mutagenesis have identified Cys-151, Cys-226, Cys-273, Cys-434, Cys-
288 and Cys-613 in Keap1 as key cysteine residues responsible for Nrf2 
activation with Cys-151 involved in activation of the Nrf2 pathway by promoting 
the binding of Keap1 to Cul3 while Cys-273 or Cys-288 are required for Nrf2 
repression (Dinkova-Kostova et al., 2002; Eggler et al., 2005, 2007; Luo et al., 
2007). Like the Kelch protein after which Keap1 was named, homo-dimerization of 
Keap1 via its BTB domain is required for it to act as a repressor of Nrf2 (Robinson 







Figure 1. 6: Structural domains of Keap1 protein with amino acid numbering. 
The BTB domain coloured purple is the Cul3 binding site and responsible for formation of Keap1 
dimer. The intervening region (IVR) is cysteine rich. The double glycine repeat (DGR) coloured 
blue contains Kelch repeats that folds into six bladed β-propeller structures each with four 
stranded anti-parallel β-sheet. It is the Nrf2 binding domain containing DLG and ETGE motifs. It 
also contains a cysteine residue at amino acid 434. The C-terminal region (CTR) also contains a 
cysteine residue at amino acid 613. Cysteine residues are depicted with red lines at the top and 
acts as redox sensors. (Li et al., 2004; Canning, Sorrell and Bullock, 2015; Gacesa et al., 2018).   
 
Under normal redox homeostasis, Nrf2 is constantly degraded by Keap1-
mediated ubiquitin proteasomal degradation in the cytoplasm maintaining low 
basal levels (Figure 1.7A) (Bryan et al., 2013; Canning, Sorrell and Bullock, 2015). 
Nrf2 attaches to the Kelch domain of Keap1 and the BTB domain of Keap1 
interacts with Cul3 forming a Keap1-cul3-Rbx1E3 ubiquitin ligase complex 
(CRLKeap1) that allows E2 to transfer ubiquitin to lysine residues in the Neh2 domain 
of Nrf2. Following ubiqutination, Nrf2 is degraded by the 26S proteasome, and 
thus a low basal level of Nrf2 is maintained in cells that are not exposed to 
electrophilic or oxidative stresses (Cullinan et al., 2004; Lau et al., 2008; Canning, 
Sorrell and Bullock, 2015; Kobayashi et al., 2004a). In the presence of oxidative 
stress, modification of reactive cysteine residues in Keap1 results in a 
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conformational change of the E3 ubiquitin ligase that prevents Keap1 from 
degrading Nrf2. Subsequently synthesized Nrf2 translocates into the nucleus 
where it heterodimerizes with a small Maf protein that ultimately leads to activation 
of expression of ARE-dependent antioxidant genes (Zhang, 2006). On recovery of 
cellular redox homeostasis by Nrf2 downstream genes, Nrf2 is either degraded in 
the nucleus or transported back to the cytoplasm (Lau et al., 2008).   
The earliest theory about Keap1-Nrf2 interaction proposed that Keap1 degrades 
Nrf2 in the cytoplasm and that subsequent treatment with electrophiles or 
oxidative stressors causes Nrf2 to be released from Keap1 where it becomes free 
to move to the nucleus and initiate the expression of Nrf2 target genes (figure 
1.7B) (Itoh et al., 1999). Another school of thought proposed that the release of 
Nrf2 from Keap1 is triggered by phosphorylation of Nrf2 by protein kinase C (PKC) 
at the Neh2 domain of Nrf2 (Huang, Nguyen and Pickett, 2002; Bloom and 
Jaiswal, 2003; Numazawa et al., 2003). However live cell imaging experiments 
revealed that the interaction between Nrf2 and Keap1 is such that one subunit of 
Keap1 binds to the ETGE domain of Nrf2 forming an open conformation, followed 
by the binding of the second subunit of Keap1 to the DLG domain of Nrf2 forming 
a closed conformation allowing Nrf2 to be degraded and free Keap1 is then 
available to interact with newly synthesized Nrf2 and the cycle continues (Baird et 
al., 2013). Electrophiles and oxidative stressors however disrupt this cycle by 
inducing conformational changes in Keap1 either by modification of the key 
cysteine residues in Keap1 such that though Nrf2 is still bound to both dimers of 
Keap1, its alignment to Keap1 is incorrect preventing the ubiquitination of Nrf2. As 
such, Keap1 is not free to degrade Nrf2 and newly synthesized Nrf2 translocates 
into the nucleus and induce the transcription of its downstream genes (figure 
1.7C) (Padmanabhan et al., 2006; Hayes and Dinkova-Kostova, 2014; Baird et 





















Figure 1.7: Diagram depicting the repression of Nrf2 by Keap1. 
Nrf2 is constantly degraded by Keap1 in the cytosol under basal conditions. (B) Oxidative stress 
condition causes Keap1 to dissociate from Nrf2 leading to accumulation of Nrf2 that is transported 
to the nucleus where it binds with Maf and activates the expression of Nrf2 downstream genes. (C) 
Oxidative stress causes conformational changes in Keap1 leading to improper alignment to Nrf2 
and as such subsequently synthesized Nrf2 translocated to the nucleus and activates the 




1.4.3 Regulation of Nrf2 by GSK-3 and β-TrCP  
Glycogen synthase kinase 3 (GSK-3) a member of the CMCG proline-directed 
kinase family is a monomeric, second messenger-independent serine/threonine 
protein kinase that was first discovered to activate the ATP-Mg-dependent form of 
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type-1 protein phosphatase (Factor A) and to phosphorylate glycogen synthase 
(GS); a rate limiting enzyme in glycogen synthesis (Embi, Rylatt and Cohen, 
1980; Vandenheede et al., 1980; Kaidanovich-Beilin and Woodgett, 2011). GSK-3 
has been implicated in the regulation of insulin signaling, cell proliferation, cell 
cycle regulation, embryo development, apoptosis, inflammation, neuroplasticity 
and Wnt signalling (Jope, Yuskaitis and Beurel, 2007; Eldar-Finkelman et al., 
2010; Biswas et al., 2013). The finding that expression of Nrf2-target gene is 
inhibited by GSK-3 was first reported by Salazar et al. (2006). They showed that 
Nrf2 can be negatively regulated by GSK-3β through phosphorylation and nuclear 
exclusion preventing the transactivation of ARE-containing genes 
Hmox1,glutathione peroxidase, GST-A1, NQO1 and GCLC (Salazar et al., 2006). 
The Keap1 independent mode of Nrf2 regulation was first discovered when 
deletion of the ETGE and/or DLG motifs in the Neh2 domain of Nrf2 did not result 
in stability of Nrf2 but rather, when Neh6 domain of Nrf2 was deleted, an increase 
in the half-life of Nrf2 was observed (McMahon et al., 2004). Contained in the 
Neh6 domain are two highly conserved regions that correspond to the β- TrCP 
recognition motif DSGϕxS (Rada et al., 2011; Chowdhry et al., 2013). Evidence 
shows that Nrf2 can also be negatively controlled by the action of β-TrCP, an E3 
ligase adaptor that enables Nrf2 ubiquitination through the Skp1-Cul1-Rbx1/Roc1 
core E3 complex (SCFβ-TrCP) and GSK-3 (Chowdhry et al., 2013).  Experiments 
have shown that the Neh6 domain promotes Nrf2 degradation during oxidative 
stress condition through its β-TrCP binding sites DSGIS and DSAPGS found in 
the 329-339 and 363-379 residues of Nrf2 (Figure 1.8). An increase in Nrf2 
protein level was observed when β-TrCP1 and β-TrCP2 were deleted in MEF cells 
(Rada et al., 2011). The F-box domain of β-TrCP interacts with Skp1 adaptor 
protein while its WD40 domain binds to the substrates promoting ubiquitination of 
Nrf2 (Figure 1.9). Ubiquitination of Nrf2 by the SCFβ-TrCP unlike the ETGE and 
DLG motifs in the Neh2 domain that is functional only when both binding site 
firmly interact with Keap1, the DSGIS and DSAPGS domain of the Neh6 domain 
work independently of each other (Chowdhry et al., 2013; Hayes et al., 2015).  
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The DSGIS motif contains a functional GSK-3 phosphorylation site to which β-
TrCP binds which is absent in the DSAPGS motif and is responsible for increased 
activity of the phosphodegron (1.10) (Wu et al., 2003; McMahon et al., 2004; 




Figure 1. 8: Structure of the Neh6 domain of Nrf2 
Showing amino acid sequence of the two conserved β-TrCP binding sites of mouse (m), human 
(h), rat ®, frog (f), zebrafish (z) and chicken (ECH) with conserved residues on gray background 
and identical residues on black background aligned using the T-Coffee tool at 








Figure 1. 9: structure of β-TCP protein 
Structure depicting the binding domains of β-TrCP showing the dimerization domain (D domain), 
the Skp1 interacting domain (F box) and the WD40 repeat domain that is responsible for binding 






Figure 1. 10: Regulation of Nrf2 by Keap1 and GSK-3. 
Keap1 target Nrf2 for degradation through its Neh2 domain, electrophiles and ROS is able to 
prevent Keap1 from degrading Nrf2 through modification of the cysteines residues found in Keap1. 
Nrf2 can also be regulated by a Keap1- independent manner through the action of GSK-3 and β-




Phosphorylation by GSK-3 is a common feature in proteins such as β-catenin, 
Gli3, IκBα and securin that require degradation through the SCFβ-TrCP (Aberle et 
al., 1997; Winston et al., 1999; Tempé et al., 2006; Limon-Mortes et al., 2008; 
Hayes et al., 2015). GSK-3 is highly conserved and ubiquitously expressed having 
two isoenzymes GSK-3α and GSK-3β with molecular weights of 51 kDa and 47 
kDa respectively (Kaidanovich-Beilin and Woodgett, 2011). The two isoforms 
though generated from distinct genes have similar catalytic domains with GSK3α 
possessing a glycine rich N-terminus and are functionally different (Plattner and 
Bibb, 2012; Pandey and DeGrado, 2016). Both isoforms of GSK-3 are 
constitutively active in cell with the levels different in different tissues and an 
abundance of GSK-3β found in the brain (Woodgett, 1990; Hernández et al., 
2010). GSK-3 controls a wide array of substrates including glycogen synthase, 
beta-catenin, tau, PKA, c-Jun, c-Myc, ATP-citrate lyase etc. indicating a major role 
in regulation of cellular processes (Ali, Hoeflich and Woodgett, 2001; Rayasam et 
al., 2009). The activity of GSK-3 is highly controlled through four key mechanisms 
that are specific to each substrate (Jope and Johnson, 2004). Of the four key 
mechanisms of regulation of GSK-3, which include regulation by phosphorylation 
of GSK-3, subcellular localization of GSK3, GSK-3 containing protein complexes 
formation and regulation through phosphorylation of GSK-3 substrate; regulation 
by inhibitory phosphorylation of a regulatory serine is the most characterized 
(Woodgett, 1990; Jope, Yuskaitis and Beurel, 2007).  
 
The N-terminal region of GSK-3 is required for phosphorylation by several kinases 
such as Akt, protein kinase A (PKA), protein kinase C (PKC), and p90Rsk (Jope 
and Johnson, 2004; Hernández et al., 2010). Phosphorylation of Ser-21 in GSK-
3α and Ser-9 in GSK-3β serves as inhibitory regulatory sites for GSK-3 whereas 
its activity is positively regulated by phosphorylation at Tyr-279 and Tyr-216 for 
GSK-3α and GSK-3β respectively (Jope and Johnson, 2004; Hernández et al., 
2010; Kaidanovich-Beilin and Woodgett, 2011; Pandey and DeGrado, 2016). The 
β-strand and α-helical domains of GSK-3 must first align in a catalytically active 
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conformation before phosphorylation can occur for effective binding of the 
substrate to GSK-3 (Pandey and DeGrado, 2016).  
 
Most substrates that are phosphorylated by GSK-3 require pre-phosphorylation 
(priming) by another kinase for them to be phosphorylated by GSK-3, thus 
phosphorylation is through recognition of the S/TXXXS/T (P) consensus sequence 
in certain proteins with priming occurring at a Ser residue that is located three or 
four amino acid to the C-terminal GSK-3 phosphorylation site (Ali, Hoeflich and 
Woodgett, 2001; Forde and Dale, 2007; Kaidanovich-Beilin and Woodgett, 2011).  
The positively charged binding pocket of GSK-3 recognizes the primed 
serine/threonine residue, enabling the correct alignment of substrates within the 
active site of the kinase (Kaidanovich-Beilin and Woodgett, 2011). Some GSK-3 
substrates, such as c-Jun, c-Myc, and MARK2/PAR-1, however do not require 
priming in order for GSK-3 to phosphorylate them because the ‘priming’ site is 
represented by an acidic residue or a peptide conformation (Kaidanovich-Beilin 
and Woodgett, 2011). However, for those that requires prior phosphorylation, 
GSK-3 phosphorylates serine/threonine residues N-terminal to the priming site 
leading to multiple phosphorylation event (Boyle et al., 1991; Kaidanovich-Beilin 
and Woodgett, 2011). Kinases that have been shown to prime for phosphorylation 
of GSK-3 include cyclin-dependent kinase 5 (CDK-5), protease-activated 
receptor-1 (PAR-1), casein kinase 1 (CK 1), casein kinase 2 (CK 2), protein 
kinase C (PKC) and protein kinase A (PKA), however no specific kinase has been 
recognized as a priming kinase for GSK-3 phosphorylation of Nrf2 (Amit et al., 
2002; Nishimura, Yang and Lu, 2004; Li et al., 2006; Kaidanovich-Beilin and 








1.4.4 Regulation of Nrf2 by phosphatidylinositol-3-kinase (PI3K) 
pathway 
The regulation of Nrf2 by GSK-3 has been largely overlooked over the years as 
GSK-3 is inhibited under conventional cell culture by PI3K-protein kinase B 
(PKB/Akt) pathway which lies upstream of GSK-3 (Hayes and Dinkova-Kostova, 
2014; Tebay et al., 2015). PI3K is a serine/threonine lipid kinase involved in 
regulation of cell growth, proliferation, survival, differentiation and changes in the 
cytoskeleton due to generation of specific inositol lipids such as PKB or AKT 
(Vanhaesebroeck and Alessi, 2000). Cell survival during oxidative stress is 
regulated by the PI3K/AKT signalling pathway and offers protection against 
oxidative-induced lung injury (Lu et al., 2001; Ahmad et al., 2006; Papaiahgari et 
al., 2006; Manning BD, 2007). The evidence that PI3K plays a role in Nrf2 
regulation was first demonstrated when the PI3K inhibitor LY294002 was used to 
treat IMR-32 human neuroblastoma cells by Jeffery Johnson and colleagues. 
Their result showed that treatment of IMR-32 cells diminished tBHQ-induced 
NQO1 gene in these cells (Li, Lee and Johnson, 2002). Nrf2 activation in lung 
epithelial cells is dependent on PI3K/AKT signalling as inhibition of PI3/AKT 
caused inflammation and injury of the lungs (Papaiahgari et al., 2006; Reddy et 
al., 2015).  
 
1.4.5 Regulation of Nrf2 by protein phosphorylation 
Due to the relatively large amount of Ser, Thr and Tyr residues present in Nrf2 
protein, several protein kinases including to PKC, c-Jun N-terminal kinase (JNK), 
extracellular signal-regulated kinase (ERK), p38 MAPK, and PERK play roles in 
regulating the stability of Nrf2 (Zenkov et al., 2017). Earlier work has shown that 
phosphorylation of Nrf2 at Ser-40 by PKC weaken the binding of Keap1 to Nrf2 
causing the stabilization of Nrf2 and increased transcription of Nrf2 downstream 
genes (Huang, Nguyen and Pickett, 2000, 2002; Bloom and Jaiswal, 2003; 
Numazawa et al., 2003). MAPK has also been demonstrated to regulate Nrf2 by 
binding to ARE sequence. Inhibition of ERK and p38 MAPK was shown to result 
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in a 50% decrease in the induction of GCLC and GCLM while activation of these 
genes by pyrrolidine dithiocarbamate resulted in the activation of ERK and p38 
MAPK indicating that ERK and p38 MAPK play a role in the transcriptional 
upregulation of these Nrf2 target genes (Zipper and Mulcahy, 2000, 2003). 
Another study showed that the induction of glutathione and HO-1 by flavonoids 
butein and phloretin is mediated by ERK1/2 signalling pathway resulting in 
increased nuclear translocation of Nrf2 (Yang et al., 2011). The transcription start 
site of the Nrf2 locus contains Jun and Myc binding sites and has been shown to 
regulate Nrf2 in tumour cells (Denicola et al., 2011). Induction of Nrf2 target genes 
by phenethyl isothiocyanate (PEITC) in PC-3 cells resulted in an increase in the 
phosphorylation of ERK1/2 and JNK1/2 and this induced the nuclear translocation 
of Nrf2 (Xu et al., 2006). 
 
It is also important to note that Nrf2 can also be regulated by competitive protein 
interactors such as p21, SQSTMI/p62, IκB kinase β (IKKβ) which competes with 
Nrf2 for Keap1 binding thus increasing Nrf2 activity (Hayes et al., 2010). 
Contained in the p62/SQSTM1 is an evolutionarily conserved Keap1 binding 
region that has an STGE binding motif that is closely related to the ETGE motif of 
Nrf2. This region causes p62/SQSTM1 to competitively bind to Nrf2 acting as an 
activator of Nrf2 (Jain et al., 2010; Komatsu et al., 2010). The presence of an ARE 
in the gene promoter region of p62/SQSTM1 indicates a possible mechanism by 
which Nrf2 can regulate its own gene expression (Jain et al., 2010). The C-
terminal region of p21Cip1/WAF1 can associate with the DLG motif of Nrf2 blocking 
Keap1 activity resulting in stabilization of Nrf2 thereby promoting cell survival in 
response to oxidative stress (Taguchi, Motohashi and Yamamoto, 2011).  
 
CR6-interacting factor 1 (CRIF1), a protein known to regulate the cell cycle and to 
serve as a transcription cofactor, has also been reported to negatively regulate 
Nrf2 by promoting its degradation in both oxidized and reduced stress conditions 
(Kang et al., 2010). Seven in absentia homolog (Siah) 2, an E3 ubiquitin ligase 
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protein that mediates the ubiquitination and subsequent proteasomal degradation 
of target proteins, has also been reported to repress Nrf2 in a Keap1-independent 
manner during low oxygen conditions in the cells (Nakayama, Qi and Ronai, 2009; 
Buchwald et al., 2013; Gopalsamy, Hagen and Swiminathan, 2014). Adenosine 
monophosphate-activated protein kinase (AMPK) has also been observed to 
phosphorylate Nrf2 at Ser-550 leading to accumulation of Nrf2 in the nucleus (Joo 
et al., 2016). Upstream of both Keap1 and GSK-3 lies mTOR signaling whose 
active site contains several phosphorylation site and as such predicted to play a 
role in regulation of Nrf2 (Tebay et al., 2015). In response to several stimuli such 
as nutrients, growth factors and energy, mTOR is able to regulate cell growth and 
division (Efeyan and Sabatini, 2010). mTORC1 is inhibited by AMPK via 
phosphorylation of Raptor, a member of its complex at Ser-351 in the STGE motif 
of p62/SQSTM1 thereby minimizing Keap1 autophagosome-mediated 
degradation of Nrf2 (Ichimura et al., 2013). mTORC2 has also been reported to 
regulate Nrf2 via PI3K-Akt signalling in cells (O’Reilly et al., 2006; Sarbassov et 
al., 2005). So far, the repression of Nrf2 by GSK-3 has been shown to occur 
through several upstream pathways either through SCFβ-TrCP, PI3K, and mTOR 
(Bendavit et al., 2016; Rada et al., 2011; Yang et al., 2018). However, a role for 
activation of tyrosine kinases has also been proposed for promoting the regulation 
of Nrf2 via GSK-3 (O’Reilly et al., 2006).  
 
 
1.5 Cancer chemoprevention 
 
1.5.1 Role of Nrf2 
In studying cancer chemoprevention, one has to understand that unlike other 
diseases, cancer is a multistage process that arises from a single benign lesion 
growing into nearby normal tissues to moving through walls of blood vessels or 
lymph nodes or tissues or organs to growing into distant parts of the body known 
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as stage IV (metastasis) cancer (Hanahan and Weinberg, 2000; Stratton, 
Campbell and Futreal, 2009; Hanahan and Weinberg, 2011). The use of natural 
or synthetic agents to impede, block or reverse the process of carcinogenesis is 
the basis of cancer chemoprevention. Interference of carcinogen-cell interaction in 
normal cells, alteration of proliferation rate in premalignant cells, modulation of 
metabolism and disposition of endogenous and environmental carcinogens 
through anti-mutagenic, antioxidative, anti-inflammatory and anti-hormonal 
mechanism are effective strategies employed by these agents in cancer 
prevention (Waun Ki Hong, 1997; Kwak, Wakabayashi and Kensler, 2004) Cancer 
chemoprevention dates back to early 1950’s when decrease in cancer incidence 
was observed in rats fed with high doses of carcinogenic azo dyes were prior fed 
small quantities of 3-methylcholanthrene (Richardson and Cunningham, 1951; 
Zhang, 2006). However, 3-methylcholanthrene is itself carcinogenic and thus 
ensuing research over years established the effectiveness of non-carcinogenic 
organic compounds to block carcinogenesis; some isolated from plants and others 
as synthetic drugs as anti-carcinogens (Stutman, 1974; Henry et al., 1981; Zhang, 
2006). The inhibition of chemical induced carcinogenesis using phenolic 
antioxidants such as BHA has long been recognized to prevent cancer initiation 
(Wattenberg, 1973; Benson et al., 1978). Some of the chemopreventive 
mechanisms involve phase II drug metabolizing enzymes to facilitate 
chemoprevention. Long et al., (2000) showed that loss of NQO1 in mice caused 
susceptibility to benzo(a)pyrene induced carcinogenesis. Overexpression of 
GSTP1 in human prostrate adenocarcinoma LNCaP cells containing a silenced 
GSTP1 gene caused a decrease in cytotoxicity and DNA damage induced by an 
heterocyclic amine carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine 
(PhIP) (Nelson et al., 2001; Kwak, Wakabayashi and Kensler, 2004). Most of 
these anticarcinogenic compounds induce cytoprotective genes through the Nrf2 
antioxidant pathway suggesting a role for the CNC-bZIP protein in cancer 
chemoprevention (Wang et al., 2007).  
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The binding of Nrf2 to the promoter region of cytoprotective genes in cells in 
response to electrophiles and oxidants suggest a role for Nrf2 in mediating cellular 
response (Baird and Dinkova-Kostova, 2011; Itoh et al., 1997). As discussed 
earlier, the existence of several mutations in cells arising from exposure to 
electrophiles and ROS may lead to initiation of carcinogenesis. As Nrf2 plays a 
major role in combating electrophilic and redox stresses in cells, it is pertinent that 
Nrf2 would play a major role in cancer chemoprevention. Nrf2 is able to prevent 
carcinogenesis by either promoting the enzymatic breakdown and excretion of 
chemical carcinogens, reduction of ROS or by promoting the repair of oxidative 
damage through expression of Nrf2 downstream genes.  Reduced Nrf2 activity 
would mean loss of cytoprotection and thus increased risk of development of 
carcinogenesis. Cancer cells attain malignancy by altering Nrf2 activity through 
inactivation of Keap1 or gain-of-function mutation in NFE2L2 (Taguchi and 
Yamamoto, 2017). Nrf2 inhibits the initiation of carcinogenesis because it induces 
drug metabolizing enzymes and antioxidant enzymes that inactivate chemical 
carcinogens (Yu and Kensler, 2005; Zhang, 2006). Mutant Nrf2-null mice 
demonstrate that ARE-driven genes provide protection against oxidative stress 
and reactive xenobiotics; Nrf2 knockout mice exhibit enhanced susceptibility to 
carcinogenesis suggesting that Nrf2 can sometimes act as a tumour suppressor 
known as the good side of Nrf2 (Rotblat, Melino and Knight, 2012). Low 
expression of drug-metabolizing and antioxidative enzymes such as GST, NQO1 
and peroxiredoxin 1 in liver, intestine and forestomach has been reported in Nrf2 
knockout mice (Ramos-Gomez et al., 2001; S et al., 2002; Yu and Kensler, 2005) 
showing that Nrf2 influences intrinsic resistance to carcinogenesis. The induction 
of ARE-driven cytoprotective genes by cancer chemopreventive agents is also 
attenuated in Nrf2-null mice (McMahon et al., 2001; S et al., 2002). Loss of Nrf2 in 
mice results in increased susceptibility to toxicity evoked by environmental and 
chemical stress due to 30-70% decrease in expression of NQO1 and GST in Nrf2 
null mice as opposed to wild-type mice (Ramos-Gomez et al., 2001). Also, 
hepatotoxicity induced by intake of acetaminophen was alleviated in mice 
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deficient in Nrf2 as opposed to wild-type mice (Ramos-Gomez et al., 2001; Fahey 
et al., 2002). The presence of harmful DNA-damaging effects of estrogens was 
reduced by pharmacological activation of Nrf2 using sulforaphane (SFN), or by 
genetically knocking down Keap1 in MCF-10A cells (Yang et al., 2013). The 
administration of chemical inducers of Nrf2 such as oltipraz, SFN, TBE-31 before 
challenging with carcinogens has been shown to reduce the progression of 
cancer (Hayes et al., 2000; Nioi and Hayes, 2004; Knatko et al., 2015). 
 
The role of Nrf2 in the initiation, progression and growth of cancer cannot be 
overemphasized. Decades of research on the induction of Nrf2 through 
electrophiles that activate the gene using Nrf2-/- mice shows the protective role of 
Nrf2 activation in the prevention of carcinogenesis. However, Nrf2 has also been 
known to function as an oncogene as it is constitutively active in some cancers 
and has led to favoring the progression of such cancers.  
 
1.5.2 Upregulation of Nrf2 in cancer 
Nrf2 is upregulated in some carcinoma cells (Zhang, 2006). This observation 
seems contradictory to the initial belief that the Keap1-Nrf2 system helps prevent 
cancer. However, the knowledge that cancer cells often acquire increased 
antioxidant and drug metabolizing activities possibly explains their acquirement of 
malignancy and cytoprotective function (Taguchi and Yamamoto, 2017). The 
upregulation of Nrf2 in cancer cells has been reported to arise either by: (i) 
presence of somatic mutations within the genes encoding Nrf2, Keap1 or Cul3 ; 
(ii) epigenetic silencing of Keap1; (iii) accumulation of proteins that interfere with 
the binding of Nrf2 to Keap1 such as p62/Sqstm1 and p21; (iv) modification of 
cysteine residues in Keap1 by oncometabolites (Taguchi, Motohashi and 
Yamamoto, 2011; Menegon, Columbano and Giordano, 2016; Taguchi and 
Yamamoto, 2017). The presence of high Nrf2 protein levels therefore increases 
expression of genes that are required for cytoprotection, conferring resistance to 
both chemotherapy and radiotherapy in such cancer cells (Ramos-Gomez et al., 
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2003; Taguchi and Yamamoto, 2017). Sequence analysis of the Neh2 domain of 
Nrf2 has revealed the presence of mutations around the DLG and ETGE motifs 
that stops Keap1 from ubiquitinating Nrf2 (Zhang, 2010; Fukutomi et al., 2014). 
Shibata et al. (2008b) reported the presence of somatic mutation in the DLG and 
ETGE motif of patients with a history of smoking or suffering from squamous cell 
carcinoma resulting in accumulation of Nrf2 and suppression of the transcription 
factor using siRNA knockdown resulted in sensitizing the cells to 
chemotherapeutic reagents. The loss of repression of Keap1 arising from either 
somatic mutations of the ETGE and DLG motifs of Neh2 domain of Nrf2 or 
epigenetic changes causes the up-regulation of Nrf2 in some tumor cells such as 
lung, liver, ovary, stomach, head and neck (Singh et al., 2006; Ohta et al., 2008; 
Shibata et al., 2008b; a). Missense mutations in the Keap1 gene in human lung 
adenocarcinomas (Ohta et al., 2008; Shibata et al., 2008a) have been reported, 
with mutations identified across the BTB, DGR, IVR, and NTR domains (Table 
1.3) (Taguchi, Motohashi and Yamamoto, 2011). The cancer genome atlas 
(TCGA) has documented a 25 -35% upregulation of Nrf2 in lung adenocarcinoma 
(Collisson et al., 2014a), 8% in urothlial bladder carcinoma (TCGA, 2014), 5% in 
head and neck squamous cell carcinoma (TCGA Network, 2015), with mutations 
in Keap1 serving as second most genetic lesion in lung adenocarcinoma and 
fourth most common in lung squamous cell carcinoma (Hammerman et al., 2012; 
Lawrence et al., 2014). Mutations of Nrf2 and Keap1 genes that prevent Nrf2 
degradation by CRLKeap1 are often seen in cancer cells leading to increased 
expression of Nrf2-target genes. This can lead to increased cell proliferation of 
cancer cells as well as resistance to therapeutic drugs through activation of drug 
efflux systems (Ohta et al., 2008; Taguchi, Motohashi and Yamamoto, 2011). 
Mutation in PTEN often leading to Nrf2 upregulation has also been reported in 








Mutation Domain Tissue Reference 
V167F BTB Lung (Singh et al., 2006) 
C23Y NTR Breast (Nioi and Nguyen, 2007) 
Q284L IVR Lung (Singh et al., 2006) 
543insC IVR Gallbladder (Shibata et al., 2008a) 
D77V Neh2 ETGE Lung (Shibata et al., 2008b) 
D77A Neh2 ETGE Lung (Kim et al., 2010) 
W24C Neh2 DLG Lung (Shibata et al., 2008b) 
D29G Neh2 DLG Head and neck (Shibata et al., 2008a) 







Other mechanisms responsible for Nrf2 up regulation in cancer cells include: (i) 
hypermethylated DNA at promoter region of Keap1; (ii) oncometabolites that 
modify Keap1; (iii) competitive protein interactors that disrupt Keap1-Nrf2 binding; 
(iv) transcriptional up regulation via oncogene-dependent signaling (Mitsuishi, 
Motohashi and Yamamoto, 2012; Jaramillo and Zhang, 2013). The presence of 
these various mutations either in Keap1 or Nrf2 that leads to activation of Nrf2 in 
Table 1.3: Some mutations in Keap1 and NFE2L2 found in cancer 
Examples of Keap1 and NFE2L2 mutations found in cancer cells. Point and mis-sense 
mutations with the domain in Keap1 and Nrf2 as well as the tissue within which the mutations 




several human cancers has been seen to promote tumorigenesis and promote 
chemoresistance by upregulation of glutathione, thioredoxin, and drug efflux 
pathways (Singh et al., 2010; Shibata et al., 2011; Fukutomi et al., 2014; Rojo de 
la Vega, Chapman and Zhang, 2018).  
 
 
1.5.3 Inducers of Nrf2 as anticancer agents 
Several structurally diverse small molecules of endogenous and exogenous origin 
upregulate the Keap1-Nrf2 pathway (Baird and Dinkova-Kostova, 2011). Inducers 
of Nrf2 function by protecting the body from chemical carcinogens and by 
promoting the detoxification of carcinogens arising from the environment (Taguchi 
and Yamamoto, 2017). 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (oltipraz) a 
dithiolethione has been shown to be a potent inducer of GST and other phase II 
enzymes in cells (Kensler and Helzlsouer, 1995; Kwak, Wakabayashi and 
Kensler, 2004) Administration of oltipraz caused significant reduction of gastric 
tumour induced by benzo(a)pyrene in wild-type mice but had no effect when Nrf2 
was lost in these cells (Ramos-Gomez et al., 2003). An earlier work reported a 
daily dose of oltipraz administered in a two month clinical trial for hepatocellular 
cancer resulted in significant increase in the level of aflatoxin-mercapturic acid 
secreted into the urine (Wang et al., 1999). Acting as an effective 
chemopreventive drug in an array of cancer including lung, bladder, colon, liver, 
mammary gland and skin cancer models, oltipraz has passed in into phase II 
clinical trial for the treatment of cancer and has shown to increase the expression 
of phase II transcript levels and enzymes in humans (Kelloff et al. 1994; Kensler & 
Helzlsouer 1995; Kwak et al. 2004; Taguchi & Yamamoto 2017).  
SFN an isothiocyanate isolated from the cruciferous plant broccoli on the basis of 
its ability to induce phase II drug metabolizing enzyme NQO1 has been used in 
the treatment of cancer (Singletary and MacDonald, 2000; Fahey et al., 2002; 
Kwak, Wakabayashi and Kensler, 2004; Yeh and Yen, 2009). Dopaminergic-like 
neuroblastoma cell line SH-SY5Y treated with SFN resulted in significant increase 
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in total GSH, NQO1, GSH-transferase and GSH reductase leading to increase 
resistance to H2O2 or 6-hydroxydopamine (6-OHDA) induced toxicity (Tarozzi et 
al., 2009). Extract from SFN-enriched broccoli sprout used in treatment of mouse 
and human keratinocytes resulted in increased expression of phase II enzymes 
and glutathione resulting in decrease tumour burden in a dose dependent manner 
(Dinkova-Kostova et al., 2006).  
Synthetic triterpenoids that are potent inducers of cytoprotective enzymes and 
inflammatory inhibitors have also been used as potent Nrf2 inducers (Yates et al., 
2007). The triterpenoids CDDO-ethyl amide and CDDO-methyl ester (CDDO-Me) 
when fed to lung adenocarcinoma induced A/J mice resulted in an 86% to 92% 
average tumour burden respectively (Liby et al., 2009). Subsequent work in VC1 
lung cancer cells and A/J mung cancer mice using CDDO-imidazole (CDDO-Im) 
and CDDO-Me and dimethyl fumarate (DMF) showed the triterpenoids activated 
Nrf2 pathway and significantly reduced average tumour number, size and burden 
as opposed to control group however, DMF though induced Nrf2 weakly was seen 
to increase the severity of the tumour (To et al., 2015). 
 
Another common inducer of Nrf2 is the tert-butylhydroquinone (tBHQ), an 
aromatic organic compound that is a metabolite of BHA commonly used as a 
synthetic food antioxidant (Gharavi, Haggarty and El-Kadi, 2007). tBHQ has been 
shown to induce phase II enzymes via an Nrf2 dependent mechanism and also to 
exhibit anti-carcinogenic ability (Gharavi, Haggarty and El-Kadi, 2007). In another 
research conducted by Duan et al. (2014), it was seen that tBHQ suppressed 
arsenic-induced hepatocellular toxicity in human hepatocytes via induction of Nrf2. 
The FDA has approved the use of dimethyl fumarate; an Nrf2 inducer for the 
treatment of multiple sclerosis and also, bardoxolone methyl (CDDO-Me or RTA 
402) has also passed into phase II clinical trials for pulmonary hypertension and 
chronic kidney disease (Taguchi and Yamamoto, 2017). Also, inducers such as 
SFN, carnosol and curcumin are also in clinical trials and are been used as 
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dietary supplements for the treatment of cancer (Sporn and Liby, 2012; Taguchi 
and Yamamoto, 2017). 
 
 
1.5.4 Inhibitors of Nrf2 as anticancer therapy 
As Nrf2 is up regulated in tumors with mutant Keap1, there is a need to identify 
chemicals that inhibit the transcription factor because they could be effective 
anticancer drugs. The down-regulation of detoxification enzymes and drug 
excretion transporters by inhibitors of Nrf2 might diminish cell proliferation and 
would sensitize cancer cells to therapeutic drugs (Mitsuishi et al., 2012). Some 
agents that have been proposed to inhibit Nrf2 include brusatol, retinoic acid 
(Wang et al., 2007), luteolin (Tang et al., 2011), glucocorticoids (Kratschmar et al., 
2012), trigoneline (Boettler et al., 2011), ascorbic acid (Tarumoto et al., 2004), 
wogonin (Zhong et al., 2013) and some ROS producing compounds (Shaw et al., 
2011) (Figure 1.11) (Table 1.4). Although, unlike Nrf2 inducers, inhibitors of Nrf2 
have not been officially developed and would be a useful insight into the 




















Inhibitor Mechanism/Potency Reference 
Brusatol Keap1-independent (1-10 
nM) 
(Olayanju et al., 2015; 
Ren et al., 2011) 
Retinoic acid Keap1-independent. 
Through the Neh7 domain 
(1-10 µM) 
(Wang et al., 2007; 
Valenzuela et al., 2014) 
Luteolin Keap1-independent (1-10 
µM) 
(Tang et al., 2011; 
Chian et al., 2014) 
Cortisol Unknown (1-10 µM) (Kratschmar et al., 
2012) 
Trigoneline Inhibition of proteasome 
activity (1-10 µM) 
(Boettler et al., 2011; 
Arlt et al., 2013) 
Isoniazid Prevents Nrf2 
translocation by inhibiting 
extracellular signal 
regulated kinase 1 
(ERK1) (1-10 µM) 
(Chen et al., 2013; 
Verma et al., 2015) 
Wogonin Keap1-dependent (1-10 
µM) 
(Zhong et al., 2013; 





Brusatol a plant extract from Brucea javanica (L) Merr. (Simaroubaceae) has been 
reported to inhibit ARE-luciferase activity and diminish Nrf2 protein levels in MDA-
MB-231-ARE-Luc stable cell line by Zhang and her group. Ren et al. (2011) 
reported the identification of brusatol a quassinoid with the ability to inhibit Nrf2 
and which was able to sensitize cancer cells to cisplatin and other 
Table 1.4: Examples of Nrf2 inhibitors. 
Some Nrf2 inhibitors that has been shown to target Nrf2 in cells. Possible mechanism 
of action and potency is described. 
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chemotherapeutic drugs through reduction in Nrf2 protein expression. 
Subsequent work by Olayanju et al. (2015) showed that brusatol inhibit Nrf2 in a 
Keap1-independent manner. 
 
Retinoic acid (RA), a derivative of vitamin A is involved in the regulation of cell 
proliferation, differentiation and morphogenesis as well as promoting apoptosis 
and inhibiting tumourigenesis via cell growth suppression and cellular 
differentiation stimulation (Wang et al., 2007; Duester, 2008; Valenzuela et al., 
2014). RA acts via the retinoic acid receptors (RAR-α, -β, and –γ) and the retinoid 
X receptors (RXR-α, -β, and –γ) to regulate gene expression functioning as 
transcriptional regulator by forming a heterodimer between RXR and RAR 
(Soprano, Qin and Soprano, 2004; Wang et al., 2007).  Wang et al. (2013) 
showed that RA antagonizes the expression of Nrf2 target genes by an interaction 
between RXRα and Nrf2 through an RXRα binding region in Nrf2 designated as 
the Neh7 domain. RXRα repression is likely due to inhibition of the recruitment of 
Nrf2 coactivators. Although not much is known about what domain of RXRα is 
responsible for its inhibitory action and calls for further investigation. 
 
Another group of compounds that inhibit Nrf2 are the some flavonoids, which 
exhibit high anti-proliferating activity and can sensitize cancer cells to anti-cancer 
therapy (Kanadaswami et al., 2005). Epigallocatechin 3-gallate (EGCG) a 
flavonoid found in green tea has been reported to inactivate Nrf2 in non-small-cell 
lung cancer (NSCLC) A549 cells (Kweon et al., 2006). Furthermore 3᾿,4᾿,5,7-
tetrahydroxyflavone (also known as luteolin) was reported to act as a potent and 
selective inhibitor of Nrf2 (Tang et al., 2011). Notably, inhibition of ARE-driven 
gene expression in NSCLC A549 cells by luteolin was found to sensitize the cells 
to treatment with several anticancer drugs such as oxaliplatin, bleomycin and 




Also shown to inhibit Nrf2 activity in pancreatic adenocarcinoma (PDAC) cells is 
trigonelline, a coffee alkaloid identified by (Boettler et al., 2011) to interfere with 
Nrf2 activation by inhibiting the NMP-mediated induction of Nrf2 downstream 
genes. (Arlt et al., 2013) went further to report the repression of Nrf2 activity in 
PDAC cell lines and Human pancreatic duct cell line H6c7 by trigonelline as well 
as decreasing proteasomal activity of Nrf2 resulting in cell apoptosis. 
 
Isoniazid a widely used antitubercular drug has also been shown to inhibit ARE 
activities in human and mouse cell lines. (Chen et al., 2013) reported the inhibition 
of ARE-luciferase activity and mRNA expression levels of several ARE-dependent 
antioxidant genes by isoniazid under both oxidative stressed and basal 






Figure 1.11: Structures of Nrf2 inhibitors. 
Chemical structures of known Nrf2 inhibitors discussed in this thesis. 
 
1.6 Aims of this thesis 
With the constant prevailing incidence in cancer and the role of Nrf2 in prevention 
of cancer, it is important to understand the mechanisms that regulate Nrf2 either 
in non-cancerous cells where Nrf2 has been to shown to antagonize the initiation 
of cancer and in the post-initiation stages of cancer where Nrf2 has been shown 
to support the promotion of cancer. Nrf2 has been shown to be regulated by 
Keap1 via its Neh2 domain and by GSk-3-β-TrCP via its Neh6 domain. The 
regulation by Keap1 has been the focus of several researches and it is believed 
that activation of Nrf2 by ROS or electrophiles is by modification of the key 
cysteine residues found in Keap1. With the knowledge that Nrf2 is also regulated 
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by GSK-3, one question that came to mind was if electrophiles are able to activate 
Nrf2 through the GSK-3-β-TrCP axis as opposed to modulating Keap1. This 
question also comes with the revelation that PI3K inhibitors has been shown to 
block the induction of Nrf2-target genes by several researches (Lee et al., 2001; 
Nakaso et al., 2003). Upstream of GSK-3 is PI3K and so we aimed to see if 
inducers of Nrf2 would regulate Nrf2 via Keap1 or through regulation of the GSK-
3-β-TrCP axis and what role those PI3K play in the induction of Nrf2 by Nrf2 
activators and if it the role of PI3K is dependent on Keap1 or GSK-3 axis of Nrf2 
regulation. The aims of the thesis are therefore: 
1. To study the effect of several inducing agents that activate Nrf2 by inhibiting 
Keap1 and/or the β-TrCP/GSK-3 axis; 
2. To determine the role of PI3K in the induction of Nrf2-target genes; 
3. To determine the mechanism by which chemical inhibitors of Nrf2 suppress its 
activity; 
4. To study the effect of Nrf2 repression on oxidative stress, metabolic pathways, 






2 Materials and methods 
2.1 Materials 
All chemicals and reagents were of high analytical standard and obtained as 
stated in text. SFN was obtained from LKT laboratories (>98% pure) (St Paul, 
Minnesota, USA). tBHQ (≥ 98% pure) was obtained from Sigma-Aldrich (Poole, 
Dorset, UK). LY294002 (≥ 98% pure), MK2206 (≥ 98% pure), PI-103, ferulic acid, 
and CT99021 were obtained from Selleckchem (Houston, USA). Curcumin, 
carnosol and diethyl maleate (DEM) were obtained from Sigma-Aldrich. CDDO-Im 
was obtained from Tocris Bioscience (Bristol, United Kingdom). PTEN inhibitor 
bpv(HOPIC) was obtained from Sigma-Aldrich.   
Dulbecco’s modified eagle medium (DMEM) containing 4.5 g/L glucose, L-
glutamine and pyruvate for cell culture were purchased from Life Technologies Ltd 
(Paisley, Scotland, United Kingdom). Opti-MEM a reduced serum medium 
containing L-glutamine, sodium pyruvate, HEPES and phenol red used for 
transfection was obtained from GIBCO Thermofisher (Paisley, Scotland, United 
Kingdom). Lipofectamine2000 used as transfection reagent was obtained from 
Invitrogen Ltd (Paisley, Scotland, United Kingdom). 
Pre-designed Taqman oligonucleotides containing probe primer set were 
purchased from Applied Biosystems (ABI) Thermofisher. Unmodified 
oligonucleotides used as Taqman primers and probes labeled with a 5ʹ 
fluorescent reporter dye, 6-carboxy-fluorescein phospharamidite (FAM) and a 3ʹ 
quenching dye, 6-carboxy-tetramethyl-rhodamine (TAMRA) designed in-house 
were synthesized and purchased from Eurofins MWG Operon (Anzingerstr, 
Germany). A list of oligonucleotides that have been used as Taqman probes and 
primers are shown in Appendix I & II. Taqman master mix was obtained from ABI 
while Omniscript RT kit used for reverse-transcription of RNA were purchased 
from Qiagen (West Sussex, United Kingdom). Short hairpin RNA (shRNA) for Nrf2 
was purchased from Sigma-Aldrich.  
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Reporter plasmids were designed in-house and are listed in Table 2.1, while 
Mission shRNA used for knockdown experiments were purchased from Sigma-
Aldrich. 
 
Plasmid DNA Promoter Experiment 
pcDNA 3.1 V5 Nrf2 His A CMV Ectopic expression 
pcDNA 3.1 Neh6+-LacZ-V5 
His A 
CMV β-Galactosidase activity 
pRL-TK Renilla  T7 Luciferase assay 
-1016/nqo5ʹ-luc ARE pGL3 Luciferase assay 
TRC2-pLKO-puro U6 shRNA knockdown 
Nrf2∆ETGE pcDNA 3.1 V5 His 
A 
CMV Ectopic expression 
Nrf2∆DSGIS pcDNA 3.1 V5 His 
A 
CMV Ectopic expression 
 
2.2 Mammalian cell culture 
2.2.1 Cell lines 
Rat liver RL-34 cells were purchased from the Japanese Cancer Research 
Resources Bank, HSRRB (Sennan-shi, Japan). AREc32 a stable ARE-reporter 
cell line containing a luciferase gene derived from MCF7 expressing the pGL-
8xARE was designed in-house (Wang, Hayes and Wolf, 2006). Immortalized wild-
type (WT) and Keap1 knockout (Keap1-/-) mouse embryonic fibroblast (MEF) cells 
were generated in-house. Monkey kidney COS1, mouse hepatoma Hepa1c1c7, 
human breast adenocarcinoma MCF7, non-small cell lung cancer (NSCLC) A549 
Table 2.1: Plasmids used in thesis with their promoter and experimental application. 
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and human lung cancer H460 cells were obtained from American Type culture 
collection (ATCC) (Teddington, Middlesex, UK). PTEN wild-type and PTEN 
knockout embryonic stem (ES) cells were kindly donated by Prof Albena Dinkova-
Kostova (originally donated by Dr Nic Lesley). 
2.2.2 Growth medium and cell culture conditions. 
AREc32 cells were maintained in DMEM, supplemented with 10% (v/v) fetal 
bovine serum (FBS) (heat inactivated, Biosera), 1% (v/v) penicillin/streptomycin 
(Pen Strep) (50U penicillin and 50 µg streptomycin) (Life technologies Ltd.) and 
0.8 mg/ml G418 (Sigma-Aldrich).  
WT and Keap1-/- MEF cells were maintained in DMEM supplemented with 10% 
(v/v) FBS, 1% (v/v) Eagle’s minimum essential medium (MEM) non-essential 
amino acids solution (Sigma-Aldrich) and 1% (v/v) Pen Strep.  
COS1, Hepa1c1c7, MCF7, A549 and H460 cells were maintained in DMEM 
supplemented with 10% (v/v) FBS and 1% (v/v) Pen Strep.  
Rat liver RL-34 cells were maintained in DMEM media supplemented with 10% 
(v/v) FBS and 1% (v/v) Pen Strep.  
PTEN wild-type and PTEN knockout embryonic stem (ES) cells were maintained 
in DMEM supplemented in 15% (v/v) pre-screened Hyclone FBS (VWR 
International Ltd) (Hunter Boulevard, Leicestershire, United Kingdom), 1% (v/v) 
100x non-essential amino acids (GIBCO), 1% (v/v) 100x sodium pyruvate 
(GIBCO), 1% (v/v) 100x Glutamine (GIBCO), 1% (v/v) Pen strep, β-
mercaptoethanol (2-ME) (Sigma-Aldrich) and 1:10 of leukocyte inhibitory factor 
(LIF) (Sigma-Aldrich) just before use.  
All cells were cultured at 37oC, 95% air and 5% CO2 in a Heraeus incubator 
routinely and passaged every 3 – 4 days. 
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2.2.3 Passaging of cell lines 
To keep cells alive and growing for extended period of cells, cells were passaged 
when they are 80-90% confluent. The medium in which cells were grown was 
removed and cells were washed with warm phosphate buffered saline (PBS) twice 
after which cells were trypsinized with 1 ml or 3 ml of trypsin (0.05% (v/v) 
(supplemented with ethylenediaminetetraacetic acid (EDTA) (0.05 mmol/l)) 
depending on flask size to allow dissociation of cell monolayer for effective cell 
removal and incubated for 3 min in the incubator. Cells were then collected by 
addition of ten volumes of complete growth media to flask to stop trypsin action 
and transferred to 50 ml falcon tube and centrifuged at 16,000 x g for 3 min at 
room temperature. The resulting pellet was then resuspended in fresh growth 
medium and the cells split into new culture flasks at optimal split ratio that would 
result in 98% growth in 3-4 days either at a ratio of 1:2 or 1:3 for MEF cells and 
1:6 for COS1, RL-34, A549 and H460 cells. 
2.2.4 Seeding of cells 
For experimental purpose, cells were seeded into either 6 cm dishes, 6-well plate, 
12-well plate or 96-well plate. After the cells had been trypsinized and split into a 
new flask, the cell number in the falcon tube was then counted using a 
haemocytometer. Cells were then seeded either into 6-well plate or 60 mm petri-
dishes in complete growth media at a density that would result in ~80% 
confluency approximately 24 hr after seeding, depending on the cell type 
employed. The seeded cells were then grown in the incubator overnight at 37oC 
(16-24 hr) prior to treatment. 
2.2.5 Treatment of cells 
To check the effect of inducers or kinase inhibitors on cells, cells that had been 
seeded as described in section 2.2.4 above were either replaced with fresh 
complete growth media containing the desired xenobiotic or reduced serum media 
(i.e. containing 1% FBS) for 16 hr for experiments involving GSK-3 and the Neh6 
domain of Nrf2. After the 16 hr nutrient-depletion, the cells were treated with the 
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desired inducing agents, kinase inhibitors for the required time period depending 
on the experiment. Drugs and dose used in experiments are listed in Table 2.2.  
 
Drugs Manufacturer Catalogue 
number 
Function Dose Used 
SFN LKT laboratories S8044 Nrf2 activator 5 µM 
tBHQ Sigma-Aldrich 8414240 Nrf2 activator 50 µM 
Curcumin Sigma-Aldrich C1386 Nrf2 activator 15 µM 
Carnosol Sigma-Aldrich 49702 Nrf2 activator 10 µM 
DEM Sigma-Aldrich O7553 Nrf2 activator 100 µM 
CDDO-Im Tocris Bioscience 4737/10 Nrf2 activator 100 nm 
Ferulic acid Selleckchem S2300 Nrf2 activator 10 µM 
LY294002 Selleckchem S1105 PI3K inhibitor 10 µM 
PI-103 Selleckchem S1038 PI3K inhibitor 1 µM 
MK2206 Selleckchem S1078 Akt inhibitor 5 µM 
CT99021 Selleckchem S1263 GSk-3 inhibitor 5 µM 
bpv(HOPIC) Sigma-Aldrich SML0-884 PTEN inhibitor 10 µM 
GSK690693 Selleckchem S113 Akt inhibitor 1 µM 
 
Table 2. 2: List of drugs in experiment. 
Drugs used in treating cells during experiment is listed with manufacturer and catalogue number 
described. Doses used were set from dose response treatment on cell line tested except 
otherwise stated. Cells were treated with 50 µM as previous experiments in the laboratory showed 
tBHQ gave the best activation of Nrf2 at this dose. Dose used for SFN was determined from 
previous research published in the laboratory (Chowdhry et a., 2013). Drugs were made up in 
DMSO and stored at -20oC. 
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2.2.6 Preparation of frozen cell stocks 
To store cells for future use and backup in case of contamination or loss of 
supply, cells are cryopreserved when they are at their maximum growth rate. Cells 
that had been trypsinized and pelleted, as described in section 2.2.3, were 
resuspended in freezing media containing 90% (v/v) FBS and 10% (v/v) dimethyl 
sulfoxide (DMSO) at a concentration of 1 x106 cells/ml aliquots in cryotubes 
(Nalgene Nunc International Corp, Naperville, USA) and stored at -80oC overnight 
in a cryo-freezing container containing isopropanol to ensure slow freezing before 
they were transferred to liquid nitrogen for long term storage. 
2.3 Preparation of stock solutions 
Buffers used for preparation of samples for electrophoresis were made and stored 
as described below. 
2.3.1 Kinase lysis buffer 
Kinase lysis buffer used for lysing and breaking open cell membrane for extraction 
of protein from cells was made following: 10% (w/v) sucrose, 50 mmol/l Tricine-
hydrochloride (Tris-HCl) pH 7.5, 1 mmol/l  EDTA pH 8.0, 1 mmol/l ethylene glycol 
tetraacetic acid (EGTA) pH 8.0, 2 mmol/l sodium vandate (Na2VO3), 10 mmol/l 
glycerophosphate, 25 mmol/l sodium fluoride (NaF), 5 mmol/l sodium 
pyrophosphate (NaP2O5), and 1% (v/v) nonidet P-40 (NP-40), made up to a total 
volume of 100 ml.  
2.3.2 RIPA lysis buffer 
RIPA lysis buffer used for lysing cell for GSK-3 catalytic activity assay was made 
following: 50 mmol/l Tris-HCl pH 7.4, 150 mmol/l sodium chloride (NaCl), 1% (v/v) 
NP-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulfate 
(SDS) and 1 mmol/l EDTA, made up to a total volume of 100 ml.  
70 
 
2.3.3 5x Laemmeli protein sample loading buffer 
This comprised the following: 100 mmol/l Tris-HCl pH 6.8, 20% (v/v) glycerol, 4% 
(w/v) SDS, 3.6 M β-mercaptoethanol, 0.05% (w/v) Bromophenol blue, made up to 
a total volume of 9 ml. The buffer was stored at -20oC until required. 
2.3.4 10x SDS-PAGE running buffer 
This comprised the following: 192 mmol/l glycine, 25 mmol/l Tris-HCl, 0.1% (w/v) 
SDS, made up to a total volume of 1000 ml. 
2.3.5 10x SDS-PAGE transfer buffer 
This comprised the following: 192 mmol/l glycine, 25 mmol/l Tris-HCl, 20% (v/v) 
methanol (MeOH) and 0.01% (w/v) SDS, made up to a total volume of 1000 ml 
and stored at 4oC prior to use. 
2.3.6 Tris-buffered saline tween-20 (TBST) washing buffer 
This compromised the following: 50 mmol/l Tris-HCl, 150 mmol/l NaCl and 0.25% 
(v/v) Tween-20. 
2.3.7 Enhanced chemiluminescence (ECL) solution 
Detection of protein after electrophoretic separation and immunoblotting was 
carried out using 1:1 dilution of ECL 1 and 2. 
ECL solution 1: 100 mmol/l Tris-HCl pH 8.5, 2.5 mmol/l Luminol (Fischer 
Scientific, Bishop Meadow road, Loughborough, United Kingdom), 0.4 mmol/l ρ-
coumaric acid (Sigma-Aldrich). 
ECL solution 2: 100 mmol/l Tris-HCl pH 8.5, 0.02% (v/v) H2O2 (Sigma-Aldrich).  
A final working solution of 1:1 ratio of ECL solution 1 and ECL solution 2 was 
made just before use.  
2.4 Protein quantification 
The amount of protein in cell lysates was quantified using the DC protein assay 
(Bio-Rad, California, USA). The DC protein assay is a colorimetric based assay 
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that measures the interaction of protein in cell lysates with alkaline copper tartrate 
solution (reagent A) and Folin reagent (reagent B) (Lowry, 1951; Lowry et al., 
1951). A standard working solution containing 20 µl of surfactant solution (reagent 
S) in every 1 ml of reagent A was prepared according to the manufacturer’s 
protocol. The mixture was vortexed and 100 µl aliquoted into a cuvette. Test 
samples and standard (4 µl each) were added to it before addition of 800 µl of 
reagent B and incubated in the dark for 15 min. The absorbance at 750 nm was 
then read using a spectrophotometer. Concentration of test samples were 
extrapolated from a set of standards containing known concentration of bovine 
serum albumin (BSA): these are 0.125, 0.25, 0.5, 0.75, 1.0 and 2.0 µg/ml). 
Samples and standards were analysed in triplicate.      
2.5 Sample preparation for electrophoresis 
Cells that had been treated with xenobiotics were washed twice in ice-cold PBS 
and lysed either in ice-cold RIPA buffer or kinase lysis buffer depending on the 
downstream analysis containing protease inhibitor tablet (Sigma-Aldrich) per 10 
ml of lysis buffer. The lysate was then centrifuged at 17,000 x g for 10 min at 4oC 
to separate cell debris using the microCL 17R centrifuge (Thermoscientific). The 
resulting clear supernatant was then transferred to 1.5 ml Eppendorf tubes and 
either stored on ice for immediate analysis or flash freeze and stored at -80oC for 
storage for later analysis. The concentration of protein in lysates was measured 
using detergent compatible (DC) protein assay according to manufacturer’s 
protocol. The samples were normalized to equal amount by diluting in 5x 
Laemmeli protein sample loading buffer and 1:10 of lysis buffer before they were 
run in sodium dodecyl sulphate (SDS) gels. For NuPAGE gels, samples were 
normalized by diluting in 4x lithium dodecyl sulphate (LDS) buffer (Invitrogen), 10x 
sample reducing agent (Invitrogen) and 1:10 of lysis buffer. Samples were boiled 
for 10 min in 100oC heating block. 
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2.6 Western blotting 
2.6.1 SDS-Polyacrylamide gel electrophoresis (PAGE) 
Proteins in cell lysates were separated electrophoretically by SDS-PAGE using 
the Bio-Rad Mini-protein 11 cell electrophoresis system according to the Laemmli 
discontinuous electrophoretic method (Laemmli, 1970). Using this method, 
proteins are separated based on size with smaller sized proteins migrating faster 
towards the anode with the aid of the denaturing properties of SDS (Peek and 
Williams, 2001; Bonifacino, 2011; Gallagher, 2012; Madigan et al., 2012). 
Separated proteins were transferred to a membrane that produces a band for 
each protein which will be visualized by binding to antibody that is specific to the 
protein of interest (Mahmood and Yang, 2012).  
2.6.1.1 Polyacrylamide-gel electrophoresis 
Polyacrylamide gels were made following the composition shown in Table 2.3 to 
contain two different layers, a lower resolving gel containing 375 mmol/l Tris-HCl 
pH 8.8 that allows separation of protein into different sizes and an upper stacking 
gel containing 126 mmol/l Tris-HCl pH 6.8 that allows samples to stack into a 
single sharp band. The percentage of the polyacrylamide stacking gel made was 
always 5% (w/v), however, based on the molecular weight of the protein of 
interest, different polyacrylamide percent gels were made for the resolving gel 
with a high molecular weight protein ran in a lower percent gel and a lower 
molecular weight protein ran in a higher percent gel. Polymerization of 
polyacrylamide gels is based on copolymerization of acrylamide and bis-
acrylamide initiated by ammonium persulfate (APS) and 
tetramethylethylenediamine (TEMED). All components of the gel solutions were 
added first with the exception of TEMED that was added just before pouring into 
glass plates (1.5 cm) and allowed to set. In this process, the rate of formation of 
free radicals from persulfate is accelerated by TEMED that in turn catalyzes the 
polymerization of the gel (Chrambach and Rodbard, 1971; Allison, Agrawal and 
Moore, 1974; Chrambach et al., 1976). 
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Equal amount of protein samples extracted from cell lysates normalized with 5x 
Laemmeli protein sample loading buffer and 1:10 of lysis buffer were loaded into 
SDS gels alongside prestained standard protein marker (Invitrogen). The gels 
were run for 100 V for 10 min and 196 V for 1 hr in gel running tank containing 1x 
gel running buffer. 
 
Solution components Resolving gel  Stacking gel  
30% acrylamide mix (6%, 8%, 10%, 12% and 
15%) (v/v) 
(5%) v/v 
Tris-Cl 375 mmol/l pH 8.8 126 mmol/l pH 6.8 
10% SDS 0.1% (w/v) 0.1% (w/v) 
10% ammonium 
persulphate 
0.1% (w/v) 0.1% (w/v) 





2.6.1.2  NuPAGE gel electrophoresis 
Nupage Novex (4-12%) Bis-Tris Midi gels (Life technologies Ltd), are precast 
polyacrylamide gels designed for optimal separation of proteins and were used for 
Table 2.3: Polyacrylamide gel composition. 
A table showing the composition of individual components used in preparing resolving and 




examination of a larger number of samples in parallel using gels with 20 or 26 
wells. Samples were normalized to approximately 1 µg protein/µl using 4x LDS 
buffer, 10x sample reducing agent and 1:10 protein lysis buffer as outlined above. 
An equal volume of each sample was then loaded into 4-12% precast gradient 
gels alongside pre-stained protein marker and separated by electrophoresis using 
1x MOPS (Invitrogen) buffer at 100 V for 1 hr.   
 
2.6.2  Wet transfer of electrophoretically resolved proteins 
Resolved proteins in gels were transferred onto ImmobilonTM polyvinylidene 
difluoride (PVDF) membranes (MerckMillipore, Watford, Hertfordshire, United 
Kingdom) with a pore size of 0.45 µm that had been presoaked in methanol using 
the Bio-Rad Mini trans-Blot system following manufacturer’s wet transfer protocol. 
A transfer sandwich containing sponge, 3 filter papers, gel, PVDF membrane, and 
another 3 filter papers locked within a transfer cassette was made and placed in 
the transfer tanks. Transfer was carried out using 1x ice-cold transfer buffer at 
100V for 45 min maintaining an even temperature throughout either by placing the 
apparatus on ice or placing ice packs in the transfer tanks. 
 
2.6.3 Immunoblotting 
Following transfer of protein, the PVDF membrane was immersed in blocking 
buffer (5% (w/v) non-fat dry milk in TBST for regular antibodies, or 5% (w/v) of 
BSA/TBST phosphoprotein antibodies) for 1 hr with continuous shaking to 
saturate unbound membrane surface thereby preventing non-specific antibody 
binding. Next, the membranes were incubated with a dilution of primary antibody 
against the protein of interest overnight at 4oC. For experiments involving more 
than one protein of interest, membrane is cut at band size corresponding to the 
protein of interest before placing in appropriate primary antibody. After primary 
antibody incubation, membranes were washed three times every 5 min with TBST 
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at room temperature to remove unbound primary antibody. Thereafter, the PVDF 
membrane was incubated with a horseradish peroxidase (HRP)-conjugated 
secondary antibody that recognizes immunoglobulin G (IgG) on the primary 
antibody and binds to it for 1 hr at room temperature with continuous shaking. 
This was followed by another TBST wash (3 times for 5 min and twice for 10 min) 
at room temperature to remove any unbound secondary antibody. A list of 
antibodies and their specificity is provided in Appendix III. Secondary antibody 
was made up in 5% (w/v) dried skimmed milk in TBST in a 1: 3000 dilution.  
Visualization of bound protein was carried out by exposure of membrane to 1:1 
ratio of ECL solution and ECL solution 2 mixture evenly to cover entire surface of 
the membrane for 30 seconds before exposure to autoradiograhic X-ray film 
(Konica Minolta medical and Graphic, Inc, Banbury, United Kingdom) (in the dark) 
and developed from the compact X4 Xograph. Films were scanned using the 
Canon Inkjet MP980 series and protein bands edited using the Fotor and ImageJ. 
2.7 shRNA knockdown  
Short hairpin RNA (shRNA) obtained from Sigma-Aldrich called mission shRNAs, 
used to manipulate gene expression via RNA interference. Bacterial cultures were 
amplified from glycerol stocks of five Mission shRNA bacterial glycerol stocks 
harboring verified sequence (Table 2.4) for the human NFE2L2 gene cloned into 
pLKO.1-puro vector used in purification of shRNA plasmid DNA. Subsequently, 
A549 and H460 cells were transfected with purified plasmid to generate stable 










































Table 2.4: Mission shRNA plasmids. 
List of mission shRNA plasmids and their sequences used in generation of a stable Nrf2 knockdown in 




2.7.1 Culturing Clonal Cells 
Using a sterile loop, 100 µl of frozen Mission shRNA glycerol stock (Sigma-
Aldrich) was added to falcon tube containing 500 µl of Luria-Bertani (LB) broth 
without antibiotics and incubated at 37oC with shaking for 30 min. A portion of the 
culture (50 µl) was streaked onto LB agar plates containing 100 µg/ml carbenicillin 
(Sigma-Aldrich) and incubated overnight at 37oC in a humidified incubator. 
Individual colonies were then picked and purified according to section 2.6.2. 
2.7.1.1 Transformation of E.coli cells with plasmid DNA 
Supercompetent dH5α cells (Thermofisher) were used for transformation of 
plasmid DNA. Purified plasmid DNA (2 µg) was transformed in 50 µl of E.coli cells 
by incubation on ice for 30 min and then heat-shocked at 42oC for 45 sec and 
incubated for an additional 2 min on ice. Next the cells were incubated at 37oC for 
1 hr in an orbital shaker after addition of 500 µl of super optimal broth (SOC) 
media before they were plated onto LB agar plates containing 50 µg/ml ampicillin 
(Sigma-Aldrich) and grown overnight in a humidified incubator at 37oC. 
2.7.1.2 Preparation of frozen glycerol stock 
Bacterial culture grown overnight was aliquoted into a cryotube into which 50% 
(v/v) glycerol was added and stored at -80oC. 
2.7.2 Purification of plasmid DNA 
A single colony isolated from LB agar plates was picked and grown in LB medium 
supplemented with appropriate antibiotic and incubated for 8 hr at 37oC in an 
orbital shaker. The resulting bacterial broth (500 µl) was added to 300 ml of LB 
broth containing appropriate antibiotic and incubated overnight at 37oC in an 
orbital shaker. Next morning, bacterial cells were harvested by centrifugation at 
6000 x g for 15 min at 4oC. The supernatant was then discarded and plasmid 
DNA isolated from the pellet using the QIAfilter Maxiprep Kit (Qiagen Ltd) 
following manufacturer’s protocol. 
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2.7.3 Quantification of plasmid DNA 
Isolated plasmid DNA was quantified using a spectrophotometer at 260 nm. 
2.7.4 DNA sequence analysis 
DNA plasmid used as template alongside forward and reverse primers was used 
for sequencing using capillary electrophoresis. Identification of the sequence of 
isolated plasmid DNA was carried out in the DNA sequencing laboratory by Dr 
Andrew Cassidy based in the Division of Molecular and Cellular Pathology, 
Ninewells Hospital, UK using the 3500XL platform.   
2.7.5 Transfection of cells 
Mission shRNA and other plasmid DNA used in manipulation of cells (Table 2.1) 
were transfected using Lipofectamine2000® reagent (Invitrogen). Cells were 
seeded into a 6-well plate at a concentration that would ensure 70-80% 
confluency after overnight incubation in a humidified 37oC and 5% CO2 incubator. 
Transfection was carried out by a two-step reaction in polystyrene tubes. The first 
step reaction involved mixing 4 µl of Lipofectamine2000® in 100 µl of Opti-MEM 
media for each well and incubated at room temperature for 12 min in the dark. 
The next step reaction involved a mixture of 1- 3 µg of plasmid DNA in 100 µl of 
Opti-MEM per well in a separate tube. Once incubation of the first reaction was 
complete, 100 µl of it was added to the second reaction and incubated for 15 min 
at room temperature in the dark. Next, growth media was removed from cells, 
washed with 1x PBS before 800 µl of Opti-MEM was added to each well. Once 
incubation of step 1 and 2 mixture was complete, 200 µl of it was added drop-wise 
to cells and incubated in a humidified 37oC and 5% CO2 incubator for 4-5 hr. 
Thereafter, cells were replaced with 2 ml of fresh 10% FBS DMEM media and 
incubated for a further 24 hr in a humidified 37oC and 5% CO2 incubator until 
further analysis.  
For generation of stable shRNA Nrf2-knockdown cells, cells were trypsinized after 
24 hr transfection and transferred to a 10 cm dish before 2 µg of puromycin was 
added (a dose which had been shown to previously kill 100% of untransfected 
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cells). Transfected A549 and H460 cells were allowed to grow until colonies 
began to form with constant changing of media and addition of fresh puromycin 
every 48 hr. Once they are visible to the naked eye, colonies were picked using 
cloning cylinder (Sigma-Aldrich) by drawing around each colony with a non-
permanent marker and aspirating off the media and replacing it with PBS to wash 
colonies. Next a cloning cylinder was placed over each colony and 100 µl of 
trypsin was added and incubated for approximately 1 min to loosen cells, before 
they were transferred to a 24-well plate containing 1 ml of 10% FBS DMEM media 
and adding 2 µg of puromycin and allowed to grow until they become confluent. 
Once confluent, cells were moved up to a 6-well plate and subsequently to a small 
flask. Success of knockdown was assayed by western blot and Taqman analysis. 
2.7.6 Kill curve 
To determine an appropriate concentration of puromycin to be used during 
generation of stable NRF2-knockdown cells, the parental A549 and H460 cells 
were seeded into 6-well plates at a density of 4 x 105 cells per well in 10% FBS 
DMEM media and incubated overnight in a humidified 37oC and 5% CO2 
incubator. The following day, a range of puromycin concentrations (i.e. 0 µg, 1 µg, 
2 µg, 5 µg, 7 µg and 10 µg) was added and cells were allowed to grow for 10 
days. Using the microscope, the minimum concentration of puromycin required to 
kill off all the cells in the plate in a specific period of time was determined. The 
ideal concentration required would be the lowest concentration of puromycin that 
would kill off all the cells on the plate in the shortest possible time.     
2.8 Colony formation assay 
A549 cells were seeded in a 10 cm dish at a seeding density of 250 cells/dish. 
Cells were allowed to grow in 37oC, 5% CO2 incubator in 10% FBS DMEM media 
for about 2- 3 weeks till individual colonies started to form. Cells were fed twice 
every week with fresh 10% FBS DMEM media. Once individual colonies were 
visible, cells were washed with ice-cold PBS twice and fixed with 3 ml of methanol 
for 10 min in a rocker. After fixation was complete, cells were stained in 1:1 
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solution of 2% toludine blue O (Sigma-Aldrich) and 2% borax solution (sodium 
tetraborate decahydrate, Sigma-Aldrich) for 5 min on a rocker before the stain 
was washed off and the dish dried.       
2.9 Measurement of glutathione  
2.9.1 Monochlorobimane-based assay to measure reduced 
glutathione 
Monochlorobimane forms fluorometric reduced glutathione (GSH)-mCB adducts 
from intracellular glutathione S-transferase that can be measured using a 
microplate reader (Kamencic et al., 2000). After treatment with xenobiotics, cells 
were washed with PBS twice to remove drugs that might interfere with the assay. 
To measure GSH, a 240 μM stock solution of monochlorobimane (mCB, Sigma-
Aldrich) was prepared in sterile PBS and diluted to working solution of 40 μmol/l in 
1 ml PBS. Cells were incubated at room temp for 10 min and the fluorescence 
measured at 490 nm every 10 min for 40 min at excitation of 390 nm using the 
SpectraMax M2 plate reader (Molecular Devices, San Jose, California, United 
States).  
2.9.2 Modified Tietze assay to measure total and reduced 
glutathione  
Total glutathione levels were measured by a method based on the Tietze assay 
(Tietze, 1969) that has subsequently been modified by others. (Griffith, 1980; 
Rahman, Kode and Biswas, 2007). The assay is based on the reaction between 
oxidized glutathione (GSH) and 5,5′-dithio-bis(2 nitrobenzoic acid (DTNB) to 
produce the yellow derivative 5′-thio-2-nitrobenzoic acid (TNB) at a peak 
absorbance of 412 nm that is proportional to the concentration of GSH in the 
samples (Rahman, Kode and Biswas, 2007). In the presence of NADPH, 
glutathione adduct of GSH (GS-TNB) is reduced to GSH akin to oxidized 
glutathione (GSSG) by glutathione reductase (GR). The GSSG formed is reduced 
to 2GSH by GR and the amount of glutathione measured is equal to the sum of 
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reduced and oxidized glutathione in the sample (Rahman, Kode and Biswas, 
2007). 
[GSH]total = [GSH] + 2 x [GSSG]. 
 Cells were seeded in 10 cm dish till they were about 60% confluent on the day of 
assay and treated as described in section 2.2.5. Cells were washed with warm 
PBS twice and trypsinised. The cell pellet was harvested by centrifuging for 3 min 
at 1000 x g at 4oC. Resulting pellets were washed with 1 ml ice-cold PBS to 
remove any remaining culture media and centrifuged again for 3 min at 1000 x g 
at 4oC, before the final cell pellet was resuspended in 250 μl 0.25 M sucrose and 
a 50 μl aliquot of the suspension was kept aside for protein estimation. A 200 μl of 
2x extraction buffer (1.2% (w/v) 5-Sulfoslicyclic acid, 0.2% (v/v) Triton X-100, 
0.2% (v/v) NP-40, 0.2 M potassium phosphate buffer pH 7.5, 10 mmol/l EDTA) 
was added to the cell solution and centrifuged at 3000 x g for 4 min at 4oC. The 
supernatant was removed and used to measure the ratio of reduced glutathione 
(GSH) to oxidized glutathione (GSSG). 
Samples for GSSG were prepared by adding 6 μl of 10% (v/v) 2-vinylpyridine/1 x 
KPE buffer (0.1 M potassium phosphate, 5 mmol/l EDTA) to 250 μl samples and 
incubated at room temperature for 1 hr. Thereafter, 18 μl of 16% 
triethanolamine/1 x KPE buffer was added and incubated for 10 min at room 
temperature to quench excess 2-vinylpyridine. Serial dilutions of a stock solution 
of GSSG were made in standard buffer (0.125 M sucrose, 1 x extraction buffer, 
0.2% 2-vinylpyridine, 1% triethanolamine) to give standards of 26.4, 13.2, 6.6, 3.3, 
1.65, 0.825 and 0.4125 µmol/l GSSG to calibrate the assay. Into a sterile 96-well 
plate, 50 μl of spiked GSSG standard and samples were added in triplicate to 
wells and 40 μl of GSSG standard buffer was added to each well. A 20 μl portion 
of the resulting sample mixture was then dispensed into a new 96-well plate in 
triplicate to which were added 60 μl of DTNB (0.66 mg/ml stock solution) and 60 
μl of glutathione reductase (GR) solution (3 units/ml). These mixtures were 
incubated at room temperature for 2 min, after which, 60 μl of β-NADPH solution 
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(0.66 mg/ml) was added and the velocity (change in OD at 412/min) of the 
reaction was measured immediately using the SpectraMax M2 plate reader 
immediately.  
Total GSH was measured by adding 50 μl of spiked GSH standard (26.4, 13.2, 
6.6, 3.3, 1.65, 0.825 and 0.4125 µmol/l in GSH standard buffer (0.125 M sucrose, 
1 x extraction buffer)) to 40 μl of GSH standard buffer and 10 μl GSH sample 
lysates. A 20 μl portion of the resulting sample mixture was dispersed into sterile 
96-well plate in triplicate. Thereafter, 60 μl of DTNB solution and 60 μl of GR 
solution were added to it. Incubated at room temperature for 2 min, after which, 60 
μl of β-NADPH solution was added and read immediately in the plate reader at 
412 nm.  
Protein concentration was measured for samples and the total GSH and GSSG 
concentrations was calculated using Excel software using increment and slope 
from standard curve, accounting for protein concentration. 
2.10 Analysis of mRNA expression  
2.10.1 Extraction of total RNA from cells 
Cell cultures treated with xenobiotics or gene knockdown were washed with ice-
cold PBS twice and 40 µl/cm2 of buffer RLT (guanidine thiocyanate) containing 
1% (v/v) β-mercaptoethanol (2-Me) was added to cells and used to lyse and 
homogenize cells before they were scraped into Qiashredder and placed in a 2 ml 
collection tube and centrifuged at maximum speed for 3 min. Thereafter, 70% 
(v/v) ethanol was added to the supernatant, mixed and transferred into RNeasy 
mini spin column and centrifuged for 15 sec at 800 x g. The total RNA from cells 
was extracted using the RNeasy Mini Kit (Qiagen) according to manufacturer’s 
protocol. Isolated RNA was quantified and used for analysis or stored at -80oC for 
further analysis.  
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2.10.2 Quantification of RNA 
The total amount of isolated RNA was quantified by measuring the absorbance at 
260 nm (A260) based on the peak absorbance of ultraviolet (UV)-visible light 
emission using an ultrospec 2100 pro UV/UV spectrophotometer (Amersham 
Biosciences, Amersham, Buckinghamshire, United Kingdom). Concentration of 
RNA in samples is directly proportional to the absorbance at 260 nm based on the 
Beer-Lambert law. 
A = εcl 
Where A = absorbance, ε = extinction coefficient, c = concentration and l = path 
length. The measure is done at 260 nm because nucleic acid absorbs at UV light 
at 260 nm.  
2.10.3 Reverse-transcription of RNA 
Extracted RNA was reverse transcribed to complementary DNA (cDNA) using the 
Omniscript reverse transcription kit (Qiagen Ltd) following the manufacturer’s 
protocol.  
2.10.4 Quantitative real-time PCR (Taqman) 
The abundance of mRNA levels of gene of interest was measured using the 
Applied Biosystems 7500 fast real-time PCR system. Two primers (forward and 
reverse) and a probe that is specific to each gene plus transcribed cDNA were 
used according to manufacturer’s protocol. Samples were run in triplicate with the 
reaction occurring at 50oC for 2 min; 95oC for 10 minutes and then 40 cycles of 
95oC for 15 sec and 60oC for 1 min (Figure 2.1) and fluorescence measured at 
518 nm and excitation at 494 nm. The threshold cycle (CT) of each gene is 
reversely proportional to the amount of target molecules in the reaction (Xia et al., 
2010). The result obtained is normalized against mRNA levels of β-actin as 
internal control. It is important to note that result Taqman gene expression profile 
were analysed using the DataAssistTM-Data analysis software that filters outliers 
among replicates and normalizes the CT of test samples using a single 
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endogenous control which in this case is the CT of control or WT samples, thus 
control will always be set at zero and no error bars assigned. 
 
 
Figure 2.1: Thermo cycler settings for Real-time PCR 
Stages in the thermocycler for real-time PCR showing the different stages and their corresponding 
temperature and time in each stage. 
 
2.11 Luciferase reporter assay 
ARE reporter gene expression of RL-34 cells or cells transfected with -
1016/nqo5ʹ-luc reporter plasmid were analyzed using the luciferase reporter assay 
system (Promega). 
 
2.11.1 Dual luciferase assay 
COS1 or Keap1-/- MEF cells were seeded into 6-well plates and transiently 
transfected with mouse Nqo1 luciferase plasmid cloned into pGL3-Basic 
luciferase reporter vector (Nioi et al., 2003) and pRL-TK Renilla luciferase reporter 
plasmid 24 hr after seeding. Following recovery from transfection, cells were 
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serum-deprived for 16 hr in 1% FBS media prior to treatment with xenobiotics for 
18 hr.  Cells were washed with ice-cold PBS twice, lysed with 1x passive lysis 
buffer (Promega), vortexed briefly for 15 sec and centrifuged at 16,000 x g for 5 
min at 4oC. The resulting supernatant was transferred to a new tube and placed 
on ice for subsequent analysis using the Promega Dual-luciferase Reporter assay 
system that measures the activities of firefly and Renilla luciferase sequentially 
from a single sample (McNabb, Reed and Marciniak, 2005). The luciferase assay 
was performed by aliquoting 20 µl of cell lysate into a 96-well flat bottom 
microplate (Greiner bio-one, Stonehouse, Gloucestershire, United Kingdom) and 
100 µl of luciferase assay reagent II (LAR II). Luciferase activity was measured 
using the GloMax® 96 Microplate Luminometer with Dual injectors (Promega). 
Injectors were set to dispense 100 µl of LAR II and stop & Glo® reagent 
respectively with a 2 sec delay and a 10-sec read time. LAR II measures the firefly 
luciferase while the stop & Glo® reagent quenches firefly luminescence while 
activating Renilla luciferase. The activity of firefly luciferase is normalized to the 
activity of the control Renilla luciferase. 
2.11.2  Single luciferase assay 
For experiments with RL-34 cells expressing the pGL-8xARE, cells were seeded 
into 6-well plates and allowed to grow overnight. Thereafter, cells were serum 
deprived in 1% FBS DMEM media for 16 hr before treatment with xenobiotics for 
18 hr. Cells were lysed using 1x passive lysis buffer and luciferase assay was 
performed following a similar procedure as described in section 2.11.1 except a 
single injector dispensing 100 µl of LAR II was used. Luciferase results were 
normalized to protein concentration of samples determined by DC protein assay.   
2.12 β-Galactosidase (β-gal) activity assay 
COS1 cells were seeded into 6-well plate and allowed to grow overnight. Cells 
were then transfected with pcDNA3.1/Neh6+(lacZ)-V5 fusion protein and allowed 
to grow overnight. Once cells had recovered from transfection, they were serum 
depleted in 1% FBS DMEM media for 16 hr before treatment with different 
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inducers or inhibitors for 18 hr. Once treatment was complete, media was 
removed from cells and washed with ice-cold PBS twice. Cells were lysed by 
addition of 1x Reporter lysis buffer (RLB, Promega) to each well and incubated for 
15 min at room temperature with constant rocking. Cells were then scraped and 
transferred into labeled microcentrifuge tubes, vortexed briefly for 15 sec and 
centrifuged at maximum speed for 5 min at 4oC. The resulting supernatant was 
transferred into a fresh tube and assayed directly. β-gal assay was carried out 
using the β-galactosidase enzyme assay system (Promega) that measures the 
levels of active β-gal expressed in cells expressing the lacZ plasmid. β-
galactosidase assay is a colorimetric assay that is based on the hydrolysis of 
ortho-nitrophenyl-β-D-galactopyranoside (ONPG) to ortho-nitrophenyl (ONP) 
anion producing a bright yellow colour at 420 nm that can be quantified with a 
spectrophotometer (Figure 2.2) (Held, 2007).  
Lysates were diluted by addition of one part of 1x RLB to two part of lysates and 
50 µl of diluted lysates were transferred to 96-well plate and 50 µl of 2x assay 
buffer containing ONPG (Promega) was added to each well and incubated for 30 
min at 37oC. Reactions were stopped by addition of 150 µl of 1 M sodium 
carbonate, mixed carefully avoiding bubbles and read at 420 nm using the plate 
reader (SpectraMax M2, Molecular Devices). A standard curve containing known 
concentrations of β-gal (0, 1.0, 2.0, 3.0, 4.0, and 5.0 µmol/l) was obtained 
alongside and the activity of β-gal in samples were extrapolated from it. As an 
internal control, pRL-TK Renilla luciferase reporter plasmid was transfected 
alongside Neh6+(lacZ)-V5 protein and luciferase activity measured as described in 




Figure 2.2: Equation of reaction for β-galactosidase 
β-galactosidase catalyses the enzymatic conversion of ONPG to ONP and galactose at a peak 
absorbance of 420 nm.  
2.13 Measurement of ROS 
Measurement of ROS by DCFH-DA is based on the ability of the compound to 
penetrate cell monolayer where it is de-esterified to 2ʹ, 7ʹ, dichlorofluorescein 
(DCFH) by intracellular esterases. The presence of ROS in cells causes a further 
oxidation of DCFH to dichlorofluorescein (DCF), a highly fluorescent dye that 
emits green fluorescence upon excitation at 488 nm that is proportional to the 
levels of intracellular ROS found in cells (Hipler et al., 2002; Sarkar et al., 2006; 
Wei et al., 2010). A549 and H460 WT and Nrf2 knockdown A549 and H460 cells 
were seeded into 6-well plate at a seeding density of 400,000 cells/well in 10% 
FBS DMEM media and allowed to grow overnight in the incubator. Thereafter, 
cells were washed twice with 1x PBS and the stable non-fluorescent cell 
permeable dye 2ʹ,7ʹ- dichlorfluorescein- diacetate (DCFH-DA) (Sigma-Aldrich) 
dissolved in DMSO to a final concentration of 10 µmol/l was added to cells in 2 ml 
of Hanks balanced salt solution (HBSS) (Sigma-Aldrich) and incubated for 30 min 
at 37oC in the dark. Cells were then washed with 1x PBS twice and the 
fluorescence measured immediately using the plate reader (SpectraMax M2) at 
excitation of 488 nm, 538 nm emission and cut off of 530 nm. After plate was 
read, cells were quickly lysed in RIPA lysis buffer and the concentration of protein 
measured using the DC protein assay (Section 2.4). Fluorescence results were 
normalized against protein concentration. 
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2.14 Measurement of cytotoxicity  
Cytotoxicity in cell culture as a result of knockdown of Nrf2 was measured using 
the CellToxTM Green cytotoxicity assay (Promega) that measures the change in 
cell membrane integrity as cells begin to dye death using cyanine dye. The dye 
binds to DNA in dead cells producing a fluorescence that is proportional to the 
number of dead cells in cell culture and no fluorescence signal for cells that are 
alive (Chiaraviglio and Kirby, 2014). A549 WT and shRNA Nrf2 knockdown A549 
cells were seeded into 12-well plates in triplicate at a seeding density of 1 x104 
cells/well and incubated at 37oC, 5% CO2 incubator in 10% FBS DMEM media for 
a period of 10 days. Next day, CellToxTM green dye was added to cell at a 
concentration of 10 µl/5 ml (1:500) and incubated for 15 min in the dark and 
fluorescence measured at 485 nm excitation, 520 nm emission using the Essen 
Incucyte Zoom (Essen Bioscience). Fluorescence was measured every 48 hr with 
fresh media containing CellToxTM green dye added. 
2.15 Measurement of cell Proliferation   
Cell proliferation was measured using the Essen Incucyte Zoom (Essen 
Bioscience) that allows time lapse live cell imaging. A549 and H460 WT and Nrf2 
kd cells were seeded at 1 x 104 cells/well into 12-well plate in triplicate and 
incubated overnight at 37oC, 5% CO2 incubator. Plates were scanned in the 
Incucyte Zoom and allowed to continue growing for another 10 days with 
continuous scanning every 48 hr. The percentage confluency of cells as they 
grow was recorded. 
2.16 Measurement of PTEN  
Quantitative measurement of PTEN protein in cell was carried out by Simplestep 
enzyme-linked immunosorbent assay (ELISA)® kit (Abcam) that employs an 
affinity tag labeled capture antibody and a reporter conjugated detector antibody 
which allows for immunocapture of sample analyte in solution (Abcam). The assay 
directly the phosphoinositide product and the signal is inversely proportional to the 
amount of phosphoinositide (4,5) phosphatase produced (Abcam). Keap1-/- MEFs 
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were seeded into 6 cm dishes and grown in 10% FBS DMEM media at 37oC, 5% 
CO2 incubator for about 16 – 24 hr overnight. Cells were treated with electrophiles 
for 18 hr. Growth media was removed and rinsed with chilled 1x PBS twice. Cells 
were solubilized by addition of chilled 1x cell extraction buffer PTR directly to the 
plates. Cells were scraped into a microfuge tube and incubated on ice for 15 min 
followed by centrifugation at 18,000 x g for 20 min at 4oC. The resulting 
supernatant was transferred into clean tubes and the pellets discarded. Samples 
were either assayed directly or stored at -80oC for further use. The protein 
concentrations of samples were quantified using DC protein assay (Section 2.4). 
Samples were diluted 1: 10 in 1x cell extraction buffer PTR and assayed following 
manufacturer’s protocol. 50 µl of samples and standards (human PTEN 
recombinant protein 0, 0.125, 0.25, 0.5, 1, 2, 4, and 8 µg) into wells of antibody 
coated microplate strips and 50 µl of antibody cocktail (1:1 mixture of PTEN 
capture antibody and PTEN detector antibody) added to each well. Microplate 
was sealed and incubated for 1 hr at room temperature on a plate shaker at 400 
rpm. Wells were washed with 3 x 350 µl 1x wash buffer PT and 100 µl of TMB 
substrate added to each well and incubated for 10 min in the dark on a plate 
shaker at 400 rpm. Thereafter, 100 µl of stop solution was added to each well, 
mixed for 1 min in a plate shaker and the optical density read at 450 nm on the 
SpectraMax M2 plate reader.  
2.17 Measurement of glycogen synthase kinase-3 activity  
GSK3 catalytic activity was measured by the incorporation of radioactive [γ-32P]-
MgATP into PGS2 peptide. Posttranslational modification (phosphorylation) 
decreases the activity of GSK-3 in cells and can be measured directly by 
immunoprecipitation of the total cellular GSK-3 of the various isoforms of the 
kinase using phospho-specific antibodies that is relative to the amount of total 
protein in the cell (Cole and Sutherland, 2008). Cells were washed once with 1x 
PBS before lysed in lysis buffer (50 mM Tris-HCl pH7.4, 5 mM NaF, 1 mM Na-
pyrophosphate, 1 mM EDTA, 1 mM EGTA, 50 mM NaCl, 1% triton X-100, 0.27 M 
sucrose, protease inhibitors, 0.1% β-mercaptoethanol, 1mM Na3VO4- 300 µl/10 
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cm dish). Protein lysates were spun at 16,000 x g at 4oC for 10 min to remove 
insoluble material and protein concentration measured by DC assay. Next, an 
immunoprecipitation (IP) assay for GSK3 was performed. 500 µl of Protein G 
Sepharose beads (50% slurry in PBS) was split into two equal portions. Into one 
portion 25 µg of anti-GSK3β antibody was added and to the other portion 25 µg of 
anti-GSK3α antibody was added. Both were incubated at 4oC for 2 hr with mixing 
then spun at 6000 x g for 5 min at 4oC and the supernatant removed. A 50% 
slurry was made again with PBS. Cell lysates (200 µg at 1 mg/ml) were incubated 
with 10 µl of the anti-GSK3β beads for 12 hr at 4oC with mixing. Then spun at 
6000 x g for 5 min at 4oC and both supernatant was removed and kept. Anti-
GSK3α (10 µl) beads were added to each supernatant, incubated for 4 hr at 4oC 
with mixing. Then spun at 6000 x g for 5 min at 4oC and the supernatant 
discarded. Next, beads were washed once with 0.5 ml of cell lysis buffer mixed 
and spun at 6000 x g for 5 min at 4oC and the supernatant discarded. Beads were 
washed 1x with 1 ml of assay buffer containing 0.25 mol/l NaCl, mixed and kept 
standing for 10 min at 4oC, then spun at 6000 x g for 5 min at 4oC and the 
supernatant discarded. Beads were washed again 1x with 1 ml of assay buffer (25 
mM Tris-HCL pH7.4, 0.1 mmol/l EDTA), mixed then spun at 6000 x g for 5 min at 
4oC and the supernatant removed and discarded. GSK3 assay was then carried 
out by addition of substrate (PGS2 peptide, 10 µM), assay buffer and radioactive 
[γ-32P]-MgATP (10 mM/0.1 mM and around 0.5 x 106 CPM/nmol) in a volume of 
50 µl at 30oC for 20 min. Assay was stopped by spotting 40 µl of assay onto P81 
paper (1x1 cm square) and dropping into 75 mM orthophosphoric acid. 5x 5 min 
washes in the acid, 1x wash in acetone, air-dried, place in scintillation vial, and 1 
ml of scintillation fluid was added and counted in TriCarb scintillation counter. 
Blanks containing no cell lysate were added to experiment and a count generated 
of the stock MgATP to have an accurate CPM/nmol.  
2.18 Propidium Iodide staining for flow cytometry 
The population of cells found in the different cell cycle phases was identified using 
flow cytometry to identify DNA content in cells. The proportion of cells in G1, G2 
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and S phases can be viewed via the relative content of the DNA. Flow cytometry 
is used to purify cell population of interest by sorting cells based on the 
fluorescent protein that it is expressing (Basu et al., 2010). Propidium Iodide (PI) 
(Thermofisher) a specific fluorescent stain for DNA in flow cytometry to evaluate 
DNA content in cell cycle analysis was used for this experiment (Deitch, Law and 
White, 1982).  
A549 and H460 WT and Nrf2-kd cells were seeded into a 6 cm dish at 6 x 105 
cells/dish in 10% FBS DMEM media and grown overnight. Media from adherent 
cells was then removed next day into a 15 ml falcon tube. Cells were washed with 
1x PBS and saved in the same tube. 1 ml of trypsin was then added to lose cells 
and incubated at 37oC until cells become detached. 4 ml of 10% FBS DMEM 
media was added to cells, mixed and added to tube and spun at 800 x g for 5 min 
in the centrifuge. The supernatant was discarded, and the pellet resuspended in 1 
ml of 1x PBS and spun again for 5 min at 800 x g. The resulting supernatant was 
discarded, and 1 ml of 70% ice-cold ethanol was added to the pellet dropwise 
while vortexing to prevent clumping of cells and fixed overnight at -20oC. 
(Samples may be stored at these conditions for up to 4 weeks). Next, cells were 
centrifuged and washed with ice-cold PBS twice and 1% (w/v) bovine serum 
albumin (BSA). Cells were spun at 800 x g for 5 min and resuspended in 1 ml of 
staining buffer (50 µg/ml PI (Sigma-Aldrich), 50 µg/ml ribonuclease A (RNAse A 
(Sigma-Aldrich), 0.1% (v/v) triton x-100 in PBS). Transferred to FACS tubes and 
incubated at room temperature for 30 min in the dark. Cells were analyzed using 
flow cytometry detecting: Lin FSC-H, Log SSC-H, DNA as Lin FL2-H and using 
FL2-W and FL2-A to distinguish single cells.  
2.19 Polymerase chain reaction 
Plasmid DNA was amplified using the polymerase chain reaction (PCR). DNA 
polymerase directs the synthesis of complementary sequence of DNA from a 
small fragment (primer) that is connected to DNA strand in the 3′ end to generate 
an extended region of double stranded DNA (Valones et al., 2009). A 50 µl 
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reaction mixture containing 20 ng template DNA, 1x reaction buffer, 0.5 µmol/l 
forward and reverse primers (oligonucleotides), PCR master mix (Promega), 800 
µmol/l dNTP, and 1 µl pfu Ultra II DNA polymerase (Agilient technologies, Santa 
Clara, California, United States) was amplied using the Hybaid PCR sprint thermal 
cycler (Hybaid Ltd, Ashford, Middlesex, United Kingdom). The PCR condition 




Temperature Reaction stage Time Cycle 
95oC Denaturation 2 min 1 
95oC Denaturation 1 min 
40 58oC Annealing 30 sec 
68oC Extension 30 sec 
68oC Final extension 5 min 1 
 
 
2.20 Statistical analysis 
Results were analyzed using Graphpad Prism 6 software and Excel. Result are 
expressed as mean ± standard deviation (SD) and analyzed either with student t-
test or two-way ANOVA. Statistical significance was based on either p < 0.05, P < 
0.01 or p < 0.001. All data are a representation of two or three independent 
experiments comprising of biological replicates each done in duplicates.  
 









3.0 Dual regulation of the Nrf2 by Keap1 and GSK-3 
3.1 Introduction 
Nrf2 is mainly regulated by Keap1, a cullin-3 ubiquitin ligase substrate adaptor 
(forming CRLKeap1) that is redox sensitive (Hayes et al., 2016). A dominant view is 
that electrophiles and oxidative stressors that activate Nrf2 in cells do so by 
antagonizing Keap1, leading to stabilization and nuclear accumulation of Nrf2. It is 
well established that inducers of Nrf2 activity act by modifying key cysteine 
residues in Keap1 such as Cys-151, Cys-273, Cys-288, Cys-434 and Cys-613 
that are required for CRLKeap1 to target Nrf2 for proteasomal degradation (Zhang 
and Hannink, 2003; Wang et al., 2008b; McMahon et al., 2010; Baird and 
Dinkova-Kostova, 2011).  
The large number of cellular processes that are regulated by GSK-3 and the role 
that GSK-3 plays in several diseases such as type-2 diabetes mellitus, 
Alzheimer’s and cancer has led to the use of GSK-3 inhibitors to treat various 
diseases (Rayasam et al., 2009). GSK-3 is constitutively active in cells and unlike 
other kinases it is inactivated in response to cellular signals (Harwood, 2001; 
Rayasam et al., 2009).  Evidence indicates that serine residues within the DSGIS 
motif contained in the Neh6 domain of Nrf2 are phosphorylated by GSK-3 
promoting ubiquitylation of Nrf2 by SCFβ-TrCP  (Chowdhry et al., 2013; Hayes et al., 
2015). The ability of GSK-3 to repress Nrf2 in cells can be blocked by growth 
factors that activate the PI3K-PKB/Akt pathway leading to inactivation of GSK-3 
(Figure 3.1). 
Because Nrf2 is not only negatively regulated by Keap1 but also by the β-
TrCP/GSK-3 axis (Chowdhry et al., 2013), it is possible that antagonism of GSK-3 
might contribute to induction of Nrf2-target genes. As several research groups 
have linked electrophiles that induce Nrf2-target genes to the PI3K-PKB/Akt 
pathway (Martin et al., 2004; Kang et al., 2007; Rojo et al., 2012), it is possible 
that electrophiles that induce the expression of Nrf2-target genes might do so by 
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activating the PI3K-PKB/Akt pathway and preventing GSK-3 from phosphorylating 
the DSGIS motif in the Neh6 domain of Nrf2 that is recognized by β-TrCP.  
 
Figure 3.1: Regulation of Nrf2 by oxidative stress and growth stimuli.  
(i) Reactive oxygen species and/or electrophiles regulate Nrf2 by modifying key cysteine residues 
in Keap1 (ii) growth and/or metabolic stimuli promote the PI3K pathway that inhibits constitutively 
active GSK-3 by activating PKB/Akt that leads to stabilization of Nrf2. The hypothesis is that 
electrophiles positively regulate Nrf2 either by targeting Keap1 or by stimulating the PI3K-PKB/Akt 




3.1.1 Mechanism by which electrophiles induce the expression of 
Nrf2-target genes via antagonism of CRLKeap1 
It is believed that the ability of electrophiles to induce Nrf2-target genes is based 
on the “Hinge and latch” model of Keap1 binding to Nrf2 (Fukutomi et al., 2014; 
Taguchi and Yamamoto, 2017). In this case, the physical complex formed 
between Keap1 and Nrf2 is distorted by electrophilic inducing agents in a manner 
that prevents ubiquitination of the transcription factor by CRLKeap1 (Baird et al., 
2013; Hayes et al., 2016). Many agents that activate Nrf2 have been reported to 
form adducts with Cys-151, Cys-273, Cys-288, Cys-434 and Cys-613 of Keap1, 
with the ability of CRLKeap1 to ubiquitylate Nrf2 inversely proportional to the ability 
of the inducers to modify these cysteine residues (Zhang and Hannink, 2003; 
McMahon et al., 2010; Hayes et al., 2016). Cys-278 and Cys-288 located in the 
IVR of Keap1 have been linked to the Keap1-dependent ubiquitination of Nrf2 and 
is required for Keap1-mediated repression of Nrf2-dependent transcription under 
basal conditions (Zhang and Hannink, 2003). Mutation of this residue to alanine or 
serine resulted in an inactive Keap1 mutant, however mutation of Cys-273 to Trp 
or Cys-288 to Glu had no effect on Keap1’s ability to repress Nrf2 accumulation 
(Saito et al., 2015). Cys-151 in the BTB domain of Keap1 has also been linked to 
be critical for Nrf2 activation. Mutation of this residue results in decreased 
expression of Nrf2-target genes in both basal conditions or in response to 
electrophiles (Zhang and Hannink, 2003; Yamamoto et al., 2008; McMahon et al., 
2010). However, in 2006 Kobayashi et al, showed that treatment of cells with 
electrophiles or mutation of Cys-273 and Cys-288 of Keap1 to alanine did not 
affect the binding of Keap1 to Nrf2 but rather resulted in the impairment of Keap1-
mediated proteasomal degradation of Nrf2 (Kobayashi et al., 2006).  
 
The ability of tBHQ or SFN to induce Nrf2-target genes was decreased when 
amino acids Lys-131, Arg-135 and Lys-150 surrounding Cys-151 was replaced 
with methionine residues (McMahon et al., 2010). Analysis of the various cysteine 
residues of Keap1 also showed that Cys-151 is responsible for Nrf2 stabilization 
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in response to inducers such as tBHQ and SFN but not for arsenite-mediated Nrf2 
activation, indicating a varying mechanism of action depending on the inducer 
(Wang et al., 2008b).  
 
3.1.2 The PI3K/Akt pathway is required for induction of Nrf2-
target genes by many electrophiles  
 PI3K controls many biological functions including immune signaling due to the 
lipid second messenger that it generates (Vanhaesebroeck and Alessi, 2000; 
Vanhaesebroeck, Stephens and Hawkins, 2012). The 3ʹ-OH position of the 
inositol ring in inositol phospholipid is phosphorylated by PI3K isoenzymes to 
generate 3ʹ-PIs (Ptdlns3P, Ptdlns (3,4)P2 and Ptdlns (3,4,5)P3) that are crucial for 
activation of PKB (Vanhaesebroeck and Alessi, 2000). Activation of Nrf2 by 
hyperoxia in lung epithelial cells has been shown to be regulated by activation of 
the PI3K/AKT pathway (Papaiahgari et al., 2006). The activation of PKB/Akt by 
PI3K leads to phosphorylation of GSK-3 at Ser-9 and Ser-21 causing GSK-3 to be 
inactive and Nrf2 to be upregulated in cells (Tebay et al., 2015; Hayes et al., 
2016). 
Research carried out by Jeff Johnson in 2001 reported that the activation of the 
human NQO1-ARE by tBHQ was mediated by PI3K as pretreatment of IMR-32 
cells with LY294002 inhibited the hNQO1-ARE-luciferase expression (Lee et al., 
2001). Subsequent work by Nakaso et al. (2003) showed that inhibitors of PI3K 
blocked induction of Nrf2 target genes. Similar work by Antonio Cuadrado and his 
group in 2004 also showed a link between PI3K and Nrf2, using carnosol an Nrf2 
inducer. They showed that the induction of Nrf2-target genes using carnosol was 
significantly decreased when PI3K was inhibited in PC-12 pheochromocytoma 
cells. Inhibition of PI3K however reduced the levels of both basal and induced 
Nrf2 protein levels as well (Martin et al., 2004). Salazar et al. (2006) then showed 
that Nrf2 activity was increased via PI3K directed inhibition of GSK-3 in cells.  
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Some inducers such as tBHQ, carnosol, curcumin, ferulic acid, 1[2-cyano-3,12-
dioxooleana-1,9(11)-diene-28-oyl]imidazole (CDDO-Im), 4,17(20)-(cis)-
pregnadiene-3,16-dione (E-guggulsterone) and nordihydroguaiaretic acid (Figure 
3.2) induce Nrf2 downstream genes through a mechanism that is sensitive to 
inhibition by the PI3K inhibitor LY294002, indicating an ability to stimulate Nrf2-
directed gene induction via inactivation of GSK-3 (Kang et al., 2007; Pitha-Rowe 
et al., 2009; Ma et al., 2010; Almazari et al., 2012; Rojo et al., 2012; Hayes et al., 
2016). All these papers suggest that inducers of Nrf2-directed gene expression 
work either by antagonizing Keap1 or through another mechanism of action that is 
independent of Keap1. To examine the involvement of PI3K in activating Nrf2, two 
PI3K inhibitors LY294002 (a flavonoid derivative that has been shown to 
competitively and reversibly inhibit ATP binding site of PI3K and to inhibit ovarian 
cancer cell growth (Hu et al., 2000) and PI-103 (a multi-targeted PI3K inhibitor 
that has the ability to selectively block p110α and mTOR (Fan et al., 2006) were 
used to inhibit PI3K in a Keap1-independent system and the expression of Nrf2-
target genes assayed with and without inhibition of PI3K; structures of LY294002 







Figure 3.2: Nrf2 activators 
Chemical structures of some electrophiles that induce Nrf2 target genes discussed in this thesis. 
tBHQ: tert-butylhydroquinone, DEM: diethylmaleate, CDDO-Im: 1[2-cyano-3,12-dioxooleana-
1,9(11)-diene-28-oyl]imidazole. 
 
3.1.3 PTEN contributes to regulation of Nrf2 via the PI3K/Akt 
pathway 
The role of PI3K in regulation of Nrf2 has been reported by several research 
groups although not much is known about the mechanism by which this occurs. 
However, it has been reported that phosphatase and Tensin Homolog deleted on 
chromosome 10 (PTEN), a dual lipid and protein phosphatase tumour suppressor 
gene that is commonly mutated in human cancers, represses Nrf2 activity via 
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inhibition of formation of phosphatidylinositol 3,4,5-trisphosphate by PI3K 
(Carnero and Paramio, 2014; Taguchi et al., 2014; Rojo et al., 2014). The C-
terminal domain of phosphoinositide-dependent protein kinase 1 (PDK1) contains 
a pleckstrin homology domain (PHD) which binds to membrane bound 
phosphatidylinositol (3,4,5)-triphosphate (PIP3) stimulating the activation of PDK1 
which in turn phosphorylates Akt at Thr-308, priming it for subsequent 
phosphorylation at Ser-473 by mammalian target of rapamycin complex 2 
(mTORC2) leading to GSK-3 phosphorylation and Nrf2 activation (Figure 3.4) 
(Carnero and Paramio, 2014). Biotinylated CDDO-Im analogue was seen to 
activate the PI3K-PKB/Akt pathway through direct binding of Cys-124 in the active 
center of PTEN thus inhibiting lipid phosphatase activity of PTEN in vitro (Pitha-
Rowe et al., 2009). Also over expression of the mutant PTENC124S in MCF-10A 
cells caused the inhibition of E-guggulsterone induced expression of HMOX1 
(Almazari et al., 2012). These studies suggest that the phosphatase activity of 
PTEN is inhibited via modification of Cys-71 and Cys-124 acting as an indirect 
sensor in regulating Nrf2 through PI3K in cells (Shearn et al., 2013; Rojo et al., 
2014).  
 
How PTEN is regulated remains uncertain however, PTEN is negatively controlled 
by a multifunctional parkinsonism-associated protein DJ-1 (Kim et al., 2005; Yang 
et al., 2005). A gain-of-function screen to study the regulation of PTEN in 
Drosophila melanogaster based on UAS-GAL4 system identified DJ-1 as one of 
the genes responsible for regulation of PTEN (Brand and Perrimon, 1993; Kim et 
al., 2005). Yokota et al. (2003) showed that knockdown of DJ-1 using small 
interfering RNA (siRNA) induced cell death arising from oxidative stress, 
endoplasmic reticulum stress and proteasomal inhibition in cells with a 
corresponding reversal of phenotype when cells were rescued with over-
expression of wild-type DJ-1. Decrease phosphorylation of PKB/Akt was observed 
in mammalian cells when DJ-1 was under-expressed while hyperphosphorylation 
of PKB/Akt was observed when DJ-1 was over expressed (Kim et al., 2005). 
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Interestingly, loss of DJ-1 was shown to decrease Nrf2 activity in non-small cell 
lung carcinoma H157 cells, however, this was associated with a loss of interaction 
between Keap1 and Nrf2 (Clements et al., 2006) and no new evidence has been 
reported linking DJ1 to Keap1. This evidence shows that Nrf2 is regulated by the 
PI3K-PKB/Akt pathway and that DJ-1 negatively represses PTEN, leading to 
active PI3K-PKB/Akt that pathway that would repress Nrf2 through the GSK-3 




Figure 3.3: Inhibitors of PI3K 





Figure 3.4: PTEN regulates the PI3K-Akt pathway. 
PTEN inhibits the formation of PIP3 by PI3K. PDK1 binds to PIP3 leading to phosphorylation of 
AKT at Thr-308 and a second phosphorylation at Ser-473 by mTORC2. This second 
phosphorylation event will allow GSK-3 to be phosphorylated making GSK-3 inactive to trigger the 
inhibition of Nrf2 via the Neh6 domain of Nrf2.  
 
3.2 Experimental result 
3.2.1 Inducers can increase expression of Nrf2 target genes in a 
Keap1-independent manner 
It is well known that many thiol-reactive agents that induce Nrf2-target genes 
expression inactivate the ubiquitin ligase activity of CRLKeap1 by modifying Cys 
residues in Keap1. However, it is less clear whether such agents can induce Nrf2-
target genes in a Keap1-independent manner. To determine if Inducers can 
activate Nrf2 via a Keap1-independent mechanism, Keap1-/- MEFs were treated 
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with inducers 6 hr or 12 hr before measuring Hmox1 or Nqo1 gene expression, 
respectively; Keap1+/+ MEFs were used as a control. As anticipated, the loss of 
Keap1 in Keap1-/- MEFs resulted in higher basal levels of mRNA for Hmox1 and 
Nqo1 than was observed in Keap1+/+MEFs. When Keap1+/+ MEFs were treated 
with 50 µM tBHQ, a 10-fold increase in expression of Hmox1 and a 5-fold 
increase in expression of Nqo1 was observed as shown in Figure 3.5A. Also, loss 
of Keap1 in Keap1-/- MEFs did not prevent tBHQ from inducing Hmox1 and Nqo1 
with a 100-fold and 300-fold increase in mRNA for Hmox1 and Nqo1, respectively. 
Similarly, 100 µM DEM, 10 µM carnosol, 15 µM curcumin, 10 µM Ferulic acid and 
100 nM CDDO-Im all increased Hmox1 and Nqo1 mRNA levels in both Keap1+/+ 
and Keap1-/- MEFs (Table 3.1). However, whilst treatment with 5 µM SFN 
increased mRNA for Hmox1 and Nqo1 in Keap1+/+ MEFs, no significant increase 
in Hmox1 and Nqo1 mRNA was observed in the knockout fibroblast (Figure 3.5B). 
These results indicate that even in the absence of Keap1, inducers such as tBHQ, 
DEM, carnosol, curcumin, ferulic acid and CDDO-Im are able to transcriptionally 
activate Nrf2 downstream genes. However, in Keap1-/- MEFs, SFN did not further 
increase Hmox1 and Nqo1 mRNA above the basal level. This implies that some 
inducers such as SFN activate Nrf2-target gene expression by inhibiting Keap1 
alone, whereas others can activate Nrf2-target gene expression independently of 














Figure 3.5: Effect of Nrf2 inducers on Keap1+/+ and Keap1-/- MEFs. 
Keap1+/+ and Keap1-/- MEFs were seeded at 8 x 106 cells/6 cm dish and grown in 10% FBS DMEM 
media for 18 hr before they were transferred to reduced serum media (1% FBS DMEM) and left to 
acclimatize for 16 hr before treatment with (A) 50 μM tBHQ, or (B) 5 µM SFN for either 6 hr or 12 
hr to measure mRNA for Hmox1 or Nqo1, respectively. Relative levels of mRNA for Hmox1 and 
Nqo1 were quantified by Taqman analysis. The graphs represent the mean values from three 
independent experiments each done in duplicates. Levels of mRNA for Hmox1 and Nqo1 were 
normalized against β-actin levels. Statistical analyses were performed using graphpad prism and 
statistical significance assessed using unpaired t-test. Results significantly higher than DMSO 
vehicle control with p-values <0.01 or <0.001 are indicated with double (**) or triple (***) asterisk 




Table 3.1: Expression of Hmox1 and Nqo1 in Keap1+/+ and  Keap1-/- MEFs. 
Table shows relative fold change plus/minus standard error of mean for mRNA for Hmox1 and 
Nqo1. Keap1+/+ and Keap1-/- MEFs were treated with inducers for either 6 hr or 12 hr before mRNA 
levels for Hmox1 or Nqo1 respectively, were measured. Treatment with inducers was done in 
reduced serum 1% FBS DMEM media. Relative abundance of mRNA for Hmox1 and Nqo1 were 
quantified by Taqman analysis. Levels of mRNA for Hmox1 and Nqo1 were normalized against β-
actin levels. The results are each a representation of three independent experiments each done in 
duplicates. 
Keap1+/+ Keap1-/- 
Electrophiles Hmox1 Nqo1 Hmox1 Nqo1 
tBHQ (50 µmol/l) 10 ± 1.0 5 ± 0.9 100 ± 11.4 300 ± 74.8 
DEM (100 µmol/l) 60 ± 17.3 10 ± 2.1 300 ± 46.2 400 ± 91.0 
carnosol (10 µmol/l) 12 ± 1.9 4 ± 0.6 100 ± 13.6 400 ± 54.5 
curcumin (15 µmol/l) 29 ± 2.8 14 ± 1.0 60 ± 6.1 300 ±15.7 
ferulic acid (10 
µmol/l) 
30 ± 5.4 14 ± 1.1 100 ± 8.4 200 ± 9.1 
CDDO-Im (100 
nmol/l) 
22 ± 0.4 4 ± 0.2 60 ± 2.0 600 ± 100 






3.2.2 Increase in mRNA for Hmox1 and Nqo1 by inducers is 
dependent on Nrf2 
To check if the ability of our panel of inducers to increase the expression of 
Hmox1 and Nqo1 requires the presence of ARE sequences in their promoter 
regions, and is thus probably mediated by Nrf2, their ability to increase ARE-
driven gene expression was assessed. Using a model reporter system, it was 
found that treatment of AREc32 cells for 18 hr with 50 µM tBHQ, 100 µM DEM, 
100 nM CDDO-Im, 15 µM curcumin, 10 µM carnosol, 10 µM ferulic acid and 5 µM 
SFN increased the relative luciferase activity (Figure 3.6A). Keap1-/- MEFs, when 
transfected with murine Nqo1 gene promoter (-1016/nqo5ʹ-luc luciferase reporter 
plasmid) alongside pRL-TK Renilla Luciferase reporter plasmid also resulted in a 
significant increase in relative luciferase activity when treated with tBHQ, DEM, 
CDDO-Im, curcumin, carnosol, ferulic acid and SFN (Figure 3.6B). SFN is able to 
activate the ARE-driven luciferase activity in AREc32 cells as these cells have a 
functional Keap1 in them. It was interesting to note that SFN was still able to 
induce the ARE-driven luciferase activity in AREc32 cells and in Keap1-/- MEFs as 
well even though we propose that SFN requires Keap1 for activating Nrf2. This 
might have been because these cells were transfected with the Nqo1 gene 
























Figure 3.6: Effect of Nrf2 inducers on ARE-driven gene expression 
AREc32 reporter cells that contained a stably-transfected ARE reporter construct (A) or Keap1-/- 
MEFs that were transiently transfected with an ARE-reporter plasmid (B) were treated with 
inducing agents. In (A), the AREc32 cells were seeded at 4 x 106 cells/6 well plate and grown in 
10% FBS DMEM media for 18 hr before they were transferred to reduced serum media (1% FBS 
DMEM) and left to acclimatize for 16 hr before they were treated with 50 μM tBHQ, 100 µM DEM, 
100 nM CDDO-Im, 15 µM curcumin, 10 µM carnosol, 10 µM ferulic acid and 5 µM SFN for 18 hr. 
In (B) the Keap1-/- MEFs were transfected with the mouse Nqo1-ARE reporter plasmid alongside 
pRL-TK Renilla plasmid as internal control. Following transfection, cells were allowed to 
acclimatize in 1% FBS DMEM media for 16 hr before they were treated with inducers for 18 hr. 
Luciferase assay was measured using the Promega luciferase assay according to manufacturers’ 
protocol as described in chapter 2. Luciferase data were normalized against protein concentration. 
Statistical analyses was done using graphpad prism and statistical significance assessed using 
unpaired t-test. Results significantly higher than DMSO vehicle control with p-values <0.01, 
<0.001, or <0.0001 are indicated with double (**), triple (***) or (****) asterisk signs respectively. 
The results are each a representation of three independent experiments each done in triplicates. 
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To check whether the inducers increased the abundance of Nrf2 protein in a 
Keap1-independent system, we examined their effects on Nrf2 in A549 cells, a 
non-small lung cancer cell line containing inactive mutant Keap1. In this case, 
A549 cells were treated with tBHQ, DEM, CDDO-Im, curcumin, carnosol, ferulic 
acid and SFN for 2hr, after which the abundance of Nrf2 was measured by 
western blotting. Treatment of A549 with inducers gave a 2-fold increase in the 
abundance of Nrf2 protein by 50 µM tBHQ. By contrast, 100 µM DEM and 10 µM 
ferulic acid gave a 10-fold increases in Nrf2 protein level, while 100 nM CDDO-Im 
and 15 µM curcumin gave a 7-fold increase in the abundance of Nrf2 protein 
level. However, SFN did not increase the levels of Nrf2 protein levels (Figure 3.7i 
& ii). This result shows that inducers such as tBHQ, DEM, CDDO-Im, curcumin, 
carnosol and ferulic acid is able to activate Nrf2 protein level in a Keap1- 
independent manner, however, SFN will require Keap1 in modulating the activities 
of Nrf2 and its target genes. 
To investigate the involvement of GSK-3 in regulating Nrf2 in Keap1-/- MEFs, 
CT99021 a small molecule inhibitor of GSK-3 was used to treat Keap1-/- MEFs 
transfected with the reporter plasmid generated from the ARE-containing murine 
Nqo1 gene promoter (-1016/nqo5ʹ-luc luciferase plasmid (Nioi et al. 2003)) 
alongside pRL-TK Renilla Luciferase reporter plasmid. Inhibition of GSK-3 using 
CT99021 resulted in a dose-dependent increase in the ARE-driven gene 








Figure 3.7: Inducers increase the abundance of Nrf2 protein in Keap1-independent system 
In panel B, A549 cells were grown in 10% FBS DMEM media for 18 hr before they were treated 
with inducers for 2 hr and western blot for Nrf2 protein measured. β-actin was used as control for 
gel loading. Bottom thick band at ~100 kDa was considered as accepted band with treatment with 







Figure 3.8: Inhibition of GSK-3 increases ARE-driven gene expression. 
Keap1-/- MEFs were transfected with mouse Nqo1-ARE Plasmid alongside pRL- TK Renilla 
plasmid as internal control and treated with increasing concentration of CT99021 for 18 hr. 
Following transfection, cells were allowed to acclimatize in 1% FBS DMEM media for 16 hr. 
Luciferase activity was measured using the Promega luciferase assay according to manufacturers’ 
protocol as described in chapter 2. Luciferase data were normalized against protein concentration. 
Statistical analyses was done using graphpad prism and statistical significance assessed using 
unpaired t-test. Results significantly higher than DMSO vehicle control with p-values <0.01 is 
indicated with double (**) and n.s = not significant. The results are each a representation of three 
independent experiments. 
 
3.2.3 Inducers that stimulate Nrf2-target gene expression in a 
Keap1-independent manner inhibit GSK-3 
Since Nrf2-directed gene expression can be increased in Keap1-null cells by 
certain inducing agents, it was appropriate to test if they did so because they 
blocked repression of Nrf2 via the β-TrCP/GSK-3 axis. To test this hypothesis, 
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Keap1+/+ and Keap1-/- MEFs were treated with inducers and the amount of 
phosphorylated GSK-3 protein (i.e. inactive GSK-3) was measured using western 
blotting. Loss of Keap1 in Keap1-/- MEFs resulted in a decrease in relative amount 
of phosphorylated GSK-3 when compared with that in Keap1+/+ MEFs suggesting 
that the absence of Keap1 causes an increase in active GSK-3, which might 
represent some sort of negative feedback suggesting that in the absence of 
Keap1, regulation of Nrf2 through the Neh6 becomes heightened. Treatment with 
50 µM tBHQ caused a slight increase the phosphorylation of GSK-3α and GSK-3β 
at Ser-21 and Ser-9, respectively, in both Keap1-/- MEFs and Keap1+/+ MEFs with 
the increase more predominate in Keap1-/- MEFs (Figure 3.9A) with a 
corresponding 1-fold increase in the level of Hmox1 protein. Interestingly, when 
inhibitors of PI3K and PKB/Akt, LY294002 (10 µM) and MK-2206 (5 µM), 
respectively, which lie upstream of GSK-3, were used as controls, a slight 
decrease in tBHQ-stimulated GSK-3α and GSK-3β phosphorylation was 
observed. Also, treatment of MEFs with CT99021, a GSK-3 inhibitor that was 
used as a positive control, showed an increase in the amount of Hmox1 protein 
under both basal and induced conditions. Similar results were seen when 100 µM 
DEM (Figure 3.9B) and 10 µM carnosol (Figure 3.9C) were used to treat Keap1+/+ 
and Keap1-/- MEFs. By contrast, whilst 5 µM SFN gave a slight increase in p-
GSK-3α and p-GSK-3β in Keap1-/- MEFs, it did not increase Hmox1 protein in the 
knockout MEFs (Figure 3.9D). Treatment with tBHQ, DEM, and carnosol slightly 
increased the levels of Hmox1 and p-GSK-3 protein in Keap1+/+ and Keap1-/- 
MEFs. In all instances pre-treatment with 10 μM LY294002 or 5 μM MK-2206 
decrease the amount of phosphorylated Akt protein whereas pre-treatment with 5 
μM CT99021, a GSK-3 inhibitor showed a further increase in protein levels of p-
GSK-3 and p-Akt. 
 
The ability of these inducers to increase phosphorylation of GSK-3 shows that 
they are capable of antagonizing GSK-3 resulting in an increased abundance of 
Nrf2 protein. It is evident from this result that even in the presence of Keap1, 
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these inducers still act on GSK-3 in stabilizing Nrf2, and however, in the knock out 
fibroblast when Keap1 is absent there is a greater tendency to stabilize Nrf2 
through the β-TrCP/GSK-3 axis. Although SFN caused an increase in level of 
pGSK-3 in the Keap1-/- MEFs, it seems that this reaction is not enough to cause 






















Figure 3.9: Agents that induce Nrf2-target genes in a Keap1-independent manner increases 
GSK-3 phosphorylation decreases the activity of GSK-3. 
Keap1+/+ and Keap1-/- MEFs were seeded at 8 x 106 cells/6 cm dish and grown in 10% FBS DMEM 
media for 18 hr before they were transferred to reduced serum media (1% FBS DMEM) and left to 
acclimatize for 16 hr before treatment with 50 μM tBHQ (A), 100 μM DEM (B), 10 µM carnosol (C), 
and 5 µM SFN (D) for either 2 hr for GSK-3 and Akt protein measurement or 8 hr to measure 
Hmox1 protein using western blot. β-actin was used as control for gel loading. Pre-treatment with 
LY294002, MK-2206 or CT99021 was done for 1 hr before treatment with inducers for either 2 hr 
or 8 hr. The results are each a representation of three independent experiments. Proteins were 
loaded into 26 well NuPAGE gels and membrane was cut and probed in different antibody 
corresponding to sizes of protein of interest. 
 
To examine whether these inducers can alter Nrf2 activity by inhibiting GSK-3, 
and therefore presumably antagonizing the ability of the β-TrCP/GSK-3 axis to 
repress Nrf2, the effect of the inducing agents on GSK-3 activity assay was 
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measured. The GSK-3 enzyme activity assay was carried out with the help of Dr 
Calum Sutherland. The result showed that 50 µM tBHQ resulted in a slight 
decrease in the activity of GSK-3α and GSK-3β in Keap1-/- MEFs. Similarly, 100 
µM DEM, 100 nM CDDO-Im, 15 µM curcumin and 10 µM ferulic acid was able to 
decrease the activity of GSK-3α (Figure 3.10A) and GSK-3β in Keap1-/- MEFs 
(Figure3.10B). These results suggest that the inducers were able to inhibit GSK-3 












Figure 3.10: Agents that induce Nrf2-target genes in a Keap1-independent manner 
decreases the activity of GSK-3. 
Keap1-/- MEFs were seeded at 8 x 106 cells/6 cm dish and grown in 10% FBS DMEM media for 18 
hr before they were transferred to reduced serum media (1% FBS DMEM) and left to acclimatize 
for 16 hr before treatment with inducers for 2 hr. Immunoprecipitation (IP) of GSK-3 isoform and 
GSK-3 activity assay was carried out from 200 µg of cell lysates as input sample. For assay, 10 
µmol/l PGS2 peptide was used as substrate and around 0.5 x 106 CPM/nmol radioactive [γ-32P]-
MgATP. Results were normalized blank GSK-3α and GSK-3β containing no cell lysates. The 
results are each a representation of two independent experiments. 
 
3.2.4 Inducers that antagonize GSK-3 function through the Neh6 
domain of Nrf2 
As previous research has shown that the β-TrCP/GSK-3 axis regulates Nrf2 
through the Neh6 domain of the transcription factor, it was tested whether 
inducers that antagonize GSK3 function increases the activity of Nrf2 through the 
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Neh6 domain. First, expression plasmids for wild-type Nrf2, Nrf2∆ETGE, or 
Nrf2∆DSGIS were cotransfected with the ARE-containing murine Nqo1 gene 
promoter (-1016/nqo5ʹ-luc luciferase reporter plasmid) alongside PRL as internal 
control. Following recovery from transfection, the cells were treated with 50 µM 
tBHQ, 100 µM DEM, 100 nM CDDO-Im, 15 µM curcumin or 5 µM SFN. 
Subsequent measurement of luciferase activity revealed that tBHQ, DEM, CDDO-
Im, curcumin and SFN all increased ARE-driven luciferase activity in cells 
expressing ectopic wild-type Nrf2. By contrast, when cells expressing ectopic 
Nrf2∆ETGE were treated with the inducing agents, only tBHQ, DEM, CDDO-Im and 
curcumin significantly increased ARE-driven luciferase activity; SFN had no effect 
on luciferase activity in cells expressing ectopic Nrf2∆ETGE. When cells expressing 
the Nrf2∆DSGIS were treated with inducers, a significant increase in luciferase 
activity was observed for all inducers (Figure 3.11A). Collectively, these results 
show that all inducers stimulate ARE-driven luciferase activity in wild-type Nrf2 
with intact Neh2 and Neh6 domains. However, loss of Keap1-binding domain in 
cells expressing ectopic Nrf2∆ETGE prevented SFN from stimulating Nrf2-directed 
gene expression whereas tBHQ, DEM, CDDO-Im and curcumin were able to 
increase the activity of Nrf2∆ETGE. By contrast, deletion of the β-TrCP binding 
domain, did not affect the ability of any of the inducers to stimulate ARE-driven 
luciferase activity. These data suggest SFN will only influence Nrf2 activity by 
modulating Keap1 while others like tBHQ, DEM, CDDOIm, curcumin and ferulic 
acid can modulate Keap1 or GSK-3 in regulating Nrf2-target gene induction. 
To confirm that inducers can affect the activity of Nrf2 by attenuating the ability of 
GSK-3 to modify its Neh6 domain, COS1 cells were transfected with a plasmid 
encoding a fusion protein containing the Neh6 domain plus flanking residues (i.e. 
amino acid 290-410 of mouse Nrf2) that was linked to β-gal, which was in turn V5-
tagged (designated Neh6+-LacZ-V5) and following recovery from transfection they 
were treated with inducing agents. Measurement of β-gal activity showed that the 
abundance of Neh6+-LacZ-V5 protein was significantly increased by 50 µM tBHQ, 
100 µM DEM, 10 µM carnosol, 10 µM ferulic acid, 100 nM CDDO-Im, and 15 µM 
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curcumin, but was not significantly increased when treated with 5 µM SFN (Figure 
3.11B).  These results suggest that some inducers will only activate Nrf2 through 
antagonizing the interaction between the DLG/ETGE motifs in the Neh2 domain 
and Keap1, whereas others such as tBHQ, CDDO-Im, curcumin, carnosol, DEM, 
and ferulic acid will function independently of Keap1 by antagonizing repression of 












Figure 3.11: Xenobiotics activate Nrf2 by preventing formation of the DSGIS-containing 
phosphodegron in its Neh6 domain. 
A. COS1 cells were co-transfected with 0.25 µg of pcDNA 3.1 full length mouse Nrf2-V5 or pcDNA 
3.1 Nrf2-V5 ∆ETGE or pcDNA 3.1 Nrf2-V5 ∆DSGIS along with 0.25 ug of the -1016/nqo5ʹ-luc 
reporter plasmid and 0.25 ug of pRL-TK Renilla plasmid for 24 hr before they were serum depleted 
in 1% FBS DMEM media for 16 hr and treated with 50 µM tBHQ, 100 µM DEM, 100 nM CDDO-Im, 
15 µM curcumin or 5 µM SFN for 18 hr after which luciferase activity was measured using 
Promega Dual luciferase assay system. Results were normalized to Renilla luciferase used as 
internal control and protein concentrations B. COS1 cells were transfected with Neh6+(lacZ)-V5 
expression plasmid before treatment with 50 µM tBHQ, 100 nM CDDO-Im, 10 µM Carnosol, 15 µM 
Curcumin, 10 µM Ferulic acid, 100 µM DEM or 5 µM SFN and β-galactosidase activity measured 
using Promega β-galactosidase assay kit. Cells were co-transfected with pRL-TK Renilla plasmid 
as transfection control and result was normalized against Renilla enzyme activity. Statistical 
analyses was performed using graphpad prism and statistical significance assessed using 
unpaired t-test. Results significantly higher than DMSO vehicle control with p-values <0.05, 0r 
<0.01 are indicated with single (*), double (**) or asterisk signs respectively and n.s = not 
significant. The graphs represent the mean ± standard error of mean from three independent 
experiments each done in triplicates. 
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3.2.5 Inhibition of PI3K suppresses Nrf2 activity 
To confirm reports that PI3K contributes to regulation of Nrf2 through stimulation 
of PKB/Akt, which in turn phosphorylates GSK-3α and GSK-3β at Ser-21 and Ser-
9 respectively, leading to its inactivation, the MCF7-derived AREc32 reporter cells 
were treated with the PI3K inhibitors LY294002 and PI-103. A time-course 
analysis of AREc32 cells treated with LY294002 and PI-103 showed that 
LY294002 caused a decrease in phosphorylation of p-GSK-3α/β from 15 min and 
this lasted until 12 hr with a corresponding decrease in Nrf2 protein from 2 hr time 
point and 8 hr compared to the DMSO control of each time point. PI-103 also 
caused a decrease in p-GSK3α/β from 15 min until 8 hr but by 12 hr, the effect of 
PI-103 seemed to be curtailed (Figure 3.12A). Also, treatment with PI-103 
resulted in a decrease in Nrf2 protein from 2 hr and 8 hr time points. As a control, 
phosphorylation of Akt at Ser-473 and Thr-308 was examined as a measure of the 
effect of the inhibitors on PI3K. This showed that treatment with LY294002 and 
PI-103 decreased phosphorylation of PKB/Akt at Ser-473 and Thr-308 at time 
points measured. To assess if LY294002 can blunt activation of Nrf2 by inducing 
agents, MCF7 cells were treated with 50 µM tBHQ with or without pretreatment 
with 10 µM LY294002. This revealed that LY294002 decreased phosphorylation 
of GSK-3α and GSK-3β at Ser-9 and Ser-21 under basal and inducible conditions 
from 30 min until 12 hr (Figure 3.12B). This decrease in GSK-3 phosphorylation 
was accompanied by a corresponding decrease in both the basal and induced 
levels of Nrf2 protein level at 4 hr time point to 12 hr time point.     
Following time-course experiments, the ability of LY294002 and PI-103 to inhibit 
induction of ARE-driven gene expression by 50 µMtBHQ, 10 µM carnosol and 100 
nM CDDO-Im was also assessed. The AREc32 reporter cell line was treated with 
these inducers plus or minus pretreatment with LY294002 or PI-103 for 18 hr and 
the relative luciferase activity measured. This revealed that LY294002 and PI-103 
significantly decreased both basal and inducible ARE-driven luciferase activity 













Figure 3.12: The activity of Nrf2 is positively influenced by PI3K. 
(A) AREc32 seeded at 8 x 106 cells/ 6 cm dish were grown in 10% FBS DMEM media for 18 hr 
before they were transferred to reduced serum media (1% FBS DMEM) and left to acclimatize for 
16 hr. Cells were treated with the PI3K inhibitors LY294002 (at 10 µmol/l) and PI-103 (at 1 µmol/l) 
over time interval spanning 0- 12 hr. AREc32 cells were then harvested and immunoblotted with 
indicated antibodies. Actin was used as loading control. (B) Whole cell lysates from MCF7 cells 
treated with (50 µmol/l) tBHQ plus/minus LY294002 (10µmol/l) over time interval spanning 0-12 hr 
were resolved in Tris-Bis NuPAGE gels and immunoblotted with the indicated antibodies. Actin 
was used as loading control. Prior to treatment with tBHQ, cells were serum depleted (1% FBS 
DMEM media) for 16 hr. (C) AREc32 cells were treated with (50 µmol/l) tBHQ, (10 µmol/l) 
carnosol, and (100 nmol/l) CDDO-Im for 18hrs, therafter luciferase reporter assay was carried out 
and relative luciferase activity measured. Cells were serum depleted for 16 hr in 1% FBS DMEM 
media and thereafter pretreated with 10 µM LY294002 or 1 µM PI-103 for 1 hr. before treatment 
with inducers for 18 hr. Western blot for Nrf2 protein was carried out at 2 hr and 8 hr in a 
complementary experiment to show that induction of the ARE-driven luciferase activity 
corresponds to increased Nrf2 protein levels. Actin was used as loading control and DMSO was 
used as vehicle control. Pretreatment with inhibitors was for 1 hr in all instances. The results are 
each a representation of two independent experiments. Membranes were cut and multi-probed 




3.2.6 Inhibition of PI3K leads to a decrease in Nrf2-target gene 
expression 
Since inhibition of PI3K led to a reduction in ARE-driven luciferase reporter gene 
expression in AREc32 cells, assessment of the effect of inhibition of PI3K on the 
expression of various endogenous Nrf2-target genes and the gene encoding Nrf2 
(i.e. NFE2L2) was carried out in MCF7 cells. Thus, MCF7 cells were pretreated 
with PI3K inhibitors for 1 hr before they were treated with 50 µM tBHQ for 8 hr and 
24 hr and the mRNA levels measured. This showed that pretreatment with 
LY294002 or PI-103 decreased both basal and inducible levels of mRNA for; 







Figure 3.13: LY294002 and PI-103 represses Nrf2 gene expression in tBHQ induced MCF7 
cells.   
MCF7 cells were seeded and grown in 10% FBS DMEM media for 18 hr before they were 
transferred to 1% FBS DMEM media for 16 hr before treatment with 50 µM tBHQ or DMSO vehicle 
control for either 8 hr for Nrf2 and HMOX1 measurement or 24 hr for NQO1, AKR1B10, AKR1C1, 
GCLC, GCLM depending on gene turnover rate with or without pretreatment with 10 µM LY294002 
or 1 µM PI-103 for 1 hr. Relative levels of mRNA for HMOX1, NQO1, AKR1B10, AKR1C1, GCLC, 
GCLM, and Nrf2 were quantified by Taqman analysis. The graphs represent the mean values from 
three independent experiments. mRNA levels for target genes were normalized against β-actin 
levels. Statistical analysis was done using graphpad prism and statistical significance assessed 
using unpaired t-test. Results significantly higher than DMSO vehicle control with p-values <0.01 is 
indicated with double (**) asterisk signs. Results that are significantly lower than DMSO control 
with p-values <0.05 or <0.01 are indicated with single ($) or double ($$) signs respectively and n.s 
= not significant.  
 
The effects of PI3K inhibition on protein abundance in MCF7 cells were also 
assessed. When MCF7 cells were treated with tBHQ with or without pretreatment 
with LY294002 or PI-103 for 1 hr and 2 hr, LY294002 and PI-103 decreased Nrf2 
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protein levels under basal and tBHQ induced conditions with a corresponding 
decrease in phosphorylation of GSK3α/β for both the 1 hr and 2 hr time points 
(Figure 3.14A). Measurement of proteins encoded by Nrf2 also showed LY294002 
and PI-103 repressed both basal and induced HMOX1, NQO1 (Figure 3.14B) and 
AKR1B10 proteins (Figure 3.14C) at 8 hr, 18 hr and 24 hr. These results suggest 
that Nrf2 activity can be regulated by inhibiting PI3K. Thus, electrophiles that 





















Figure 3.14:  LY294002 and PI-103 represses Nrf2 and inducible Nrf2-target gene 
expression. 
Human mammary MCF7 cells were seeded and grown in 10% FBS DMEM media containing 4.5 
g/L glucose for 18 hr before they were transferred to 1% FBS reduced serum DMEM media (4.5 
g/L glucose) for 16 hr before treatment with 50 µM tBHQ or DMSO vehicle control with or without 
pretreatment with 10 µM LY294002 or 1 µM PI-103 for 1 hr. The proteins were resolved in SDS-
PAGE and immunoblotted with indicated antibodies. (A) protein levels of Nrf2, pGSK-3α/β, GSK-3, 
pSer-473-AKT, pThr-308-AKT were measured by western blot for cells treated for 1 hr and 2 hr. 
(B) protein levels of HMOX1 and NQO1 were measured for cells treated for 8 hr, 18 hr and 24 hr. 
(C) protein levels of AKR1B10 were measured for cells treated for 24 hr. Actin was used as 
loading control and the results is a representation of three independent experiments that are 
biological replicates.  
 
3.2.7 Regulation of Nrf2 through the PI3K-AKT-GSK3 pathway is 
independent of Keap1 
To test if the ability of PI3K inhibitors to regulate Nrf2 requires Keap1, Keap1-/- 
MEFs were treated with inducers plus or minus pretreatment with the PI3K 
inhibitor LY294002 or the PKB/Akt inhibitor MK-2206 or the GSK-3 inhibitor 
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CT99021, and expression of Nrf2 downstream genes was measured using 
Taqman RT-PCR; Keap1+/+ MEFs were used as a control. As anticipated, the 
basal levels of Hmox1 and Nqo1 were higher in Keap1-/- MEFs than Keap1+/+ 
MEFs. Interestingly, LY294002 and MK-2206 decreased the high basal 
expression of Hmox1 and Nqo1 in Keap1-/- MEFs. By contrast, CT99021 
increased the basal expression levels of Hmox1 and Nqo1 in both Keap1+/+ and 
Keap1-/- MEFs. When tBHQ was used to induce gene expression in MEFs, 
LY294002 and MK-2206 was found to repress tBHQ induced Hmox1 and Nqo1 
mRNA levels in both Keap1+/+ and Keap1-/- MEF cells (Figure 3.15A). Similarly, 
LY294002 and MK-2206 inhibited induction of Hmox1 and Nqo1 mRNA by DEM 
(Figure 3.15B), carnosol (Figure 3.15C), curcumin (Figure 3.15D), ferulic acid 
(Figure 3.15E), and CDDO-Im (Figure 3.15F) indicating that LY294002 is still able 





















Figure 3.15: Inhibition of PI3K suppresses Nrf2 activity in a Keap1 independent manner.   
(A-F) Keap1+/+ and Keap1-/- MEFs were seeded and grown in 10% FBS DMEM media (4.5 g/L 
glucose) for 18 hr before they were transferred to reduced serum media (1% FBS DMEM) (4.5 g/L 
glucose) for 16 hr before  treatment with 50 μM tBHQ (A), 100 μM DEM (B), 10 µM Carnosol (C), 
15 µM curcumin (D), 10 µM Ferulic acid (E), and 100 nM CDDO-Im (F) for either 6 hr or 12 hr to 
measure Hmox1 or Nqo1 respectively. In all instances pre-treatment with 10 µM LY294002 or 5 
µM MK-2206 or 5 µM CT99021was for 1 hr before treatment with inducers.  Relative levels of 
mRNA for Hmox1 and Nqo1 were quantified by Taqman analysis. The graphs represent the mean 
values from three independent experiments each done in duplicates. Levels of mRNA for Hmox1 
and Nqo1 were normalized against β-actin levels. Statistical analyses was done using graphpad 
prism and statistical significance assessed using unpaired t-test.  Results significantly higher than 
DMSO vehicle control with p-values <0.01 or <0.001 are indicated with double (**) or triple (***) 
asterisk signs respectively and results that are significantly lower than DMSO control with p-values 
<0.01 are indicated with double ($$) signs: n.s= not significant.  
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To further investigate whether the PI3K inhibitors require Keap1 in order to 
suppress ARE-regulated genes, a bis-sulfonamide NG284 that blocks the binding 
of Keap1 to Nrf2 (Georgakopoulos et al., 2017) was used in the AREc32 reporter 
cell line. AREc32 cells were treated with NG284 with or without pre-treatment with 
LY294002 or PI-103 for 18 hr in 1% FBS reduced serum media. NG284 increased 
ARE-driven luciferase activity in a dose dependent manner. However, when cells 
were pretreated with either LY294002 or PI-103, this increase was suppressed 
significantly (Figure 3.16). LY294002 and PI-103 were able to significantly 
decrease ARE-driven luciferase activity at basal level and even when Keap1 
interaction with Nrf2 is blocked by NG284. Measurement of Nrf2 protein level in 
these cells showed a similar result. Together these results suggest that the kinase 
inhibitors blunt Nrf2 activity via a Keap1-independent mechanism. The regulation 
of Nrf2 through the PI3K-PKB/Akt pathway is independent of the Keap1 status of 












Figure 3.16: Blocking of Keap1 binding had no effect on PI3K. 
AREc32 seeded at 8 x 106 cells/ 6 cm dish were grown in 10% FBS DMEM media for 18 hr before 
they were transferred to reduced serum media (1% FBS DMEM) and left to acclimatize for 16 hr. 
Pretreatment with LY294002 or PI-103 were done for 1 hr before cells were treated with the bis-
sulfonamide NG284 for 18 hr. Thereafter, Luciferase assay was measured using the Promega 
luciferase assay according to manufacturer’s protocol as described in section 2. Luciferase data 
were normalized against protein concentration and corrected against vehicle-treated DMSO. 5 µM 
SFN was used as positive control in this experiment.  Western blot for Nrf2 protein abundance was 
also measured. Protein levels of pSer-473-Akt were measured as control for P13K inhibitors. Actin 
was used as loading control. Statistical analyses were done using graphpad prism and statistical 
significance assessed using unpaired t-test.  Results significantly higher than DMSO vehicle 
control with p-values <0.01 are indicated with double (**) asterisk signs and results that are 
significantly lower than DMSO control with p-values < 0.05 or <0.01 are indicated with single ($) or 





3.2.8 Regulation of Nrf2 through the PI3K-AKT-GSK3 pathway is 
dependent on GSK3 
Since the above results show that PI3K inhibitors suppress Nrf2 activity in the 
absence of Keap1, it was hypothesized that inhibitors suppress ARE-driven gene 
expression by decreasing Akt activity which would in turn prevent inhibitory 
phosphorylation of GSK-3 by Akt and so allow GSK-3 to create the DSGIS-
containing phosphodegron recognized by β-TrCP. To test if inhibition of basal 
and/or inducible ARE-driven gene expression by kinase inhibitors requires GSK-3, 
COS1 cells were transfected with the Neh6+-LacZ-V5 fusion protein and treated 
with LY294002, the Akt inhibitor MK2206, the GSK-3 inhibitor CT99021 and 
several inducing agents. In these experiments, LY294002 and MK2206 caused a 
significant decrease in basal β-galactosidase activity and tBHQ- and ferulicacid-
inducible β-galactosidase activity. By contrast, inhibition of GSK-3 by CT99021 
gave a significant increase in basal β-gal activity and an increase in tBHQ- and 
ferulic acid-inducible β-galactosidase activity (Figure 3.17A). 
Assessment of whether the ability of PI3K inhibitors to repress Nrf2 is abolished 
by inhibition of GSK-3 was carried out by measuring the ARE-driven luciferase 
activity in the AREc32 reporter cell line treated with increasing concentrations of 
CT99021 plus/or minus LY294002 or PI-103. The results showed that CT99021 
modestly increased luciferase activity in a dose-dependent manner. Importantly, 
the increase in ARE-driven luciferase activity caused by CT99021 was not 
prevented by LY294002, suggesting inhibition of GSK-3 is dominant over 
inhibition of PI3K (Figure 3.17B). Similarly, the increase in ARE-driven luciferase 
activity caused by CT99021 was not prevented by PI-103 at the lowest 
concentration of CT99021 (Figure 3.17B). However, with increasing concentration 
of CT99021, the increase in ARE-driven luciferase activity caused by CT99021 
was blocked by PI-103. This may be because of the non-specificity of PI-103 or a 
dose effect or that PI-103 can suppress Nrf2 activity via an alternative mechanism 
not yet explored. PI-103 is a non-specific PI3K inhibitor, inhibiting both the PI3K 
pathway and the mTOR pathway. These results therefore suggest that the ability 
135 
 
















Figure 3.17: Inhibition of kinase activity suppresses Nrf2 activity in a GSK-3-dependent 
manner. 
(A) COS1 cells were seeded at 6 x 106 cells into 6-well plates and grown overnight until cells were 
about 70% confluent before transfection. Cells were transfected with plasmid encoding the 
Neh6+(lacZ)-V5 fusion protein, allowed to grow overnight before treatment with 50 µM tBHQ, 10 
µM Ferulic acid, or DMSO control for 18 hr in 1% reduced serum media (1% FBS DMEM). 
Pretreatment with 10 µM LY294002 or 5 µM Mk2206 or 5 µM CT99021 was done for 1 hr in 1& 
FBS DMEM media. β-galactosidase activity was measured using the Promega β-galactosidase kit 
according to manufacturer’s protocol using spectrophotometer. Cells were co-transfected with 
pRL-TK Renilla plasmid as transfection control and result was normalized against Renilla enzyme 
activity. (B) AREc32 cells were seeded at 5 x 106 cells/ 6-well plate and grown in 10% FBS DMEM 
overnight. Cells were treated with increasing concentration of CT99021 plus or minus 10 µM 
LY294002 or 1µM PI-103 for 18 hr in 1% reduced serum media.  Pretreatment with LY294002 or 
PI-103 were done for 1 hr. Luciferase assay was measured using the Promega luciferase assay 
according to manufacturers’ protocol as described in section 2. Luciferase data were normalized 
against protein concentration. Statistical analyses were done using graphpad prism and statistical 
significance assessed using unpaired t-test. Results significantly higher than DMSO vehicle 
control with p-values <0.05 or <0.01 are indicated with single (*) or double (**) asterisk signs 
respectively and results that are significantly lower than DMSO control with p-values <0.01 are 




3.2.9 PTEN functions as a sensor protein for agents that induce 
Nrf2 
A biotinylated analogue of the Nrf2 activator CDDO-Im was shown by Mike Sporn 
and colleagues to protect retinal cells from oxidant induced cell death through 
activation of antioxidant genes in a manner that led to phosphorylation of Akt 
through direct binding to Cys-124 in the active site of PTEN (Pitha-Rowe et al., 
2009). This led these authors to conclude that stimulation of the PI3K-Akt pathway 
by electrophiles is mediated by inhibition of PTEN activity. Subsequent work by 
Almazari et al. (2012) also indicated that the Nrf2 activator Guggulsterone 
increased HMOX1 expression via modification of PTEN and subsequent 
stimulation of phosphorylation of Akt. It is therefore possible that other Nrf2 
inducers can similarly inhibit PTEN thereby promoting Nrf2 activation because 
they activate the PI3K-PKB/Akt pathway and thus cause inhibitory 
phosphorylation of GSK-3.  
To assess the role of PTEN in inducing Nrf2-target genes, PTEN-wildtype and 
PTEN-knockout embryonic stem (ES) cells were treated with increasing 
concentrations of MK2206 and increasing concentrations of another Akt inhibitor 
called GSK690693. The results showed that loss of PTEN in the knockout ES 
cells caused an increase in Nrf2 protein levels. Treatment with Akt inhibitor 
MK2206 resulted in a decrease in Nrf2 protein at the higher concentration of 
MK2206 (10 µM) and treatment with GSK690693 resulted in a decrease in Nrf2 
protein abundance at the lowest concentration (1 µM) of the inhibitor in PTEN-
wildtype ES cells, however, treatment with both Akt inhibitors resulted in a 
decrease in Nrf2 protein levels in PTEN-knockout ES cells (Figure 3.18A). To 
further assess the effect of PTEN on Nrf2, PTEN activity was inhibited using a 
chemical inhibitor bpv(HOPIC). Inhibition of PTEN using bpv(HOPIC) in A549 
cells resulted in an increase in Nrf2 protein levels (Figure 3.18B). Bpv(HOPIC) 
caused a dose response increase in phosphorylation of Akt with 10 µM 
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bpv(HOPIC) giving the best corresponding increase in Nrf2 protein level. When 50 
µM tBHQ was used to treat Keap1+/+ and Keap1-/- MEFs and the expression of 
Hmox1 and Nqo1 assayed, it was observed that tBHQ caused an increase in the 
induction of Hmox1 and Nqo1 genes with a further increase when cells were 
treated with both bpv(HOPIC) and tBHQ (Figure 3.18C). A further question was to 
assess if inducers can directly inhibit PTEN phosphatase activity. To do this, 
Keap1-/- cells were treated with inducers for 18 hr and analysis of PTEN 
phosphatase levels showed that inducers gave a significant decrease in PTEN 
levels (Figure 3.18D). These results show that PTEN play a role in promoting Nrf2 
induction through the PI3K-Akt-GSK3 pathway and that inducers such as tBHQ 
would promote the induction of Nrf2 in the absence of Keap1 by directly 




















Figure 3.18: PTEN negatively controls Nrf2.  
(A) Mouse PTEN-wildtype (PTEN-WT) and PTEN-knockout (PTEN-KO) ES cells were treated with 
the Akt inhibitors MK2206 (5 µmol/l and 10 µmol/l) and GSK690693 (at 1 µmol/l and 10 µmol/l) for 
2 hr before Nrf2, GSK3, pGSK3, Akt and pAt protein levels were measured and 18 hr before 
NQO1 and GCLM protein levels were measured; actin was measured as a loading control. Loss of 
protein phosphates in PTEN-knockout ES cells, when compared with PTEN-wildtype cells, 
resulted in an increase in Nrf2 protein levels and this increase was attenuated by the Akt 
inhibitors. (B) Human A549 cells were treated with increasing concentrations of PTEN inhibitor 
bpv(HOPIC) (at 5 µmol/l and 10 µmol/l) for 2 hr for Nrf2 and pS473 Akt protein levels were 
measured; actin was measured as a loading control. (C) Keap1+/+ and Keap1-/- MEFs were treated 
with the PTEN inhibitor bpv(HOPIC) plus/minus Nrf2 inducer tBHQ for 6 hr or 12 hr to measure 
mRNA for Hmox1 or Nqo1 respectively. Relative levels of mRNA for Hmox1 and Nqo1 were 
quantified by Taqman analysis. The graphs represent the mean values from two independent 
experiments. Levels of mRNA for Hmox1 and Nqo1 were normalized against β-actin levels. 
Statistical analysis was done using graphpad prism and statistical significance assessed using 
unpaired t-test.  (C) Keap1-/- MEFs were seeded at 7 x 106 cells/6-cm dishes and grown in 10% 
FBS DMEM media for 18 hr before they were transferred to reduced serum media (1% FBS 
DMEM) and left to acclimatize for 16 hr. They were then treated with 50 µM tBHQ, 10 µM DEM, 
100 nM CDDO-Im, 15 µM curcumin, 10 µM ferulic acid and 5 µM SFN for 18 hr and the amount of 
PTEN measured by ELISA. The amount of PTEN protein in samples was normalized against 
amount of PTEN protein in standards with known protein concentration. The amount of PTEN 
corresponds to the amount of PI(4,5)P2 produced in reaction corresponding to the activity of of 
PTEN. Results significantly higher than DMSO vehicle control with p-values <0.05 or <0.01 are 
indicated with single (*) or double (**) asterisk signs respectively. The graph displays the mean 




Since Nrf2 regulates several aspects of cell physiologies going beyond its redox-
regulating capabilities, stringent control of this transcription factor is necessary. 
Keap1 targets Nrf2 for degradation in the cytoplasm, maintaining a relatively high 
turnover rate in the cytoplasm with Nrf2 possessing a short half-life of about 10- 
20 min (Nguyen et al., 2003; Stewart et al., 2003; Kobayashi et al., 2004b; Smith 
et al., 2015) . Activation of Nrf2 signalling and induction of Nrf2-target genes that 
ensures the enzymatic detoxification and excretion of chemical carcinogens, 
repair of oxidative damage or quenching of reactive oxygen species has ensured 
that targeting of Nrf2 in cancer prevention a prime research interest. Several 
studies on how Nrf2 is regulated in cancer prevention and treatment have been 
extensively published but new insights to the context of each regulatory pathway 
is still necessary. It has previously been shown that inducers of Nrf2 modulate the 
binding of Keap1 to Nrf2, however several lines of evidence also point to the fact 
that Nrf2 can be regulated in a Keap1-independent manner. This chapter exposes 
a new mechanism by which inducers of the Nrf2 pathway increase the expression 
of Nrf2-target genes through prevention of its degradation by the SCFβ-TrCP E3 
ubiquitin ligase.  
In this chapter, it is demonstrated that inducers of Nrf2 are able to regulate the 
expression of its target genes in a Keap1-independent manner. It has been widely 
demonstrated that many agents that induce Nrf2-target genes do so by modifying 
key cysteine residues in Keap1 preventing Keap1-mediated Nrf2 turnover (Zhang 
and Hannink, 2003; McMahon et al., 2003; Yamamoto et al., 2008). In a previous 
study, nordihydroguaiaretic acid (NDGA) was shown to increase Nrf2 and Hmox1 
protein levels in Keap1-/- MEFs(Rojo et al., 2012). Interestingly, this work has 
found that other inducers such as tBHQ, DEM, carnosol, curcumin, ferulic acid 
and CDDO-Im also activate Nrf2-target gene in Keap1-independent manner. This 
is consistent with the work by Yamamoto et al. (2008) where mutation of Cys-151 
to serine did not abolish the stabilization of Nrf2 and induction of reporter genes in 
response to tBHQ. However, consistent with previous literature (Zhang and 
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Hannink, 2003; Yamamoto et al., 2008) that show that SFN modifies Cys-151 in 
Keap1 for it to activate Nrf2, SFN was unable to induce Nrf2-target gene in Keap1-
/- MEFs.  
As stated earlier, Nrf2 is also negatively regulated by GSK-3 signalling leading to 
ubiquitylation through SCFβ-TrCP (Rojo, Sagarra and Cuadrado, 2008; McMahon et 
al., 2004; Rada et al., 2011; Chowdhry et al., 2013). GSK-3 is constitutively active 
in cell regulating just about 100 proteins involved in glycogen metabolism, 
transcription, translation, cell cycle progression and apoptosis (Doble, 2003). 
Phosphorylation of GSK-3α and GSK-3β at Ser-21 and Ser-9 respectively leads to 
its deactivation (Doble, 2003). Consistent with this, the result obtained showed 
that inducers that regulate Nrf2 independently of the Keap1 status of the cell do 
so by increasing the phosphorylation of GSK-3 in Keap1-/- MEFs at Ser-21 and 
Ser-9 of GSK-3α and GSK-3β respectively. Here it is reported for the first time 
that tBHQ, CDDO-Im, DEM, and ferulic acid decrease the activity of GSK-3α and 
GSK-3β in a ‘hot’ assay. One thing that is noticeable from the results obtained is 
that inducers also phosphorylate GSK-3 even in the presence of Keap1. The 
ARE-driven luciferase activity in cells expressing Nrf2∆ETGE show all inducers with 
the exception of SFN increasing luciferase activity consistent with the hypothesis 
that these inducers activate Nrf2 in a keap1-independent mechanism. However, in 
cells expressing Nrf2∆DSGIS, the ability of these inducers to increase ARE-driven 
luciferase activity was not aborted but instead promoted the increase in luciferase 
activity. This indicates that these inducers target both the Neh6 domain and the 
Neh2 domain. This is consistent with study by (Rojo et al., 2012) which show that 
NDGA promoted longer half-life for protein fused to the Neh2 domain of Nrf2 and 
protein fused to the Neh6 domain demonstrating that NDGA targets both the 
Neh2 and the Neh6 degrons. This chapter therefore show that most inducers can 
regulate Nrf2 through targeting of both the Neh2 domain and the Neh6 domain 




Several signal-transduction pathways such as PI3K-Akt/PKB, p90RSK MAPK, and 
mTOR regulate GSK-3 through mediating phosphorylation of the kinase (Frame 
and Cohen, 2001; Sutherland, 2011). Activation of PI3K-Akt by growth factor 
stimulation inhibits GSK-3 through phosphorylation at Ser-21 in GSK-3α and Ser-
9 in GSK-3β  (Van Weeren et al., 1998; Doble, 2003). Activation of Nrf2-target 
genes by tBHQ, ferulic acid, CDDO-Im, 4-hydroxyl-2-nonenal (4-HNE), acrolein 
and curcumin through PI3K/Akt signalling has been highlighted by several studies 
in different cell systems (Lee et al., 2001; Martin et al., 2004; Li, Cha and Surh, 
2006; Kang et al., 2007; Chen et al., 2009; Ma et al., 2010). Inhibition of PI3K was 
also shown to block the induction of Nrf2-target genes in similar studies (Nakaso 
et al., 2003; Martin et al., 2004; Salazar et al., 2006). Therefore, analysis of the 
role played by PI3K in our panel of inducers using two PI3K inhibitors, LY294002 
and PI-103. It is observed that inducers increased the phosphorylation of GSK-3α 
and GSK-3β at Ser-21 and Ser-9 respectively and inhibition of PI3K blocked the 
increased phosphorylation by tBHQ. Inhibition of PI3K also blocked the induction 
of ARE-driven luciferase activity as well as Nrf2-target gene induction. This is 
consistent to what other studies has found (Lee et al., 2001; Nakaso et al., 2003; 
Martin et al., 2004; Salazar et al., 2006). Although all these different research 
groups have outlined the involvement of PI3K-Akt signalling in activation of ARE-
driven genes and which this work have confirmed, they have however not 
described if this induction mediated by PI3K is Keap1 dependent. The results 
reported in this chapter show that the regulation of Nrf2 through the PI3K-PKB/Akt 
signalling pathway is independent of Keap1. Inhibition of PI3K by LY294002 or 
Akt by MK-2206 repressed Nrf2-target gene induction mediated by inducers in a 
Keap1-/- MEFs. Blocking of Keap1-Nrf2 interaction using the bis-sulfonamide 
NG284 did not stop the kinase inhibitors from decreasing ARE-driven luciferase 
activity.  
Several of the studies mentioned earlier have demonstrated that PI3K-Akt 
signalling regulate GSK-3 through phosphorylation and other studies have linked 
induction of Nrf2-target genes to be stimulated by PI3K, not much has been 
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shown to formally link the induction of Nrf2-target genes by inducers mediated 
through the PI3K-Akt signalling pathway to the inhibition of GSK-3. Salazar et al. 
(2006) came close when they identified that the cross-talk between the survival 
signal elicited by PI3K-Akt and the induction of antioxidant genes was mediated 
by GSK-3β. Therefore, the findings in this chapter show that inhibition of GSK-3 
abolished the ability of PI3K inhibitor to repress Nrf2. Beside growth factors, the 
PI3K signalling pathway is also regulated by PTEN via AKT phosphorylation at 
Thr-308 and Ser-473 relaying signals to downstream target protein involved in cell 
proliferation, survival, cell death and cell transformation (Bader et al., 2005; Cully 
et al., 2006). Deficiency of PTEN arising as a consequence of mutation of the 
gene leads to constitutive activation of PI3K-AKT signalling pathways (Wu et al., 
1998). A study by (Kensuke et al., 2009) showed that inhibition of PI3K-Akt/PKB 
pathway by PTEN prevented the tBHQ-induced ARE-driven gene activation in 
Jurkat human leukemia cells. Other studies also show that activation of PTEN 
prevented induction of Nrf2 target genes (Pitha-Rowe et al., 2009; Almazari et al., 
2012). Cys-71 and Cys-124 in PTEN has been shown as sensor for Nrf2 
regulation through PI3K in cells (Pitha-Rowe et al., 2009; Shearn et al., 2013; 
Rojo et al., 2014). The hypothesis therefore was that inducers of Nrf2 that function 
via the PI3K-Akt pathway will do so by inhibiting PTEN directly. The data reported 
show that PTEN-knockout ES cells expresses increased levels of Nrf2 protein and 
increased induction of Nrf2-target genes that is consistent with the literature. 
Pharmacological inhibition of PTEN led to increase in expression of Nrf2-target 
genes in a Keap1-independent manner and promoted tBHQ-induced expression 
of Nrf2-target gene. Inhibition of PTEN in cells lacking Keap1 showed an increase 
in Nrf2 protein levels and in expression of its target genes, showing that the role of 
PTEN in regulation of Nrf2 is independent on Keap1. We show for the first time 
that our panel of inducers directly decreased PTEN phosphatase activity in a 
Keap1-independent manner.  
This chapter sheds more light on the mechanism(s) by which pharmacological 
inducers activate Nrf2. Thus, inducers of Nrf2-target gene expression can 
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increase Nrf2 activity both in the absence and presence of Keap1. Activation of 
Nrf2 by electrophilic inducers in the absence of Keap1 arises by inhibitory 
phosphorylation of GSK-3 resulting from activation of PKB/Akt and as a 
consequence of direct inhibition of PTEN protein, thereby preventing the 
formation of the phosphodegron in the Neh6 domain of Nrf2. It has also been 
shown that compounds that steriochemically inhibit the activity of GSK-3, such as 
CT99021, are a separate class of non-electrophilic inducers that work 







4.0 Mechanism and therapeutic value of inhibition of Nrf2 CNC-
bZIP transcription factor in cancer. 
4.1 Introduction 
In order to maintain cellular homeostasis arising from ROS imbalance, several 
adaptive mechanisms are activated, including the induction of genes encoding 
phase I, II and III detoxification proteins and antioxidant enzymes (Itoh et al., 
1997; Miao et al., 2005; Bryan et al., 2013). Within the heterodimer, Nrf2 is 
responsible for gene transactivation and it maintains redox homeostasis by 
inducing the expression of over 200 cytoprotective genes in response to redox 
stressors (Hayes and Ashford, 2012). Alongside its role in cellular defense, Nrf2 
also plays a role in cell differentiation, proliferation, hematopoiesis and the 
regulation of fatty acid metabolism (Bryan et al., 2013). 
Nrf2 functions to inhibit the initiation of carcinogenesis but recent evidence shows 
that Nrf2 is also up-regulated in many types of cancer, and may play a significant 
role in tumour growth and resistance to anti-cancer therapies (Ren et al., 2011). 
The involvement of Nrf2 in cancer promotion was first observed when 
hepatocellular carcinoma (HCC) was showed upregulation of Nrf2 and GSTP1 
(Ikeda, Nishi and Sakai, 2004). More evidence of the role of Nrf2 in promoting 
tumourigenesis and chemoresistance in cancer has surfaced. Many studies have 
shown increased Nrf2 expression in many human cancers and that activation of 
Nrf2 in cancer helps to promote the progression of cancer. Nrf2+/+ mice 
administered with urethane to induce lung carcinoma developed higher number of 
kRas-mutated adenocaninoma in the later tumorigenic stages, with 60% of mice 
exhibiting large palpable nodules >5 mm as opposed to Nrf2-/- mice (Satoh et al., 
2013). In this study, Nrf2-/- though developed tumours faster at the early stage of 
urethane administration, exhibited a markedly reduction in tumour number and 
size at 24 weeks post urethane administration suggesting that the abundance of 
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Nrf2 in these mice is critical for the progression of lung cancer (Satoh et al., 
2013). In another study, A/J mice that were given vinyl carbamate to induce 
carcinogenesis and treated with sulforaphane to activate Nrf2 or brusatol to inhibit 
Nrf2 before and after tumour development showed that activation of Nrf2 
prevented the initiation of cancer in mice group that were pretreated with 
electrophiles but activation of Nrf2 promoted the progression of pre-existing 
tumours and inhibition of Nrf2 with brusatol was able to stop the progression of 
the tumours (Tao et al., 2018).  
Suppression of expression of detoxification enzymes and drug efflux pumps by 
inhibitors of Nrf2 might diminish cancer cell proliferation and sensitize tumours to 
therapeutic drugs. There is therefore a need to inhibit Nrf2 activity in tumours in 
which it is up-regulated. The aim of this chapter is to study what effect the 
repression of Nrf2 has on oxidative stress, cell growth and proliferation in tumour 
cells with high Nrf2 expression levels and also to understand what fuels the 
increased proliferation exhibited by cancer cells having increased Nrf2. 
 
4.1.1 Mutation frequencies of Keap1 and Nrf2 in cancer 
The accumulation of Nrf2 in cancer cells has been attributed to either somatic 
mutation of Keap1 and/or Nrf2 (Shibata et al., 2008b), or epigenetic modification 
of Keap1 promoter region (Wang et al., 2008a; Satoh et al., 2013). The 
identification of somatic mutation in the Kelch-like repeat domain of Keap1 in two 
lung cancer cell lines was the first to be described in the Nrf2 pathway 
(Padmanabhan et al., 2006). Mutation in Keap1 resulted in a significant 
diminished binding to Nrf2 subsequently leading to increased expression of Nrf2-
target genes  was reported in this study (Padmanabhan et al., 2006). In several 
human cancers, gain of function mutations in Keap1 and Cul3 have also been 
identified (Padmanabhan et al., 2006; Singh et al., 2006; Nioi and Nguyen, 2007; 
Ohta et al., 2008; Shibata et al., 2008a). 
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Somatic mutation of NFE2L2 in 11 out of 103 patients a study in lung cancer cell 
has been reported (Shibata et al., 2008b). Mutation in Nrf2 gene has also been 
seen in several cancers including lung, head, esophagus and neck carcinoma 
(Shibata et al., 2008b, 2011; Kim et al., 2010). High-resolution copy-number 
analysis in 125 HCC and whole exome sequencing on 24 of these tumours 
identified 6.4% mutation in NFE2L2 gene (Guichard et al., 2012). Similar studies 
on 300 HCC from Japanese individuals identified 3.7% mutation in NFE2L2 gene 
(Fujimoto et al., 2016). In another whole exome sequencing in 87 HCC patients, 
reported 8% mutation in Keap1 gene (Cleary et al., 2013). 25 mutations in 
NFE2L2 and 2 mutations in Keap1 were identified in 38 analyzed preneoplastic 
lesions in rat HCC (Zavattari et al., 2015).   
An analysis of tumour tissues from 1,391 patients with non-small cell lung cancer 
(NSCLC)  using next-generation sequencing (NGS) showed 11.3% and 3.5%  
mutation frequency of Keap1 and NFE2L2 respectively and no patient with 
mutation in Keap1 and Nrf2 responding to systemic first, second or third line of 
treatment (Frank et al., 2018). 
 
4.1.2 Nrf2 and cell proliferation 
Imbalanced redox consumption and signalling and high proliferation are all 
hallmark of cancer cells (Hanahan and Weinberg, 2011). The rate at which cancer 
cells proliferate has been shown by several studies to be dependent on the status 
of Nrf2 in cells. In a study to examine the effect of Nrf2 in three human lung 
cancer cell lines with different degree of Nrf2 activation, knockdown of Nrf2 using 
RNAi technique showed a significant decrease in cell proliferation rate in A549 
cells with high levels of Nrf2 (Homma et al., 2009). However, the inhibitory effect 
on cell proliferation by Nrf2 knockdown in this study was much lower in NCI-H292 
cells having moderate levels of Nrf2 and no effect on LC-AI cells with low levels of 
Nrf2. In a similar study in NSCLC A549 and H460 cells, depletion of Nrf2resulted 
in a pronounced decrease in cellular proliferation (Singh et al., 2008). In another 
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study on patients with primary malignant brain tumours, upregulation of Nrf2 
resulted in decreased survival and overall devastating outcome that was 
associated with increased cell proliferation and oncogenic transformation (Fan et 
al., 2017).  
Genes associated with cell proliferation including Bmpr1a, Ifg1 and jag1 have 
been identified as direct targets of Nrf2 by a genome-wide ChiP-sequencing 
analyses (Malhotra et al., 2010). Other Nrf2 target genes Cdkn1a and Cdkn2b 
have been shown to ack as cell cycle inhibitors (Malhotra et al., 2010). Through 
regulation of ROS, Nrf2 is able to control cell proliferation. Loss of the CncC bZIP-
CNC transcription factor in drosophilia intestinal stem cells has been reported to 
increase ROS and proliferative rate (Tsai et al., 2013). By regulating the enzymes 
involved in synthesis and reduction of thioredoxin and glutathione, Nrf2 is able to 
increase their cellular amount resulting in the elimination of ROS.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
4.1.3 Nrf2 alters NADPH generation, pentose phosphate pathway 
and fatty acid metabolism 
A switch in metabolism is one hall mark of cancer (Hanahan and Weinberg, 
2011). Microarray and ChiP-sequencing analysis has revealed that by activating 
the enzymes involved in metabolism and PPP, Nrf2 is able to regulate cell 
proliferation (Mitsuishi et al., 2012; Malhotra et al., 2010; Hirotsu et al., 2012). The 
regulation and consumption of the reducing agent NADPH used in anabolic 
reactions has been linked to Nrf2 via regulation of enzymes involved in NADPH 
generation (Wu, Cui and Klaassen, 2011; Mitsuishi et al., 2012; Thimmulappa et 
al., 2002). Nrf2-/- MEFs exhibit lower levels of NADPH and the NADPH/NADP+ 
ratio compared to wild-type MEFs (Singh et al., 2013).  
The major building block for the synthesis of triacylglycerides in the body is fatty 
acids (Santos and Schulze, 2012). Functioning as second messengers, lipids play 
a major role in signalling and as energy storage (Santos and Schulze, 2012). 
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Acetyl CoA serving as a precursor for fatty acid synthesis (FAS) is converted to 
malonyl-CoA which is itself involved in the elongation of fatty acids via the action 
of fatty-acid synthase (FASN) (Santos and Schulze, 2012). The role of Nrf2 in 
regulating lipid metabolism was first observed when genetic or pharmacological 
upregulation of Nrf2 caused change in expression of genes involved in lipid 
metabolism (Yates et al., 2009). Genetic upregulation of Nrf2 in Keap1-/- MEFs 
resulted in a decrease in the expression of genes involved in fatty acid synthesis 
and an increase in the expression of genes involved in fatty acid oxidation (Paek 
et al., 2012). The mRNA expression levels of Nrf2 and its target genes was shown 
to be suppressed in wild-type MEFs fed with a high fat diet (HFD) (Tanaka et al., 
2008). Fumarate a metabolite in the Krebs cycle has been reported to activate 
Nrf2 through succination of cysteine residues in Keap1 and fumarate hydratase 
(FH) deficiency-induced type-2 papillary renal carcinoma (pRCC) shows elevated 
Nrf2 expression (Adam et al., 2011). 
 
4.2 Experimental results 
4.2.1 Effect of Nrf2 knockdown on anti-oxidant genes and 
reactive oxygen species on tumour cells using shRNA. 
To understand the effect of inhibition of Nrf2 in cancer cells, two human NSCLC 
cell lines A549 and H460 having upregulated levels of Nrf2 due to somatic 
mutations in KEAP1 gene were used. Nrf2 was knock down (Nrf2-kd) in A549 and 
H460 cells using the mission shRNA and positive clones were picked, re-cultured 
and probed for knockdown efficiency. Of the five shRNA plasmids used, western 
blot analysis of each clone showed an 80% knockdown efficiency with plasmid E 
(Table 2.1) in A549 Nrf2-kd cells with a corresponding decrease in mRNA gene 
expression levels (Figure 4.1A&B) and a 70% knockdown efficiency for plasmid B 




Since the expression of genes involved in redox homeostasis, cytoprotection and 
drug metabolism are regulated by Nrf2, next the effect of Nrf2-kd on genes 
involved in redox homeostasis, cytoprotection and drug metabolism was 
analysed. Knockdown of Nrf2 resulted in a 70% - 80% decrease in mRNA levels 
of NQO1, HMOX1, GCLC and GCLM in shRNA Nrf2-kd A549 cells (Figure 4.2A). 
Using western blot to measure protein levels of Nrf2-target genes, a similar 70% - 
80% decrease in protein levels of HMOX1, AKR1B10, AKR1C1, GCLM, GCLC, 
and NQO1 was observed (Figure 4.2B). A similar 60% - 70% decrease was 
observed when mRNA levels of Nrf2-target genes were analysed in shRNA Nrf2-
kd H460 cells (Figure 4.2C) and a corresponding decrease in protein levels of 












Figure 4.1: Knockdown of Nrf2 in A549 and H460 cells 
 A549 and H460 were seeded into 6-well plates at a density of 4 x105 cells/well and grown 
overnight in 10% FBS DMEM media. Cells were transfected with five Mission shRNA (A-E) and a 
non-target shRNA control and allowed to grow in 10% FBS DMEM media following puromycin 
selection, positive clones were selected and knockdown efficency measured by western blot and 
taqman analysis. Panel A: Taqman NFE2L2 gene expression levels of A549 cells. Panel B: 
western blot for A549 cells. Panel C: Taqman NFE2L2 gene expression for H460 cells. And panel 
D: western blot for Nrf2 protein levels for H460 cells. Relative mRNA gene expression for NFE2L2 
gene was performed using Taqman analysis and normalised against β-actin levels. Statistical 
analyses were performed using graphpad prism and statistical significance assessed using 
unpaired t-test. Results that are significantly lower than sh-control with p-values <0.05, <0.01 or 
<0.001 are indicated with $, $$ or $$$ signs respectively. The graph represent the mean values 
from 2 independent experiments and is relative to the CT values obtained for sh-control samples. 
For western blot for protein samples, β-actin was used as a loading control. The result is a 




























Figure 4.2: Knockdown of Nrf2 decreased Nrf2-target gene expression 
A549 Nrf2-kd and H460 Nrf2-kd cells with their corresponding wild-type cells were seeded into 6 
cm dishes at a of 7 x 105 cells/dish in 10% FBS DMEM media for about 18-24 hr. RNA and protein 
were extracted and Taqman analysis and western blot were carried out to measure the expression 
of Nrf2-target genes. Panel A: Taqman gene expression for HMOX1, NFE2L2, NQO1, GCLC, 
GCLM, AKR1B10, and AKR1C1 for A549 cells. Panel B: western blot for A549 cells measuring 
protein abundance for HMOX1, AKR1B1, AKR1C1, GCLM, and NQO1. Panel C: Taqman gene 
expression levels for NFE2L2, NQO1, HMOX1, GCLC and GCLM for H460 cells. And panel D: 
western blot for H460 cells measuring protein abundance for Nrf2, AKR1C1, GCLM, GCLC, and 
NQO1. Relative mRNA gene expression for Nrf2-target genes was performed using Taqman 
analysis and normalised against β-actin levels. Statistical analyses were performed using 
graphpad prism and statistical significance assessed using unpaired t-test. Results that are 
significantly lower than wild-type (WT) cells with p-values <0.01 or <0.001 are indicated with $$ or 
$$$ signs respectively. The graph represent the mean values from 3 independent experiments 
and is relative to the CT values obtained for WT samples. For western blot for protein samples, β-





The Keap1-Nrf2 pathway has been shown to regulate cytoprotective response 
against endogenous and exogenous stress caused by ROS through regulating 
the expression of proteins involved in scavenging ROS (Kovac et al., 2015). 
Therefore, the level of ROS in these cells were analysed after knockdown of Nrf2.  
A549 Nrf2-kd cells showed an increase in the levels of ROS when Nrf2 was 
genetically knocked down (Figure 4.3A). Knockdown of Nrf2 in H460 cells caused 













Figure 4.3: Depletion of Nrf2 resulted in an increase in ROS in lung cancer cells 
To measure the level of ROS in A549 and H460 Nrf2 knocked down cells in comparison to 
wildtype (WT), A549 and H460 cells were seeded in triplicate into 6-well plate  at a density of 4 x 
105 cells/well and grown overnight in 10% FBS DMEM media. The level of ROS is measured by 
spectrophotometric analysis using the DCFH-DA dye. DCFH-DA measures the amount of reactive 
oxygen species produced. The amount of DCF produced is normalised against the amount of 
protein in cells after protein quantification. Results that are significantly higher than WT with p-
values <0.01 are indicated with double (**) asterisk signs. The results are a representation of three 
independent experiments all including 3 technical replicates. 
 
4.2.2 Effect of Nrf2 knockdown on cell growth and proliferation in 
tumour cells using shRNA. 
One major characteristic of cancer cells is increased proliferation and an 
imbalance in redox signalling (Fan et al., 2017). ROS has been shown act as 
second messenger, driving cellular signalling (Liou and Storz, 2010). Cell growth, 
proliferation and death is regulated and modulate by ROS status of the cell 
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environment (Sauer, Wartenberg and Hescheler, 2001; Day and Suzuki, 2006). 
Lower levels of ROS especially hydrogen peroxide have been reported to induce 
tumour growth (Day and Suzuki, 2006). Since Nrf2 is one of the major regulators 
of ROS, it will therefore control the levels of cell proliferation. Fan et al. (2017) 
showed that over-expression of Nrf2 in patients with malignant brain tumours 
increased cell proliferation and oncogenic transformation. As knockdown of Nrf2 
caused an increase in ROS levels in A549 and H460 cells, the effect of Nrf2 
knockdown on cell growth and proliferation was next assayed. Cell proliferation 
rate in A549 and H460 cells were measured using the Incucyte cell count 
proliferation assay and showed that knockdown of Nrf2 caused a significant 
decrease in cell proliferation rate in shRNA Nrf2-kd A549 cells (Figure 4.4A) and 
shRNA Nrf2-kd H460 cells (Figure 4.4B). To confirm the effect of Nrf2 knockdown 
on cell proliferation, colony formation assay was performed to show the number of 
colonies formed when Nrf2 was knocked down in cancer cells. The result show 
that knockdown of Nrf2 caused a significant decrease in the number of viable 
colonies formed in A549 Nrf2-kd cells (Figure 4.4C) and in H460 Nrf2-kd cells as 
opposed to wild-type. The results suggest that the elevated levels of Nrf2 in A549 


























Figure 4.4: Nrf2 enhances cell proliferation and growth 
A549 (A) and H460 WT (B) and Nrf2-kd cells were seeded into 12-well plates at a density of 
10,000 cells/well in 10% FBS DMEM media and incubated at 37oC 5% CO2 incubator overnight. 
Next day, plates were scanned in the Incucyte Zoom and repeated every 48 hr over a period of 10 
days. The media was changed every 48 hr and afterwards, the percentage of confluency obtained 
on each day was plotted against time elapsed. For colony formation, A549 (C) and H460 WT (D) 
and Nrf2- kd cells were seeded at 250 cells/10 cm dish in 10% FBS DMEM media for 18 days until 
visible colonies begin to appear. Cells were then fixed and stained in a solution of 2% toludine 




4.2.3 Nrf2 regulates cellular glutathione 
By regulating the transcription of enzymes involved in glutathione synthesis, Nrf2 
is able to regulate cellular levels of glutathione. Since knockdown of Nrf2 resulted 
in a decrease in expression of the two subunits of glutamate-cysteine ligase: 
GCLC and GCLM, a rate limiting enzyme required for synthesis of glutathione and 
also an increase in ROS, the effect of Nrf2 knockdown on cellular glutathione 
levels were ascertained. Knockdown of Nrf2 resulted in a 2-fold decrease in 
cellular glutathione in A549 Nrf2-kd cells (Figure 4.5A) and H460 Nrf2-kd cells 
(Figure 4.5B). An experiment by Reddy and His colleagues  showed that Nrf2 is 
able to regulate cell proliferation in pulmonary epithelial cells through regulating 
cellular glutathione levels (Reddy et al., 2007a). As knockdown of Nrf2 resulted in 
a decrease in cell proliferation and cellular glutathione levels, there was the need 
to check if restoration of glutathione in A549 Nrf2-kd cells would result in 
restoration of cell growth in comparison to the parental cell lines. To do this, A549 
Nrf2-kd cells were treated with the antioxidant N-acetylcysteine (NAC), a prodrug 
for L-cysteine used for production of glutathione in systems where it has been 
depleted. The results showed that treatment of WT and Nrf2-kd A549 cells with 
NAC caused an increase in the cellular glutathione in both A549 WT and A549 
Nrf2-kd cells (Figure 4.5C). NAC caused a 5-fold increase in cellular glutathione in 
A549 WT cells, and a 2-fold increase in A549 Nrf2-kd cells. When cells 
proliferation rate was measured in A549 WT and A549 Nrf2-kd plus/minus NAC, 
an increase in cell proliferation was observed in both A549 WT and A549 Nrf2-kd 
cells with treatment with NAC (Figure 4.5D). The result therefore shows that 
decrease cell proliferation is due to the decrease in glutathione levels as NAC 

















Figure 4.5: Cellular GSH reduction causes a decrease in A549 cell proliferation 
A549 and H460 WT and Nrf2-kd cells were seeded into 6-well plate at 4 x 105 cells/well in 10% 
FBS DMEM media and incubated overnight. Next day cells were harvested, and glutathione levels 
measured by monochlorobimane assay to measured reduced glutathione in A549 (A) and H460 
(B). The results were normalised against protein concentration in cells. In panel C, A549 WT and 
A549 Nrf2-kd cells were seeded into 10 cm dish at a density of 6 x 105 cells/dish in 10% FBS 
DMEM media and incubated overnight. Next day, cells were treated with 100 µg of NAC for 24 hr 
thereafter cells were harvested, and glutathione levels measured by modified Tietze glutathione 
assay. The concentration of reduced glutathione was normalized against protein concentration of 
samples. In D, A549 WT and Nrf2-kd cells were seeded into 12-well plate at 1,000 cells/well in 
10% FBS DMEM media. Next day, 100 µg NAC was added, and the cell proliferation rate was 
scanned using the Incucyte Zoom. Plates were returned to the incubator and allowed to grow for 
another 10 days and scanned every 48 hr with media changed to fresh 10% FBS DMEM media 
containing 100 µg NAC. Results that are significantly higher than WT with p-values <0.05 or <0.01 
are indicated with single (*) or double (**) asterisk signs respectively, while results significantly 
lower than WT control with p-values <0.05 or <0.01 are indicated with a single $ or double $$ 




4.2.4 Nrf2 controls cell proliferation by regulating the expression 
of metabolic genes 
Rapid tumour growth requires an adequate supply of nutrients and metabolic 
intermediates to serves as building blocks (Mitsuishi et al., 2012; DeBerardinis et 
al., 2008). Nrf2 has been shown to contribute to accelerated proliferation of 
cancer cells and to redirect glucose and glutamine into anabolic pathways in 
cancer cells (Mitsuishi et al., 2012). To understand how Nrf2 is controlling cell 
proliferation in cancer cells, examination of what effect the disruption of Nrf2 has 
on expression of genes involved in biosynthesis of macromolecules was carried 
out. The mRNA levels of genes involved in PPP including glucose-6-phosphate 
dehydrogenase (G6PD), phosphogluconate dehydrogenase (PGD), transaldolase 
1 (TALDO1), was measured. Also, the genes required for NADPH synthesis 
including malic enzyme 1 (ME1), pyruvate dehydrogenase lipoamide kinase 4 
(PDK4) and isocitrate dehydrogenase 1 (IDH1) was measured by TAqman. The 
results obtained showed that knockdown of Nrf2 in A549 cell resulted in an 
approximate 70% decrease in G6PD, PGD1 and TALDO1 genes involved in 
pentose phosphate pathway (Figure 4.6A).  Similarly, knockdown of Nrf2 in A549 
cells resulted in an approximate 50% decrease in ME1, IDH1, and PDK4 genes 
involved in NADPH production and carbohydrate metabolism (Figure 4.6B).  
Evidence has also shown that Nrf2 is involved in fatty acid metabolism. To check 
this, mRNA levels of genes involved in fatty acid metabolism was analysed in 
A549 WT and Nrf2-kd cells. Knockdown of Nrf2 resulted in a significant decrease 
in expression level of the peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), acyl-
coenzyme A oxidase 2 (ACOX2), carboxylesterase 1 (CES1) and carnitine 
palmitoyltransferase 1(CPT1). However, Knockdown of Nrf2 caused a significant 
increase in the expression of acetyl-coenzyme A acyltransferase 1 (ACAA1) and 














Figure 4.6: Nrf2 knockdown alters the expression of genes involved in PPP, NADPH 
production and fatty acid oxidation.   
A549 WT and Nrf2-kd cells were seeded at 7 x 105 into 6 cm dishes in 10% FBS DMEM media 
and allowed to grow overnight. Taqman gene expression levels of G6PD, PGD1, and TALDO 
involved in PPP was measured (A). In panel B, Genes expression levels of ME1, IDH1 and PDK4 
involved in NADPH was measured. In panel C, Taqman Analyses of gene expression profile of 
fatty acid oxidation genes ACOX1, ACOX2, CPT1 and CES 1, SCD1 and ACAA1 is represented. 
Expression levels were normalized against β-actin mRNA. Multiple t-test analyses showed that 
results significantly higher than WT with p-values <0.05 or <0.01 are indicated with single (*) or 
double (**) asterisk signs respectively, while results significantly lower than WT control with p-
values <0.05 or <0.01 are indicated with a single $ or double $$ respectively. Each result is a 
representation of three independent experiments.    
 
4.2.5 Decreased cell proliferation is not as a result of cell death 
To ascertain if the decrease in cell proliferation observed when Nrf2 was knocked 
down in A549 and H460 cells was as a result of cell death, A549 WT and Nrf2-kd 
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cells were stained with celltox green dye that gives a fluorescence signal when 
bound to dead cell that is proportional to the number of dead cells in a culture and 
allowed to grow. Incucyte analysis of cell viability showed little or no cell death in 
A549 Nrf2 kd cells even though cell proliferation is decreased as opposed to A549 
WT (Figure 4.7). This suggests that the decrease in cell proliferation is not as a 
result of the cells death. 
 
 
Figure 4.7: Loss of Nrf2 not associated with cell death 
A549 WT and Nrf2-kd cells were seeded into 12-well plate at 1,000 cells/well in 10% FBS DMEM 
media. Celltox green dye was added next day and plate scanned using the Incucyte Zoom. Plates 
were returned to incubator and allowed to grow for another 10 days and scanned every 48 hr with 
media changed to fresh 10% FBS DMEM media containing celltox green dye. A549 WT cell is 
shown in green line; A549 Nrf2-kd cell is grown as blue line while A549 Nrf2-kd cell expressing the 
green dye is shown as red line. 
 
4.2.6 Nrf2 and cell cycle Protein 
As Nrf2 caused a decrease in cell proliferation, and this was not due to cell death, 
next examination of cell cycle progression to verify if the decrease in cell 
proliferation and growth was as a result of an arrest in the cell cycle. A previous 
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study using brusatol, an Nrf2 inhibitor in mouse reported that inhibition of Nrf2 was 
associated with cell cycle arrest (Lin et al., 2018). An earlier study in Nrf2-/- 
primary epithelial culture also reported that Nrf2 deficiency led to oxidative stress 
and DNA lesions that was accompanied by impairment of the cell cycle (Reddy et 
al., 2008). Several well characterized genes have been reported to be responsible 
for cell cycle progression including the cyclins and cyclin-dependent kinases (Lin 
et al., 2018). Western blot analysis of some cell cycle protein in A549 and H460 
WT and Nrf2-kd cells showed that knockdown of Nrf2 caused a decrease in the 
protein levels of cyclin A, cyclin B and p-CDC2 (Tyr15) in both A549 (Figure 4.8A) 
and H460 Nrf2-kd cells (Figure 4.8B). Next, using FACS and staining with PI the 
total amount of cell in the phases of the cell cycle was determined. Knockdown of 
Nrf2 in A549 cells caused a decrease in number of cells entering the S phase 
suggesting a G0/G1 phase arrest (Figure 4.8C). However, knockdown of Nrf2 in 
H460 showed no significant change in the amount of cell entering the S phase 






































Figure 4.8: Nrf2 knockdown caused a decrease in cell cycle protein 
A549 and H460 cells were seeded at 7 x 105 cells/6 cm dish in 10% FBS DMEM media and 
allowed to grow overnight. The protein levels of some cell cycle proteins were measured via 
western blot for A549 WT against A549 Nrf2-kd cells (A) and H460 WT against H460 Nrf2-kd cells 
(B). FACS analysis for cell cycle phases were performed for A549 WT against A549 Nrf2-kd cells 
(C) and H460 WT against H460 Nrf2-kd cells (D). Multiple t-test analysis showed that results 
significantly higher than WT with p-values <0.05 or <0.01 are indicated with single (*) or double 
(**) asterisk signs respectively, while results significantly lower than WT control with p-values 
<0.05 or <0.01 are indicated with a single $ or double $$ respectively. The abbreviation n.s 
represents statistical analysis results that are not significant. The results are a representation of 





Lung cancer with a significantly lower survival rate than the majority of epithelial 
malignancies is one of the leading cause of cancer-related death (Best et al., 
2018). Increased ROS has been reported in several cancer cell and are involved 
in cell cycle progression and proliferation, cell survival and apoptosis, energy 
metabolism, cell morphology, angiogenesis and maintenance of tumour stemness 
(Liou and Storz, 2010). However, tumour cells also express increased levels of 
antioxidant proteins to detoxify ROS creating a balance of the intracellular ROS 
levels required for driving cancer cells (Liou and Storz, 2010). Nrf2 has been 
reported to control the expression of antioxidant genes in response to ROS in 
cells. This chapter confirms that knock down of Nrf2 in A549 and H460 caused a 
significant increase in the level of intracellular ROS. This result is consistent with 
that reported by Singh et al. (2011) were knockdown of Nrf2 was able to induce 
the generation of ROS, suppress tumour growth and increased sensitivity to 
chemotherapeutic drugs. Similar results were also reported by Shao et al. (2018).  
High levels of Nrf2 in cancer cells correlate with poor prognosis due not only to 
their resistance to chemo- and radio-therapy but also due to their increased 
proliferative rate (McDonald et al., 2010; Solis et al., 2010; Bai et al., 2016). Cells 
need to proliferate for proper functioning of tissues, embryo development and 
death, however the rate of proliferation in tumour cells is heightened. A549 and 
H460 cells had higher proliferative rate as opposed to A549 Nrf2-kd cells. 
Knockdown of Nrf2 resulted in a decrease in cell proliferation and colony 
formation in both A549 and H460 cells. This decrease in cell proliferation is 
consistent with result shown by (Homma et al., 2009). 
Proliferating cells use-up abundant nutrient including glutamine and glucose 
(DeBerardinis et al., 2008). Studies have shown that glutathione is essential for 
cells to proliferate effectively. By regulating the key enzymes required for 
glutathione synthesis Nrf2 is able to regulate glutathione synthesis. The result 
reported in this chapter shows that knockdown of Nrf2 caused a decrease in 
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GCLC and GCLM. Measurement of the total cellular glutathione revealed a high 
level of glutathione in A549 and H460 which was decreased when Nrf2 was 
genetically knockdown in these cells. To confirm if glutathione was indeed 
required for the cells ability to proliferate, A549 Nrf2-kd cells were treated with 
NAC. The result show that NAC increased cellular glutathione levels in both A549 
WT and A549 Nrf2-kd cells. This increase also correlated with an increase in the 
proliferative rate of the cells. A549 cells proliferated more on treatment with NAC 
while A549 Nrf2-kd cells also expressed an increase in their rate of proliferation. 
This confirms that the decrease in cell proliferation observed in Nrf2 knockdown 
can be attributed to the glutathione levels in these cells.   
Cells that are actively proliferating take up nutrients in excess beyond the 
requirement for bioenergetic need and shunt metabolites into pathways that 
promote biosynthesis (DeBerardinis et al., 2008). One hallmark of cancer cell is 
the ability to switch metabolic pathway. Microarray and Chip sequencing data 
reveal that by activating metabolic genes involved in pentose phosphate pathway, 
Nrf2 is able to regulate cell proliferation (Malhotra et al., 2010; Mitsuishi et al., 
2012). By generating NADPH, the pentose phosphate pathway is able to prevent 
oxidative stress (Moon and Giaccia, 2015). The flux of glucose either through the 
glycolysis or PPP is controlled by G6PD. By controlling the expression of G6PD 
Nrf2 is able to favour biosynthetic reactions (Wu, Cui and Klaassen, 2011). Also, 
the non-oxidative phase of the PPP is also regulated by Nrf2. TALDO1 has been 
reported to have a functional ARE sequence in its promoter and such is a direct 
target for Nrf2 (Malhotra et al., 2010; Chorley et al., 2012). Consistent with 
previous research, Nrf2 is able to upregulate G6PD, PGD, TALDO1, ME1 and 
IDH1. Knockdown of Nrf2 showed a significant decrease in the expression of 
these genes. By mediating the expression of these genes, Nrf2 is able to alter 
glucose and glutamine metabolism to promote cancer cell proliferation. Proteomic 
analysis of Nrf2 deficient mice has reported that Nrf2 controls lipid metabolism 
(Kitteringham et al., 2010). Several lipases involved in the degradation of 
triglycerides and phospholipids and fatty acid oxidation has been reported to be 
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reported by Nrf2. The results obtained in this chapter confirms that Nrf2 is able to 
regulate lipid metabolism. Knockdown of Nrf2 caused an increase in SCD1 an 
enzyme that catalyses the rate limiting step in unsaturated fatty acid synthesis. 
Repression of SCD1 by Nrf2 reduces the biosynthesis of monounsaturated fatty 
acid (Flowers and Ntambi, 2008). Nrf2 knockdown also caused a decrease in the 
expression of ACOX1, ACOX2, CES1 and CPT1.  
Based on the observation that impairment of Nrf2 compromises or delays entry to 
the M-phase of the cell cycle, Nrf2 has been described to be required for the 
transition from G2-phase to M-phase in the cell cycle (Reddy et al., 2008; Zou et 
al., 2015). Activation of Cdk1/cyclin B1 pathway is required for G2/M transition. 
Measurement of cdc2 and cyclin B1 protein abundance in A549 and H460 cells 
shows that Nrf2 knockdown caused a decrease in cdc2 and cyclin B1 proteins 
consistent with this observation. A member of the cyclin family functioning in the 
regulation of cell cycle progression, cyclin A is able to activate two different cyclin-
dependent kinases (CDK), CDK1 and CDK 2 in both S phase and mitosis(Yam, 
Fung and Poon, 2002).  Western blot data of cyclin A showed a decrease in the 
protein abundance of the cell when Nrf2 was knocked down. Consistent with this, 
FACS analysis of A549 cells revealed a decrease in the number of cells in the S 
phase suggesting a G0/G1 arrest in A549 Nrf2-kd cells as opposed to A549 cells. 
This data is different from previous research that reported a G2/M phase arrest 
(Reddy et al., 2008; LIN et al., 2018). However, both reports have not studied 
human cancer cells but have looked at mouse. Further work to confirm this data is 
advised.    
Consistent with previous reports, the data presented in this chapter reveal that 
knockdown of Nrf2 in cancer cells results in a decrease in the expression of Nrf2-
target genes encoding phase II drug-metabolising enzymes and enzymes 
involved in the neo-synthesis of glutathione. The loss of Nrf2 also caused a 
decrease in ROS levels in these cells consistent with the ability of Nrf2 to control 
ROS imbalance. Nrf2 knockdown in these cancer cells caused a decrease in cell 
proliferation and growth and this is due to a corresponding decrease in 
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glutathione synthesis as treatment with NAC resulted in a rescue of cell 
proliferation rate. The decrease in cell proliferation was shown to be independent 
of cell death but might be due to decrease in nutrient supply, impairment of 
biosynthesis of macromolecules required for growth and decrease in 






























5.1 Nrf2 activators function in both Keap1 and Keap1-
independent mechanism in Nrf2-target gene induction 
The ability of Nrf2 to transactivate genes encoding proteins involved in redox 
homeostasis, stress response, drug metabolism, drug transport and intermediary 
metabolism has made it a useful cytoprotective transcription factor in cancer 
prevention. Controlled Nrf2 upregulation has been seen to protect cells against 
the initiation of many types of cancer (auf dem Keller et al., 2006; Thimmulappa et 
al., 2008). Nrf2-/- mice despite their normal embryonic development and lifespan, 
readily develop tumours when exposed to chemical carcinogens, validating the 
role of Nrf2 in cancer prevention (Ramos-Gomez et al., 2001). However, co-
administration of Nrf2 activators and a carcinogen results in reduced tumour 
volume (Yates et al., 2006).  
Recent research has focused on the ability of many foods and traditional 
medicines to activate Nrf2 thus serve as therapeutic drugs. Natural electrophiles 
contained in some of these food target Cys-151 in Keap1 leading to an increased 
abundance of Nrf2 and subsequent induction of genes encoding antioxidants, 
phase II detoxification enzymes and transporters, validating their use for 
therapeutic benefit (Harder et al., 2015). The two most studied Nrf2 activators are 
SFN generated from glucoraphanin within broccoli through the actions of 
myrosinase (Zhang et al., 1992); and cinnamaldehyde isolated from cinnamon by 
deamination of L-phenylalanine into cinnamic acid through the action of 
phenylalanine lyase (PAL) (Singh et al., 2007; Gutzeit, and Ludwig-Muller, 2014.). 
Administration of SFN to mice protected them against development of 7,12-
dimethylbezan(a)anthracene-induced skin tumour (Xu et al., 2006). Lung 
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carcinogenesis in A/J mice caused by tobacco was also seen to be suppressed by 
treatment with SFN (Conaway et al., 2005). In humans, consumption of broccoli 
has been linked with prevention of colon, lung, breast, liver and prostate cancer 
(Spitz et al., 2000; Seow et al., 2002; Ambrosone et al., 2004; Joseph et al., 2004; 
Kensler et al., 2005). Evaluation of the chemopreventive properties of broccoli 
sprout in a phase II clinical trial in China revealed that SFN decreased aflatoxin-
DNA adducts in humans (Kensler et al., 2005). Cinnamaldehyde was shown to 
decrease tumour in colorectal cancer by inducing Nrf2-target genes (Long et al., 
2015). Another well studied chemopreventive natural product capable of 
activating Nrf2 is curcumin. Increased expression of Nrf2, and inhibition of 
oxidative stress, inflammation and DNA adduct formation was seen in 
benzo(a)pyrene-induced liver and lung carcinogenesis when curcumin was 
administered in the diet (Garg, Gupta and Maru, 2008; Thimmulappa et al., 2008). 
Bardoxolone-methyl (CDDO-Me) and dimethylfumarate (DMF), two other Nrf2 
activators has passed into clinical trials and the clinic respectively. However, due 
to safety issues, bardoxolone was retracted at phase III clinical trial. Increased 
glomerular infiltration rate in patients with chronic kidney disease was ascribed to 
prolong bardoxolone treatment in phase II clinical trials for the treatment of 
diabetic nephropathy using bardoxolone (Pergola et al., 2011; Zhang, 2013; Chin 
et al., 2018).  
Due to the presence of the two degradation degrons within the Neh2 and Neh6 
domains, Nrf2 is controlled primarily at the level of protein stability by Keap1 and 
β-TrCP. Keap1 as the primary regulator of Nrf2 as discussed previously is subject 
to oxidative and electrophilic modification. SFN present in cruciferous vegetables 
such as broccoli has been shown to target the Keap1 at Cys-151 (Zhang and 
Hannink, 2003). CDDO-Me has been reported to interact with Cys-151 in the BTB 
domain of Keap1, interfering with the Keap1/cul3 interaction leading to Nrf2 
activation (Cleasby et al., 2014). DMF has also been shown to alkylate cysteine 
residues in Keap1 preventing ubiquitination and promoting stabilization and 
subsequent activation of Nrf2-target genes (Phillips and Fox, 2013). Other than 
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sharing the ability to modify sulfhydryl groups of cysteines by oxidation and adduct 
formation, xenobiotic compounds that activate Nrf2 are diverse in nature (Rojo et 
al., 2012). Different electrophiles modify cysteine residues in Keap1 in their own 
way in activation of Nrf2 displaying a unique pattern of cysteine modification 
(Dinkova-Kostova et al., 2002; Eggler et al., 2005; Hong, Freeman and Liebler, 
2005; Hong et al., 2005; Fujii et al., 2010) A recent study has shown that 
nordihydroguaiaretic acid (NDGA) increased Nrf2 and Hmox1 levels through 
inhibiting the phosphorylation the Neh6 domain in Nrf2 by GSK-3 (Rojo et al., 
2012). With the increased tendency for Nrf2 activators to target cysteines and 
multiple signalling pathways, one major fear with the Nrf2 activators used as 
pharmacological agents is occurrence of cytotoxicity arising as a result of off-
target effects. An understanding of the physiological or pathological state under 
which a specific E3 ubiquitin ligase will play a dominant role in regulating Nrf2 is 
required for effectively activating Nrf2 for disease prevention. Our result shows 
that Nrf2 activators increase the expression of Nrf2 target gene in a Keap1-
independent manner. tBHQ, CDDO-Im, DEM, curcumin, carnosol, and ferulic acid 
increased the expression of Nqo1 and Hmox1 genes in Keap1-/- MEFs.  
The evidence that Nrf2 is inhibited by GSK-3 was first demonstrated in a study on 
Skn-1, an orthologue of Nrf2 present in Caenorhabditis elegans. The result shows 
that phosphorylation of Skn-1 protein mediated by GSK-3 prevented the nuclear 
accumulation of Skn-1 and subsequent activation of phase II detoxification genes 
(An et al., 2005). Earlier work by McMahon et al. (2004) revealed that Nrf2 is 
negatively regulated by another domain other than Neh2 because when the 
ETGE Keap1-binding motif in the Neh2 domain is deleted, the mutant Nrf2 protein 
was still found to possess a short half-life. Specifically, examination of Nrf2 
deletion mutants not targeted by Keap1 (e.g. including Nrf2∆116-131, Nrf2∆177-193, 
Nrf2∆329-339, Nrf2∆329-379 and Nrf2∆363-379), revealed that only those that lack the 
Neh6 domain (i.e. Nrf2∆329-339 and Nrf2∆363-379) exhibited increased stability 
(McMahon et al., 2004). GSK-3 was subsequently identified to inhibit Nrf2 by 
preventing the nuclear accumulation of the CNC-bZIP factor (Salazar et al., 2006; 
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Rojo, Sagarra and Cuadrado, 2008). The repression of Nrf2 by GSK-3 was found 
to be independent of Keap1 and controlled by two β-TrCP recognition motif 
(Chowdhry et al., 2013) through the Neh6 domain. In this thesis, treatment of 
Keap1-/- MEFs with inducers of Nrf2 increased the phosphorylation of GSK-3 at 
Ser-21 and Ser-9 moderately. Furthermore, use of a ‘Hot’ assay to measure GSK-
3 activity showed a slight decrease in the activity of GSK-3α and GSK-3β 
following treatment with Nrf2 electrophilic activators. Collectively, the results 
presented in this thesis revealed a Keap1-independent mechanism for induction 
of Nrf2-target gene by electrophiles through prevention of GSK-3/β-TrCP-
dependent degradation of Nrf2 via its Neh6 domain.   
5.2 Contribution of the PI3K-Akt/PKB signaling pathway to 
pharmacological induction of Nrf2-target gene expression 
PI3K mutation frequency has been observed in 11% of human lung 
adenocarcinomas (Collisson et al., 2014b).  There has been suggestion, that 
activation of Akt/PKB is regulated by ROS (Ushio-Fukai et al., 1999) in a manner 
in which inhibitors of the Akt/PKB signalling pathway would suppress Nrf2-target 
gene while growth factor signalling would drive the activation of Nrf2-target gene 
through inactivation of GSK-3. Another study also show that nerve growth factor 
prevents the accumulation of ROS by  a mechanism that is dependent on 
PI3K/Akt-dependent induction of Hmox1 (Salinas et al., 2003). In a study to 
understand how several stress proteins are upregulated by oxidative stress in 
dopaminergic neurons in the pathogenesis of Parkinson’s disease, PI3K was 
identified as important. In this study, PI3K-related signaling controlled the 
activation of Nrf2 and inhibitors of PI3K signalling blocked nuclear translocation of 
Nrf2 and its target protein (Nakaso et al., 2003). All of these studies therefore 
show that the activation of PI3K-Akt/PKB kinase signalling pathway is required for 
the induction of ARE-driven genes. 
Several studies have shown that many xenobiotics stimulate cell signalling 
cascades that participate in Nrf2 regulation. An initial study by the lab of Jeffery 
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Johnson reported that the activation of the human NQO1-ARE by tBHQ was 
mediated by PI3K and not extracellular signal-related kinase (ERK 1/2) in IMR-32 
cells (Lee et al., 2001). Antonio Cuadrado and his colleagues also showed that 
the induction of ARE-driven genes by carnosol required the activation of the PI3K-
Akt/PKB kinase signalling pathway (Martin et al., 2004). Several studies also 
highlighted the role of PI3k-Akt signalling in the induction of ARE-gene battery by 
tBHQ (Kang et al., 2001, 2002; Zhang et al., 2015b). In addition, several studies 
reported that inhibition of PI3K using LY294002 impairs the induction of ARE-
driven gene activation by tBHQ, 4-HNE, curcumin, ferulic acid and CDDO-Im 
(Chen et al., 2009; Kang et al., 2007; Li, Lee and Johnson, 2002; Li, Cha and 
Surh, 2006; Ma et al., 2010). In chapter 3 of this thesis, it was shown that 
inhibition of PI3K by LY294002 and PI-103 caused a decrease in basal Nrf2 
protein levels and in tBHQ, carnosol, and CDDO-Im ARE-driven and Nrf2-target 
gene expression consistent with previous research (Lee et al., 2001; Nakaso et 
al., 2003; Martin et al., 2004). Another key discovery was that regulation of Nrf2 
through the PI3K-Akt/PKB signalling pathway is independent of Keap1 as 
inhibition of PI3K repressed Nrf2-target gene induction in Keap1-/- MEFs.  
As discussed earlier, the activity of PI3K-Akt is negatively regulated by PTEN 
(Cantley and Neel, 1999; Gericke, Munson and Ross, 2006). PTEN has been 
implicated as a tumour suppressor in lung cancer cells, with 27% of human 
tumours harboring mutation in the PTEN gene (Best et al., 2018; Collisson et al., 
2014b). Mutation of the PTEN gene or genetic knockdown of PTEN activates Akt  
(Salmena, Carracedo and Pandolfi, 2008). Results in chapter 3 of this thesis 
confirm this as PTEN-knock-down ES cells, as well as pharmacological inhibition 
of PTEN causes an increase in phosphorylation of Ser-473 in Akt. This activation 
of Akt led to an increase in Nrf2 protein abundance. This is in accordance with the 
study by Kensuke et al. (2009) that showed that mutation of PTEN in Jurkat 
human leukemia cells led to tBHQ-induced expression of ARE-driven genes. 
Analyses of the crystal structure of PTEN revealed that Cys-71 and Cys-124 form 
disulphide bonds upon oxidation with ROS causing loss of phosphatase activity 
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(Lee et al., 2002; Cho et al., 2004; Seo et al., 2005). Consistent with the idea that 
Cys-124 in PTEN is essential for the activity of PTEN (Kim et al., 2008a), E-
guggulsterone induced expression of Hmox1 was blocked when Cys-124 was 
mutated confirming that this residue required for PTEN activity (Almazari et al., 
2012). Results presented in chapter 3 also show that inducers of Nrf2 decrease 
the amount of PTEN protein. Nrf2 activators that target PI3K are able to do this by 
inhibiting PTEN allowing inactivation of GSK-3 by phosphorylation of its N-
terminal Ser residue, preventing GSK-3 from negatively regulating Nrf2 by SCFβ-
TrCP.  
 
5.3 Loss of Nrf2 in lung cancer cells causes reduced cell 
proliferation 
With a significantly lower survival rate, lung cancer is a major cause of cancer-
related death globally with an especially poor prognosis in advanced non-small-
cell lung cancer cases (Yamadori et al., 2012; Best et al., 2018). Mutations 
resulting in dysregulation of the Keap1/Nrf2 stress response has been observed 
in 23% of lung adenocarinomas (Govindan et al., 2012; Collisson et al., 2014b). 
The major aim of improved anti-cancer drug over the last couple of years is to 
prevent cancer cell growth and progression with as few side effects as possible. 
High levels of Nrf2 in cancers has been linked with poor prognosis, due not only to 
their ability to resist chemo and radio-therapy but also due to their robust 
proliferation (McDonald et al., 2010; Solis et al., 2010; Bai et al., 2016; Best et al., 
2018). The proliferative rate of cells has been reported to depend on the status of 
Nrf2 with cells expressing dominant negative Keap1 gene proliferating faster than 
cells expressing wildtype Keap1 and this is in turn proliferates faster than cells 
expressing a dominant negative NFE2L2 (Homma et al., 2009; Lister et al., 2011; 
Zhang et al., 2015a, 2016). By maintaining the redox balance and generation of 
antioxidants, Nrf2 is able to promote tumourigenesis and cancer cell proliferation. 
Whilst high ROS may stimulate growth, high ROS may also cause apoptosis and 
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senescence. Thus, high Nrf2 levels may have different effect on cancer cells. In 
the initiation, progression and survival phenotype of cancer, ROS has been 
shown to play a major role. (Kwee, 2014; Okon and Zou, 2015; Poillet-Perez et 
al., 2015). Since Nrf2 confers cytoprotection against oxidative stress, A549 and 
H460 cells possess high ROS levels in them. Knockdown of NFE2L2 gene in 
these cells resulted in decrease in ROS levels as well as decrease in cell 
proliferation rate which is consistent with previous literature. Nrf2 makes use of 
ROS as an arbitrator to pass on Nrf2-activating signals to cellular programs that 
modify proliferation and differentiation (Murakami and Motohashi, 2015). 
Liver regeneration is delayed in Nrf2-deficient mice after partial hepatectomy with 
a decrease in number of proliferating hepatocytes and an increase in apoptotic 
hepatocytes (Beyer et al., 2008). Activation of the PI3K-Akt signalling pathway 
during liver regeneration has been reported to be attenuated in Nrf2-deficient 
mice following partial hepatectomy suggesting a role for Nrf2 in the regulation of 
growth factor signalling (Beyer et al., 2008). Another study described 
accumulation of Nrf2 in livers of Keap1::PTEN double knockout mice causes 
hepatomegaly promoting proliferation of liver cells (Taguchi et al., 2014). Thus, a 
crosstalk between Nrf2 and the PI3K-Akt pathway would appear to support cell 
growth and cell fate in various tissues (Murakami and Motohashi, 2015). 
The cell cycle regulators Cdkn1a (p21) and Cdkn2b (p15) have been identified by 
Chip-sequencing analyses to be novel Nrf2 target genes (Malhotra et al., 2010) 
that may provoke stress-induce cell cycle arrest in response to oxidative stress. 
Nrf2-deficient hepatocytes show accumulation of Wee1 and hyperphosphorylation 
of cdk1 during liver degeneration causing a G2/M arrest (Zou et al., 2015). 
Activation of Cdk1/cyclin B1 pathway drives the transition into G2/M phase. The 
G2/M arrest caused by Nrf2 deficiency has been shown to be rescued by 
supplementation with glutathione proposing that glutathione is a considerable 
modifier of cell cycle status downstream of Nrf2  (Reddy et al., 2008).  
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The role of glutathione in promoting cell proliferation has been shown by many 
studies (Reddy et al., 2007b; a; Ishimoto et al., 2011). Therefore, the ability of 
Nrf2 to enhance glutathione synthesis in tumours is one-way Nrf2 promote cancer 
cell proliferation. The result in chapter 4 showed that A549 and H460 cells 
increase the expression of GCLC and GCLM and increase levels of GSH 
explaining that Nrf2 may increase the synthesis of GSH. Knockdown of Nrf2 in 
these cells caused a decrease expression of GCLC and GCLM and a decrease in 
GSH leading to decreased cell proliferation. “Normal” non-cancer cells and 
disease tissues utilizes metabolism in order to accomplish energy-dependent 
processes. As opposed to quiescent cells, cancer cells possess different 
metabolic activities as proliferating cells require abundant nutrients for the 
synthesis of cellular components including lipids, proteins and nucleic acid.  Nrf2 
activates metabolic genes involved in glucose and glutamine metabolism, 
contributing to reprogramming of cell proliferation (Mitsuishi et al., 2012). 
Particularly, four key enzymes required for driving the PPP are regulated by Nrf2 
including G6PD, PGD, TKT and TALDO1. Results in chapter 4 of this thesis show 
that Nrf2 knockdown decreases the expression of G6PD, PGD, and TALDO 
consistent with previous studies. Alteration in metabolic flux, shunting of glycolytic 
intermediates into the PPP is mediated by activation of Nrf2 enhancing purine 
nucleotide synthesis (Mitsuishi et al., 2012; Singh et al., 2013). Glutathione 
synthesis and lactate production are also enhanced by Nrf2 through regulation of 
glutamine metabolism. The major mechanism essential for the Nrf2-mediated 
increase in cell proliferation is through facilitating the PPP.  
Aside from controlling intracellular glutathione and ROS, Nrf2 also negatively 
regulates lipid biosynthesis. Genetic (Keap1-KO) or pharmacological activation of 
Nrf2 using CDDO-Im downregulated the expression of three critical enzymes 
involved in fatty acid synthesis (FAS) including fatty acid synthase (FASN), ATP-
citrate lyase (ACLY) and stearoyl CoA desaturase (SCD) (Yates et al., 2009). 
Accumulation of lipid was also observed in the livers of Nrf2-KO mice, in 
comparison to wild-type mice in nutritional models of non-alcoholic steatohepatitis 
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(Chowdhry et al., 2010; Sugimoto et al., 2010). ACYL is the catalytic enzyme that 
function as a precursor of acetyl CoA for FAS and has been shown by 
immunoblotting and proteomics analysis to be significantly higher in Nrf2-KO mice 
in comparison to their wild-type in a similar study (Kitteringham et al., 2010). The 
reduced expression of SCD in the presence of constitutively active Nrf2 is 
expected to lower FAS as SCD1 is involved in catalyzing mono-unsaturated fatty 
acid biosynthesis giving rise to oleic acid and palmitoleic acid, key substrates for 
the formation of phospholipids, triglycerides, cholesterol esters and alkyl-2,3-
diacylglycerols (Miyazaki and Ntambi, 2003; Flowers and Ntambi, 2008). Hepatic 
expression of SCD1 in Nrf2-KO mice correlates to a higher triglycerides levels 
compared to wild-type mice (Tanaka et al., 2012). In cancer, lipid metabolism is 
altered (Santos and Schulze, 2012). The breakdown of beta-oxidation gives 17 
molecules of ATP generating energy (Berg, L. and Stryer, 1988). By enhancing 
beta-oxidation of fatty acids, Nrf2 upregulation is able to generate energy required 
for building block of macromolecules.   
 
5.4 Conclusion and future work: chapter 3 
Study by Best et al. (2018) showed that loss of Keap1 alone caused no 
morphological changes however, combined loss of Keap1 and PTEN resulted in 
the formation of lung adenocarcinomas characterized by reprogramming of the 
PPP. What remains unclear is what conditions favour induction of Nrf2 via Keap1-
Cul3-Rbx1 E3 ligase over GSK-3/β-TrCP E3 ubiquitin ligase.  
With Nrf2 promoting cancer, one would wonder whether activation of Nrf2 can 
lead to cancer and what importance is studying the mechanism of action of Nrf2 
activators. To date, no evidence has been presented suggesting that Nrf2 
activators increase the rate of tumour growth or even stimulate initiation of cancer. 
For example, evaluation of the post-initiation effects of oltipraz, a known Nrf2 
activator, on aflatoxin B1-induced preneoplastic foci in rat model of hepatic 
tumourigenesis  revealed that oltipraz neither inhibited nor enhanced tumour yield 
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or burden (Maxuitenko et al., 1993). Therefore, for the purpose of 
chemoprevention, transient activation of Nrf2 in pre-cancerous cells by 
pharmacological activators of Nrf2 is safe. An understanding of which E3 ubiquitin 
ligase will play a dominant role in activation of Nrf2 by inducers is essential and 
would help improve the specificity of Nrf2-based therapies.  Most compounds are 
able to activate more than one kinase cascade; however, they exhibit preference 
to some.   
The results outlined have therefore demonstrated that Cys-151, Cys-273 and Cys-
288 of Keap1 are not the sole sensor for Nrf2 inducers required for stabilizing and 
transcriptionally activating Nrf2 but rather a Keap1-independent mechanism that is 
based on phosphorylation via the PI3K and PTEN.  
One thing that is clear is that Keap1-dependent regulation of Nrf2 is 
predominantly in the cytoplasm and loss of Keap1 activity results in nuclear 
accumulation of Nrf2. A good future experiment which this thesis has not covered 
will be to analyze the effect of the inducers in activating Nrf2 in the subcellular 
compartment within the cell. It has been reported that β-TrCP, the receptor 
component of the SCF E3 ubiquitin ligase required for degradation of Nrf2 through 
the Neh6 domain is localized in the nucleus (Lassot et al., 2001) as well as GSK-3 
that can be found both in the nucleus and cytoplasm (Chiara and Rasola, 2013). It 
would seem that the components required for ubiquitinating Nrf2 through the 
Neh6 domain are located in the nucleus. Another experiment that could be done 
is to find if inhibition of PI3K will alter nuclear localization of Nrf2 and if it does 
require Keap1 or β-TrCP.  
It has been proposed that GSK-3 phosphorylates Ser residues that overlap a 
DSGIS338 destruction motif in the central Neh6 domain of Nrf2 (Rada et al., 2011). 
When phosphorylated, DSGIS338 is recognized by β-TrCP and so allows the S-
phase kinase-associated protein-1 (Skp1)-cullen-1-F-box ubiquitin ligase to target 
Nrf2 for proteasomal degradation (Rada et al., 2012; Chowdhry et al., 2013). Also, 
a second recognition motif DSAPGS378 in the Neh6 domain of Nrf2 is recognized 
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by β-TrCP that contributes to the turnover of the transcription factor by SCFβ-TrCP 
though it does not seem to be phosphorylated (Chowdhry et al., 2013). Although 
we were able to show that the Neh6 is required for inducible Nrf2 activity by tBHQ, 
DEM, CDDO-Im, carnosol, curcumin and ferulic acid, it would be interesting to 
know whether inducers that inhibit PI3K require β-TrCP1 and/or β-TrCP2 in order 
to activate Nrf2 activity. One thing we have shown is that regulation of Nrf2 by 
inducers that target PI3K is independent of Keap1 and so it would be great to 
establish if these are dependent on β-TrCP1 and/or β-TrCP2. Also, it would be 
ideal to check the effect of inducers that inhibit PI3K result in inhibition by GSK-3 
of phosphorylation of Nrf2 at both the Ser-342 and Ser-347 sites. This experiment 
will prove that inducers that target the Neh6 domain as we saw in our experiment 
is due to phosphorylation of these residues by GSK-3.  
5.5 Conclusion and future work: chapter 4 
With the insight that Nrf2 promotes the survival of cancer cells (referred to as the 
“dark side of Nrf2”) studies on how to repress Nrf2 in cancer cells have been 
underway. Several studies has indicated that Nrf2 is responsible for 
chemoresistance (Cho et al., 2008; Kim et al., 2008; Tarumoto et al., 2004; Wang 
et al., 2008). Many proteins that are now known to be encoded by Nrf2-target 
genes, have been shown to contribute to the observed dependence of 
chemoresistance and cancer promotion on Nrf2; these include genes for 
antioxidants and detoxifying enzymes (Kim et al., 2007; Was et al., 2006; Black 
and Wolf, 1991; Wang et al., 2008a; Schisselbauer et al., 1990). In chapter 4 of 
this thesis, it was shown that non-small-cell lung cancer cell lines A549 and H460 
express increased levels of HMOX1, NQO1, GCLC, GCLM and AKR1C1 and 
Knockdown of Nrf2 in these cell lines decreased their basal expression level. By 
contrast, increased expression of Nrf2 has been linked to promotion of cell 
proliferation as observed by a decrease in cell proliferation when Nrf2 was 
knocked down in A549 and H460 cells. Knockdown of Nrf2 also caused a 
decrease in colony formation.   
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Rapid tumour growth requires an adequate supply of nutrients, metabolic 
intermediates to serve as building blocks. Glucose and glutamine uptake is critical 
in the metabolic shift observed in cancer cells. We have shown that decrease in 
Nrf2 in A549 and H460 cells caused a decrease in cellular glutathione levels. As 
Nrf2 controls the expression of glucose transporter, more work is needed to be 
done to check the expression of glucose transporter gene. 
Cancer cells utilizes large nutrient supply and maintains high levels of anabolism 
(Mitsuishi et al., 2012). Nrf2 has been shown to redirect glucose and glutamine 
into anabolic pathway (Mitsuishi et al., 2012). It was shown that loss of Nrf2 
decrease the expression of G6PD, PGD1, TALDO, ME1, IDH1 and PDK4. It was 
also show that Nrf2 regulates lipid metabolism providing energy source required 
for cell proliferation.     
The growth inhibition is likely attributed in part to its induction of cell cycle arrest at 
the G1 phase in A549 Nrf2-kd cells. Further experiments to confirm this 
hypothesis still need to be done.  
Selective activation of glutathione rescues cell proliferation in A549 Nrf2-kd cells 
indicating the major mechanism underlying accelerated cell proliferation in cancer 
cell having high Nrf2 levels is by Nrf2 controlling the supply of nutrients and 
generation of metabolites for building block and energy metabolism.  
Future work that needs to be done to strengthen this work includes: 
1. Analyze the effect of Nrf2 on more cell cycle proteins such as Cdkn1a 
(p21), cdkn2b (p15), FOX3a, cyclin E and retinoblastoma (pRB) 
2. We need to carry out Brdu staining to confirm S phase arrest.  
3. Also, we need to test if loss of Nrf2 reduces glucose, cysteine and glycine 
levels. 
4. Test if loss of Nrf2 reduces autophagy that will cause a reduction in the 
supply of metabolites requires for synthesis of macromolecules. 
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5.6 Limitations of study and future work  
Like with every research, there are some short comings and limitations to the 
result shown. Some of the limitations presented include: 
1. The N-number for sample size was small. Experiments were only set up 
as duplicates and sometimes triplicates and only covered 3 biological replicates. 
To effectively draw conclusions, more N-number would have been appropriate.  
2. Blots were not always clear and inability to include densitometric analysis 
of blots made conclusions difficult. It would have been better to include 
densitometric data for blots shown to strengthen result. 
3. This study covered both MEFs and human cancer cell lines to show that 
results were not specific to only MEFs but also applicable in human cancer cell 
line. However, using a large number of cell lines reduced scope for biological 
replication. 
5.7 Conclusion 
It has become progressively clear that Nrf2 promotes survival not only for normal 
cells but for cancer cells functioning as a tumour suppressor and as an oncogene. 
In normal cells, activation of Nrf2 using electrophiles that would induce the 
expression of Nrf2-target gene has been and still being used as chemoprotective 
drugs. The general consensus is that electrophiles that activate the Nrf2 pathway 
do so by modifying cysteine residues in Keap1. This thesis shows that activators 
of Nrf2 not only function through Keap1 but through a Keap1 independent 
manner. The role of PI3K-Akt/PKB signalling pathway in regulating Nrf2 has also 
been studied and showed that activators of Nrf2 that function independent of 
Keap1 do so by activating the PI3K-Akt/PKB signaling pathway, through 
decreasing PTEN and decreasing the activity of GSK-3 from promoting the 
ubiquitylation of Nrf2. It is shown that activators that target the PI3K-Akt/PKB 
pathway do this independently of Keap1. Nrf2 activators have also been shown to 
target both the Neh2 domain and the Neh6 domain of Nrf2 indicating that both 
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domains of Nrf2 are indeed involved in stabilization of Nrf2 by inducers to activate 
Nrf2.  
In cancer cells having high Nrf2 level promoting the growth and resistance to 
chemotherapy, knockdown of Nrf2 is able to decrease cell proliferation rate and 
decrease colony formation. This thesis show that decrease in cell proliferation is 
not due to cell death but due to regulation of metabolic genes required for 
generation of NADPH, purine biosynthesis and lipid metabolism. The ability of 
Nrf2 to control glutathione synthesis also has been shown to control cell 
proliferation in these cells. Knockdown of Nrf2 in A549 and H460 resulted in a 
decrease in GSH rate; and activation of glutathione using NAC rescued cell 
proliferation.  
Understanding of how Nrf2 can be activated in non-cancerous cells to promote 
cell survival and prevention of cancer and how Nrf2 can be targeted for inhibition 
in cancer cells having elevated levels of Nrf2 is very important for controlling 
increased cell proliferation associated with cancer cells and subsequently 
chemoresistance. As there are still no specific and effective Nrf2 inhibitors for 
therapeutic purposes, pharmacological targeting of pathways involved in 
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7.1 Appendix I 
 
 
Table 7.1: Predesigned Taqman probes/primers (human) for gene expression assay  


























7.2 Appendix II 
 
Table 7.2: Unmodified oligonucleotides used as Taqman probes and primers 
Gene TaqMan primer probe sequences (5’-3’) 
ACTIN FW primer 





HMOX1 FW primer 










7.3 Appendix III 
Table 7.3: Antibodies used in PAGE-electrophoresis 
 
 
Antibody Company and catalogue number Dilution 
Rabbit anti-NRF2 Abcam (ab62352) 1:1000 
Rabbit anti-NQO1 In house 1:2000 
Rabbit anti-Phospho 
GSK-3α/β (Ser9/21) 
Cell signalling Technology (93318) 1:1000 
Rabbit anti-Phospho 
AKT (Thr 308) 
Cell signalling Technology (4056S) 1:1000 
Rabbit anti-GSK-3α/β Cell signalling Technology (5676S) 1:1000 
Rabbit anti-Phospho 
AKT (Ser473) 
Cell signalling Technology (4060S) 1:1000 
Rabbit anti-AKT (Pan) Cell signalling Technology (4691S) 1:1000 
Rabbit anti-AKR1B10 Home made 1:2000 
Rabbit anti-AKR1C1 Home made 1:2000 
Rabbit anti-GCLM ThermoFisher Scientific (PA5-26111) 1:1000 
Rabbit anti-HMOX-1 BioVison (3391-100) 1:1000 
Rabbit anti- GCLC Invitrogen (PA5-16581) 1:1000 
